

Pharmaceutical Management Agency

December 2010

New Zealand Pharmaceutical Schedule



December 2010

Volume 17 Number 3

Editor

Kaye Wilson

email: schedule@pharmac.govt.nz

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington

Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates. Annual subscription includes three Pharmaceutical Schedule books, 12 updates and occasional information on rule changes and news items. The Schedule is distributed free of charge to over 9,000 health professionals, and is also available on an annual subscription.

Prices

\$22.22 One Schedule book

\$4.44 One Update

\$120.00 Annual subscription

All prices include postage and exclude GST.

Production

Typeset automatically from XML and T_EX.

See www.pharmac.govt.nz/schedule/archive/ for the XML version of this Schedule.

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency



ISSN 1179-3686 pdf

ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Introducing PHARMAC 2

Section A General Rules **12**

Section B Alimentary Tract & Metabolism **25**

Blood & Blood Forming Organs **40**

Cardiovascular System **47**

Dermatologicals **57**

Genito Urinary System **68**

Hormone Preparations – Systemic **75**

Infections – Agents For Systemic Use **82**

Musculoskeletal System **99**

Nervous System **115**

Oncology Agents & Immunosuppressants **143**

Respiratory System & Allergies **160**

Sensory Organs **166**

Various **171**

Section C Extemporaneous Compounds (ECPs) **172**

Section D Special Foods **179**

Section E Practitioner's Supply Orders **199**

Rural Areas **203**

Section F Dispensing Period Exemptions **204**

Section G Safety Cap Medicines **206**

Index 209

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

Members of the PHARMAC Board

Stuart McLauchlan
Anne Kolbe

Kura Denness
David Moore

David Kerr
Jens Mueller

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

Murray Georger, CE MidCentral DHB, attends PHARMAC's Board meetings as an observer.

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Māori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;
- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively. The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule. Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

Section H of the Pharmaceutical Schedule also identifies new Pharmaceuticals used in hospitals, which have been or are being assessed by PHARMAC, the results of that analysis being available to DHB Hospitals via PHARMAC's website.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets without specific Hospital Exceptional Circumstances approval.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Carl Burgess	MBChB, MD, MRCP (UK), FRACP, FRCP, physician/clinical pharmacologist, Chair
Stuart Dalziel	MBChB, PhD, FRACP
Ian Hosford	MBChB, FRANZCP, psychiatrist
Sisira Jayathissa	MMedSc (Clin Epi), MMBS, MD, MRCP (UK), FRCP (Edin), FRACP, FAFPHM, Dip Clin Epi, Dip OHP, Dip HSM, MBS
George Laking	MD, PhD, FRACP
Jim Lello	BHB, MBChB, DCH, FRNZCGP, general practitioner
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Peter Pillans	MBBCh, MD, FCP, FRACP, clinical pharmacologist
Mark Weatherall	BA, MBChB, MAppStats, FRACP
Howard Wilson	BSc, PhD, MB, BS, Dip Obst, FRNZCGP, FRACGP, general practitioner, Deputy Chair

Contact PTAC C/-Advisory Committee Manager , Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

The PHARMAC Team

The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation.

Matthew Brougham	Chief Executive	Geoff Lawn	Applications Developer / Team Leader IT
Lauren Abernethy	Funding and Procurement Assistant	Geraldine MacGibbon	Therapeutic Group Manager
Kate Adams	Health Economist	Janet Mackay	Access & Optimal Use Programme Manager
Paul Alexander	Health Economist	Rachel Mackay	Manager, Schedule and Contracts
Richard Anderson	Network and Systems Administrator	Trish Mahoney	Contract Manager
Katie Appleby	Hospital Exceptional Circumstances Panel Co-ordinator	Scott Metcalfe	Chief Advisor Population Medicine / Public Health Physician
Jason Arnold	Team Leader, Analysis	Peter Moodie	Medical Director
Graham Beever	General Counsel	Deborah Nisbet	Receptionist
Diana Beswethrick	HR Manager	Hew Norris	Analyst
Stephen Boxall	Creative Director	Leigh Parish	PA to Medical Director
Davina Carpenter	Records Manager	Marama Parore	Manager, Access & Optimal Use & Māori Health
Christine Chapman	Therapeutic Group Manager	Chris Peck	Analyst
Mary Chesterfield	MS and CML/GIST Co-ordinator	Angela Pirika	Senior Receptionist
Steffan Crausaz	Manager, Funding and Procurement	Sharon Ponniah	Access and Optimal Use Programme Manager
Andrew Davies	Procurement Initiatives Manager	Matthew Poynton	Analyst/Health Economist
Rachelle Davies	Office Manager / Corporate Team Assistant	Rachel Pratt	Community Exceptional Circumstances Panel Co-ordinator
Jessica Dougherty	Executive Assistant to Chief Executive	Dilky Rasiah	Deputy Medical Director
Sean Dougherty	Funding Systems Development Manager	Kyle Reid	Tender Analyst
Anrik Drenth	Database Analyst	Awhimai Reynolds	Māori Health Manager
Kim Ellis	Access & Optimal Use Co-ordinator	Brian Roulston	Contract Manager
Simon England	Communications Manager	Fiona Rutherford	Senior Policy Analyst
Jackie Evans	Therapeutic Group Manager	Rico Schoeler	Manager, Analysis and Assessment
John Geering	Systems Architect	Merryn Simmons	PHARMAC Seminar Series Co-ordinator
Rachel Grocott	Health Economist / Team Leader Assessment	Liz Skelley	Finance Manager
Susan Haniel	Advisory Committee Manager	Jude Ulrich	Manager, Corporate and External Relations
David Harland	Health Economist	Jayne Watkins	Team Leader, Medical Team
Ben Healey	Analyst	Bryce Wigodsky	Communications Advisor
Hayden Holmes	Panel Co-ordinator (Growth Hormone/PAH)	Greg Williams	Therapeutic Group Manager
Karen Jacobs	Access & Optimal Use Programme Manager	Kaye Wilson	Schedule Analyst
Helen Knight	Accounts Payable Co-ordinator	Stephen Woodruffe	Therapeutic Group Manager
		Sue Anne Yee	Therapeutic Group Manager
		Michael Young	Analyst

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section **A** lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section **C** lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section **D** lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section **E** Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section **E** Part II lists rural areas for the purpose of PSOs.
- Section **F** lists the Community Pharmaceuticals dispensing period exemptions.
- Section **G** lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section **H** lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:

- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV) Pharmaceuticals and DV Limit.
- Part III lists Assessed Pharmaceuticals, which have been or are being assessed by PHARMAC and, where such assessment is available, PHARMAC's opinion regarding the use of the Assessed Pharmaceuticals in hospitals. DHB Hospitals are not obliged to implement those recommendations.
- Part IV lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Glossary

Units of Measure

gram	g	microgram.....	µg	millimole.....	mmol
kilogram.....	kg	milligram.....	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

Abbreviations

Ampoule	Amp	Granules.....	Gran	Suppository	Supp
Capsule	Cap	Infusion.....	Inf	Tablet.....	Tab
Cream.....	Crn	Injection.....	Inj	Tincture.....	Tinc
Device.....	Dev	Linctus.....	Linc	Trans Dermal Delivery	
Dispersible.....	Disp	Liquid.....	Liq	System.....	TDDS
Effervescent.....	Eff	Long Acting.....	LA		
Emulsion.....	Emul	Ointment.....	Oint		
Enteric Coated.....	EC	Sachet	Sach		
Gelatinous	Gel	Solution.....	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

CE Compounded Extemporaneously.

CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.

ECP Extemporaneously Compounded Preparation.

HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

OP Original Pack – subsidy is rounded up to a multiple at whole packs.

PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.

* Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.

‡ Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations.

✓ Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.

s29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:

- be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
- be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

Definitions		
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements
[HP3]	Subsidised when dispensed from pharmacies that have a Special Foods Service appended to their Pharmacy Services Agreement by their DHB.	Available from selected pharmacies that have an exclusive contract to dispense Special Foods.
[HP4]	Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)	Available from selected pharmacies that have an exclusive contract to dispense 'Hospital Pharmacy' [HP4] pharmaceuticals.

Patient costs

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a ✓ in the product's Schedule listing.

SALBUTAMOL		
Aerosol inhaler 100 µg per dose.....	3.80	✓Fully subsidised brand
	(6.00)	Higher priced brand

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee.

PRESCRIPTION CHARGE

From 1 September 2008, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$3 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$3 co-payments.

Prescriptions from the following providers are approved for \$3 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, ophthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

$$\text{Manufacturer's surcharge to patient} = (\text{price} - \text{subsidy}) \times 1.86$$

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being

\$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals and Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the Funder (in particular, the relevant DHB) from its own budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet. It can be used to calculate the cost of a prescribed Community Pharmaceutical. This site at <http://www.pharmac.govt.nz> takes into account the quantity of Community Pharmaceutical prescribed as well as the patient's age, whether the patient has a community services card, high use health card or prescription subsidy card, the fee for pharmacy services and prescription charges.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the prescriber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131
Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patient's name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Exceptional Circumstances policies

The purpose of the Exceptional Circumstances policies are to provide:

- funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule (“Community Exceptional Circumstances”); or
- an assessment process for the DHB Hospitals to determine whether they can fund medication, to be used in the community, in circumstances where the medication is neither a Community Pharmaceutical nor a Discretionary Community Supply Pharmaceutical and where the patient does not meet the criteria for Community Exceptional Circumstances (“Hospital Exceptional Circumstances”); or
- an assessment process for DHB Hospitals to determine whether they can fund pharmaceuticals for the treatment of cancer in their DHB Hospital, or in association with Outpatient services provided in their DHB hospital, in circumstances where the pharmaceutical is not identified as a Pharmaceutical Cancer Treatment (“Cancer Exceptional Circumstances”) in Sections A-H of the Pharmaceutical Schedule.

Upon receipt of an application for approval for Community Exceptional Circumstances or Hospital Exceptional Circumstances, the Exceptional Circumstances Panel first decides whether an application will be assessed initially under the Community Exceptional Circumstances criteria or the Hospital Exceptional Circumstances criteria. Cancer Exceptional Circumstances is a separate process.

Hospital Exceptional Circumstances

If the application is first assessed but not approved under the Community Exceptional Circumstances criteria, the Exceptional Circumstances Panel may recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances.

If the application is first assessed under the Hospital Exceptional Circumstances criteria, the Exceptional Circumstances Panel may:

- a) recommend against the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget, in which case a DHB Hospital must not fund the pharmaceutical from its own budget;
- b) recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances, in which case a DHB Hospital may, but is not obliged to, fund the pharmaceutical from its own budget;
- c) defer its decision until further assessment under the Community Exceptional Circumstances criteria can be undertaken; or
- d) recommend interim funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances until further assessment under the Community Exceptional Circumstances criteria can be undertaken.

Permission to fund a pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that such funding is cost-effective for the relevant DHB in the region in which the patient resides.

If the patient being treated with a pharmaceutical under Hospital Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Applications for Hospital Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Hospital Exceptional Circumstances Panel
PHARMAC, PO Box 10 254
Wellington

Phone: (04) 916 7521
or fax (09) 523 6870
Email: ecpanel@pharmac.govt.nz

Cancer Exceptional Circumstances

Permission to fund a pharmaceutical for the treatment of cancer from the Hospital's own budget under Cancer Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that the proposed use meets the criteria.

If the patient being treated with a pharmaceutical under Cancer Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Community Exceptional Circumstances

In order to qualify for Community Exceptional Circumstances approval one of the following criteria must be met:

- a) the condition must be rare; *or*
- b) the reaction to alternative funded treatment must be unusual; *or*
- c) an unusual combination of circumstances applies.

Rare and unusual are considered to be in the order of less than 10 people nationally.

Where one of the above Community Exceptional Circumstances entry criteria is met, the application may then be further examined under supplementary criteria, assessing suitability of the pharmaceutical, clinical benefit, the cost effectiveness of the treatment, and the patient's ability to pay for the treatment. Where these documented criteria are met, a subsidy sufficient to fully fund the pharmaceutical will be made available to the specific patient on whose behalf the application was made.

Community Exceptional Circumstances funding is only available where the criteria are met and is not available for financial reasons alone.

Applications for Community Exceptional Circumstances, Hospital Exceptional Circumstances and Cancer Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Community Exceptional Circumstances Panel
PO Box 10 254
Wellington

Phone (04) 916 7553
or fax (09) 523 6870
Email: ecpanel@pharmac.govt.nz

SECTION A: GENERAL RULES

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 December 2010 and is to be referred to as the Pharmaceutical Schedule Volume 17 Number 3, 2010. Distribution will be from 20 December 2010. This Schedule comes into force on 1 December 2010.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Assessed Pharmaceuticals" means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Cancer Exceptional Circumstances" means the policies and criteria administered by PHARMAC relating to the ability to fund, from a DHB hospital's own budget, pharmaceuticals for the treatment of cancer that are not identified as Pharmaceutical

Cancer Treatments in Sections A-H of the Pharmaceutical Schedule.

“**Class B Controlled Drug**” means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

“**Close Control**” means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply.

- a) All of the following conditions are met:
 - i) the Community Pharmaceutical has been prescribed for a patient who:
 - 1) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and
 - 2) either of the following:
 - i) in the opinion of the prescribing Practitioner is:
 - a) frail; or
 - b) infirm; or
 - c) unable to manage their medication without additional support; or
 - d) intellectually impaired; or
 - e) requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only); and
 - f) requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or
 - ii) the Community Pharmaceutical is any of the following:
 - a) a tri-cyclic antidepressant; or
 - b) an antipsychotic; or
 - c) a benzodiazepine; or
 - d) a Class B Controlled Drug; and
 - ii) the prescribing Practitioner has:
 - A) endorsed each Community Pharmaceutical on the Prescription clearly with the words “Close Control” or “CC”; and
 - B) initialled the endorsement in their own handwriting; and
 - C) specified the maximum quantity or period of supply to be dispensed at any one time.
 - b) All of the following conditions are met:
 - i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and
 - A) the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply; and
 - B) the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and
 - C) the prescriber or pharmacist has:
 - 1) written on the Prescription the words “Close Control” or “CC” (this applies to all medicines prescribed on the prescription), and
 - 2) initialled the endorsement/annotation in their own handwriting; and
 - 3) specified the maximum quantity or period of supply to be dispensed at any one time.
 - c) All of the following conditions are met:
 - i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and
 - ii) the dispensing pharmacist has:
 - A) clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “Close Control” or “CC”; and
 - B) initialled the annotation in their own handwriting; and
 - C) specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

“**Community Exceptional Circumstances**” means the policies and criteria administered by the Exceptional Circumstances Panel relating to funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical

SECTION A: GENERAL RULES

Budget is not able to be provided through the Pharmaceutical Schedule.

“Community Pharmaceutical” means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

“Contractor” means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

“Controlled Drug” means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

“Cost, Brand, Source of Supply” means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor’s annotated purchase price, brand, and source of supply.

“Dentist” means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

“Dietitian” means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

“DHB” means an organisation established as a District Health Board by or under Section 19 of the Act.

“DHB Hospital” means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

“Discretionary Community Supply Pharmaceutical” means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

“Doctor” means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

“DV Limit” means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“DV Pharmaceutical” means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

“Endorsements” - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as “certified condition”, or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes “certified condition” as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

“Exceptional Circumstances Panel” means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for administering policies in relation to Community Exceptional Circumstances and Hospital Exceptional Circumstances.

“Funder” means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“GST” means goods and services tax under the Goods and Services Tax Act 1985.

“Hospital Care Operator” means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

“Hospital Exceptional Circumstances” means the policies and criteria administered by the Exceptional Circumstances Panel relating to the ability to fund, from a DHB Hospital’s own budget, pharmaceuticals for use in the community by a specific patient where a subsidy is not available from the Pharmaceutical Budget or under Community Exceptional Circumstances.

“Hospital Pharmaceuticals” means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

“Hospital Pharmacy” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

“Hospital Pharmacy-Specialist” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist; or
if the treatment of an Outpatient with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a Practitioner endorsed with the words “recommended by [name of specialist and year of authorisation]” and signed by the Practitioner.

“As recommended by a Specialist” to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the specialist and the General Practitioner must keep a written record of the consultation.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

“Hospital Pharmacy-Specialist Prescription” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a “specialist” means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

“HSS” means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

“In Combination” means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

“Individual DV Limit” means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital’s Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

“Licensed Hospital” means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

“Lot” means a quantity of a Community Pharmaceutical supplied in one dispensing.

“Manufacturer’s Price” means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

“Maternity hospital” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

“Midwife” means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

“Month” means a period of 30 consecutive days.

“Monthly Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 30 consecutive days’ treatment;

“National Contract Pharmaceutical” means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

“National DV Limit” means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

“Not In Combination” means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

“Nurse Prescriber” means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice.

“Optometrist” means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practicing certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

“Outpatient”, in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person’s home.

“PCT” means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

“PCT only” means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

“Penal Institution” means a penal institution, as that term is defined in The Penal Institutions Act 1954;

SECTION A: GENERAL RULES

“**PHARMAC**” means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

“**Pharmaceutical**” means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

“**Pharmaceutical Benefits**” means the right of:

- a) a person; and
- b) any member under 16 years of age of that person’s family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

“**Pharmaceutical Budget**” means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals.

“**Pharmaceutical Cancer Treatment**” means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund, from their own budgets, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

“**Practitioner**” means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber or an Optometrist as those terms are defined in the Pharmaceutical Schedule.

“**Practitioner’s Supply Order**” means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

“**Prescription**” means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

“**Prescription Medicine**” means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984.

“**Private Hospital**” means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

“**Residential Disability Care Institution**” means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

“**Rest Home**” means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

“**Restricted Medicine**” means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

“**Retail Pharmacy-Specialist**” means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or, in the case of treatment recommended by a Specialist, a Prescription or Practitioner’s Supply Order and endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner.

“As recommended by a Specialist” to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the Specialist and the General Practitioner must keep a written record of consultation.

“**Retail Pharmacy-Specialist Prescription**” means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner’s Supply Order, signed by a Specialist. For the purposes of this definition, a “specialist” means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

“**Schedule**” means this Pharmaceutical Schedule and all its sections and appendices.

“**Section B**” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies included in the Schedule.

“**Section C**” of this Pharmaceutical Schedule means the list of community extemporaneously compounded preparations and galenicals eligible for Subsidies included in the Schedule.

“**Section D**” of this Pharmaceutical Schedule means the list of community special foods eligible for Subsidies included in the Schedule.

“**Section E Part I**” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies and available on a Practitioner’s Supply Order included in the Schedule.

“**Section E Part II**” of this Pharmaceutical Schedule means the list of rural areas for the purpose of community Practitioner’s Supply Orders included in the Schedule.

“**Section F Part I**” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots or 180 Day Lots, as applicable, in respect of the Community Pharmaceuticals referred to in this part of Section F;

“**Section F Part II**” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F;

“**Section G**” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for reimbursement of safety caps.

“**Section H**” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals and the lists of National Contract Pharmaceuticals and any associated DV Pharmaceuticals, of Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals included in Section H of the Schedule.

“**Section H Part I**” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals.

“**Section H Part II**” of this Pharmaceutical Schedule means the list of National Contract Pharmaceuticals, the relevant Price, an indication of whether the Pharmaceutical has HSS and any associated DV Pharmaceuticals and DV Limit.

“**Section H Part III**” of this Pharmaceutical Schedule means the list of Assessed Pharmaceuticals.

“**Section H Part IV**” of this Pharmaceutical Schedule means the list of Discretionary Community Supply Pharmaceuticals.

“**Special Authority**” means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

“**Specialist**”, in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a)
 - i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
 - ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

“**Subsidy**” means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

“**Supply Order**” means a Bulk Supply Order or a Practitioner’s Supply Order.

“**Unapproved Indication**” means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 4.6.

1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:

- a) the singular includes the plural; and
- b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regu-

SECTION A: GENERAL RULES

lation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G of the Schedule, and every preparation (having an inert base) of any of them, is hereby declared to be a Community Pharmaceutical for the purposes of the Schedule, subject to:
- 2.1.1 clauses 2.2 and 2.3 of the Schedule; and
 - 2.1.2 clauses 3.1 to 4.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G of the Schedule;
- 2.2 The following medicines, therapeutic medical devices, or related products or related things are not eligible for Subsidy:
- 2.2.1 substances, or combinations of substances, ordered for any purpose other than:
 - a) treatment of a patient's medical or dental condition; or
 - b) pregnancy tests; or
 - c) the prevention of sexually transmitted disease; or
 - d) contraception.
 - 2.2.2 substances and combinations of substances packed under pressure in aerosol cans or other similar devices, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.3 electrode jellies;
 - 2.2.4 eye drops packed in single-dose units, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.5 insect repellents and similar preparations;
 - 2.2.6 oral preparations in long-acting form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.7 substances or combinations of substances in lozenge or similar form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.8 machine-spread plasters;
 - 2.2.9 preparations prescribed as foods, unless they are specified in Section D of the Schedule;
 - 2.2.10 substances, combinations of substances, or articles, in the form of proprietary medicines or proprietary articles, unless they are deemed or declared to be Pharmaceuticals elsewhere in the Schedule;
 - 2.2.11 shampoos, other than extemporaneously prepared medicated shampoos, or shampoos specified in Sections B to G of the Schedule intended for the treatment of a patient's medical condition;
 - 2.2.12 toilet preparations;
 - 2.2.13 tooth pastes and powders;
 - 2.2.14 lubricating jellies and catheter lubricants;
 - 2.2.15 sterile diluents for nebulising solutions;
 - 2.2.16 substances in a form intended to enable delivery by transdermal diffusion or osmosis or by the insertion of any solid object or substance into the eye cavity, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.17 substances in a form intended for intravenous delivery (other than by injection), unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.18 substances packed in pre-loaded syringes known as Min-I-Jets, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.19 Community Pharmaceuticals prescribed as cough mixtures, unless they are specified in Sections B to G of the Schedule otherwise than in combination with other ingredients;
 - 2.2.20 vitamin preparations in capsule form, unless they are specified in Sections B to G of the Schedule;
 - 2.2.21 substances prescribed for use as irrigating solutions, unless it is specified in Sections B to G of the Schedule that they may be prescribed for such use.
- 2.3 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
- 2.3.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines

- Act 1981; or
- 2.3.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
- 2.3.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
- 2.3.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dietitians', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dietitian, Midwife, Nurse Prescriber or Optometrist:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity sufficient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug other than methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
- a) sufficient to provide treatment for a period not exceeding 10 days; and
 - b) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
- a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - 2) every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
- a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
- a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for

SECTION A: GENERAL RULES

Subsidy.

3.1.7 If a Community Pharmaceutical:

- a) is stable for a limited period only, and the Doctor, Dietitian, Midwife, Nurse Prescriber or Optometrist has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that may be dispensed at any one time; or
- b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
- c) is Close Control,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed:

- a) three Months if prescribed by a Midwife; or
- b) six Months if prescribed by a Doctor or Nurse Practitioner.

3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:

- a) in Lots as specified in the Prescription if the Community Pharmaceutical is Close Control; or
- b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.

3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.

3.2.4 An oral contraceptive prescribed by a Midwife is only eligible for Subsidy if the Prescription under which it has been dispensed has been written within the period of post natal care of the eligible person.

3.2.5 Where a Community Pharmaceutical in a Prescription is Close Control and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Dentists' Prescriptions

The following provisions apply to every Prescription written by a Dentist:

3.3.1 The maximum quantity of a Community Pharmaceutical that will be subsidised is as follows:

- a) where the Community Pharmaceutical is a Controlled Drug, only such quantity as is necessary to provide treatment for a period not exceeding five days; and
- b) in any other case, only such quantity as is necessary to provide treatment for a period not exceeding five days and, where the Prescription specifies a repeat, one further period not exceeding five days.

3.3.2 Notwithstanding clause 3.3.1, if, in the opinion of the Dentist, an eligible person needs extended treatment with sodium fluoride for up to three Months, the Community Pharmaceutical will be subsidised for that extended period. A Prescription for any such extended supply of sodium fluoride will be subsidised only if it is dispensed in Monthly Lots, unless the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect.

3.3.3 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed has been presented to the Contractor:

- a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
- b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.

3.3.4 No Subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:

- a) one Month from the date the Community Pharmaceutical was first dispensed; or
- b) in the case of sodium fluoride, three Months from the date the Community Pharmaceutical was first dispensed.

Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.

3.4 Original Packs, and Certain Antibiotics

3.4.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a

container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:

- a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.4.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:
- a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
 - b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.5 Dietitians' Prescriptions

The following provisions apply to every Prescription written by a Dietitian:

- 3.5.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
- a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian,
- providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.5.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

PART IV MISCELLANEOUS PROVISIONS

4.1 Bulk Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 4.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 4.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 4.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 4.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 4.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.

SECTION A: GENERAL RULES

4.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

4.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

4.2.1 Subject to clause 4.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

4.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.

4.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:

a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.

b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)

4.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:

a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:

i) is personally signed and dated by the Practitioner; and

ii) sets out the Practitioner's address; and

iii) sets out the Community Pharmaceuticals and quantities, and;

b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.

4.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

4.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

4.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

4.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

4.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 4.3.1 and 4.3.2, for the individual Patient.

4.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.

4.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

4.4 Pharmaceutical Cancer Treatments

4.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments by funding their use in the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.

4.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:

a) has Cancer Exceptional Circumstances approval;

- b) has Community Exceptional Circumstances or Hospital Exceptional Circumstances approval;
 - c) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - d) is being used and funded as part of a paediatric oncology service; or
 - e) was being used to treat the patient in question prior to 1 July 2005.
- 4.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatments with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
- a) Part 1;
 - b) clauses 2.1 to 2.3;
 - c) clauses 3.1 to 3.4; and
 - d) clause 4.4,
- of Section A of the Schedule
- 4.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 4.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under the Medicines Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 4.5 Practitioners prescribing unapproved Pharmaceuticals**
- Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:
- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
 - b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;
- Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:
- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.
- Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.
- 4.6 Substitution**
- Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical

SECTION A: GENERAL RULES

available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to:

- a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or
- b) the Practitioner having indicated their Authority to Substitute on the prescription; or
- c) the Practitioner having given their Authority to Substitute in relation to the particular prescription.

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget.

When dispensing a subsidised alternative brand, the Contractor must annotate and initial the prescription.

4.7 **Alteration to Presentation of Pharmaceutical Dispensed**

A Contractor, when dispensing a Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed but may not alter the total daily dose. If the change will result in additional cost to the DHBs, then:

- a) the Practitioner must authorise and initial the alteration; or
- b) in cases where PHARMAC has approved and notified in writing such a change in dispensing of a named Pharmaceutical due to an out of stock event or short supply, the Contractor must annotate and initial the alteration.

4.8 **Amendment of Schedule**

PHARMAC may amend the terms of the Schedule from time to time by notice in writing given in such manner as PHARMAC thinks fit, and in accordance with such protocols as agreed with the Pharmacy Guild of New Zealand (Inc) from time to time.

4.9 **Conflict in Provisions**

If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	4.50	30	✓	Gaviscon Infant
CALCIUM CARBONATE WITH AMINOACETIC ACID				
* Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$6.30 per 100 tab with Endorsement.....	3.00 (6.30)	100		Titralac
Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly.				
SIMETHICONE				
* Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml	1.50 (4.26)	500 ml		Mylanta P
SODIUM ALGINATE				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (8.60)	60		Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml	1.50 (4.95)	500 ml		Acidex
* Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed)	1.50 (8.64)	500 ml		Gaviscon
<i>(Gaviscon Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) to be delisted 1 January 2011)</i>				
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE				
Tab 600 mg	12.56	100	✓	Alu-Tab
Antidiarrhoeals				
Agents Which Reduce Motility				
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE				
* Tab 2.5 mg with atropine sulphate 25 µg	3.90	100	✓	Diastop
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO				
* Tab 2 mg	8.95	400	✓	Nodia
* Cap 2 mg	8.95	400	✓	Diamide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA0913 on the next page – Retail pharmacy	166.50	90	✓	Entocort CIR

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

▶SA0913 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:
Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy.

Renewal from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

The patient may not have had more than 1 prior approval in the last year.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)23.00 21.1 g OP ✓ **Colifoam**

MESALAZINE

Tab 400 mg	49.50	100	✓ Asacol
Tab EC 500 mg	49.50	100	✓ Asamax
Tab long-acting 500 mg	59.05	100	✓ Pentasa
Enema 1 g per 100 ml	45.96	7	✓ Pentasa
Suppos 500 mg	25.20	20	✓ Asacol
Suppos 1 g	50.96	28	✓ Pentasa

OLSALAZINE

Tab 500 mg	59.86	100	✓ Dipentum
Cap 250 mg	31.51	100	✓ Dipentum

SODIUM CROMOGLYCATE

Cap 100 mg89.21 100 ✓ **Nalcrom**

SULPHASALAZINE

* Tab 500 mg	11.68	100	✓ Salazopyrin
* Tab EC 500 mg	12.89	100	✓ Salazopyrin EN

Antihaemorrhoidals

Corticosteroids

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g	6.35	30 g OP	✓ Ultraproct
Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg	2.66	12	✓ Ultraproct

HYDROCORTISONE WITH CINCHOCAINE

Oint 5 mg with cinchocaine hydrochloride 5 mg per g	15.00	30 g OP	✓ Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	9.90	12	✓ Proctosedyl

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
Soothing Agents			
ZINC OXIDE			
Oint zinc oxide with balsam peru	4.50 (6.67)	50 g OP	Anusol
Suppos zinc oxide with balsam peru	4.47 (6.49)	12	Anusol
<i>(Anusol Oint zinc oxide with balsam peru to be delisted 1 January 2011)</i>			
<i>(Anusol Suppos zinc oxide with balsam peru to be delisted 1 January 2011)</i>			

Antispasmodics and Other Agents Altering Gut Motility			
ATROPINE SULPHATE			
* Inj 600 µg, 1 ml – Up to 5 inj available on a PSO	52.00	50	✓ <u>AstraZeneca</u>
HYOSCINE N-BUTYLBROMIDE			
* Tab 10 mg	1.62	20	✓ <u>Gastrosoothe</u>
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	8.04	5	✓ <u>Buscopan</u>
MEBEVERINE HYDROCHLORIDE			
* Tab 135 mg	18.00	90	✓ <u>Colofac</u>

Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
* Tab 200 µg	52.70	120	✓ <u>Cytotec</u>

Helicobacter Pylori Eradication			
CLARITHROMYCIN			
Tab 500 mg – Subsidy by endorsement	23.30	14	✓ <u>Klamycin</u>
a) Maximum of 14 tab per prescription			
b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.			
Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.			

H2 Antagonists			
CIMETIDINE – Only on a prescription			
* Tab 200 mg	5.00 (7.50)	100	Apo-Cimetidine
* Tab 400 mg	10.00 (12.00)	100	Apo-Cimetidine
FAMOTIDINE – Only on a prescription			
* Tab 20 mg	8.10	250	✓ <u>Famox</u>
* Tab 40 mg	11.35	250	✓ <u>Famox</u>
RANITIDINE HYDROCHLORIDE – Only on a prescription			
* Tab 150 mg	7.99	250	✓ <u>Arrow-Ranitidine</u>
* Tab 300 mg	10.94	250	✓ <u>Arrow-Ranitidine</u>
* Oral liq 150 mg per 10 ml	7.95	300 ml	✓ <u>Peptisoothe</u>
* Inj 25 mg per ml, 2 ml	8.75	5	✓ <u>Zantac</u>

‡ safety cap
 *Three months or six months, as applicable, dispensed all-at-once
 ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Proton Pump Inhibitors				
LANSOPRAZOLE				
* Cap 15 mg	3.50	28	✓	Solox
* Cap 30 mg	4.65	28	✓	Solox
OMEPRAZOLE				
For omeprazole suspension refer, page 176				
* Cap 10 mg	2.14	30	✓	<u>Dr Reddy's</u> <u>Omeprazole</u>
* Cap 20 mg	3.05	30	✓	<u>Dr Reddy's</u> <u>Omeprazole</u>
* Cap 40 mg	3.59	30	✓	<u>Dr Reddy's</u> <u>Omeprazole</u>
* Inj 40 mg	38.20	5	✓	<u>Dr Reddy's</u> <u>Omeprazole</u>
PANTOPRAZOLE				
* Tab 20 mg	1.23	28	✓	<u>Dr Reddy's</u> <u>Pantoprazole</u>
* Tab 40 mg	1.54	28	✓	<u>Dr Reddy's</u> <u>Pantoprazole</u>
* Inj 40 mg	8.75	1	✓	Pantocid IV

Site Protective Agents

SUCRALFATE				
Tab 1 g	35.50 (48.28)	120		Carafate

Diabetes

Hyperglycaemic Agents

GLUCAGON HYDROCHLORIDE				
Inj 1 mg syringe kit – Up to 5 kit available on a PSO	27.00	1	✓	Glucagen Hypokit

Insulin - Short-acting Preparations

INSULIN NEUTRAL				
▲ Inj human 100 u per ml	25.26	10 ml OP	✓	Actrapid
▲ Inj human 100 u per ml, 3 ml	42.66	5	✓	Humulin R
			✓	Actrapid Penfill
			✓	Humulin R

Insulin - Intermediate-acting Preparations

INSULIN ISOPHANE				
▲ Inj human 100 u per ml	17.68	10 ml OP	✓	Humulin NPH
▲ Inj human 100 u per ml, 3 ml	29.86	5	✓	Protaphane
			✓	Humulin NPH
			✓	Protaphane Penfill

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN ISOPHANE WITH INSULIN NEUTRAL				
▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	✓	Humulin 30/70
			✓	Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓	Humulin 30/70
			✓	PenMix 30
			✓	PenMix 40
			✓	PenMix 50
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE				
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml	52.15	5	✓	Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3 ml	52.15	5	✓	Humalog Mix 50

Insulin - Long-acting Preparations

INSULIN GLARGINE

Note: Only for patients meeting one of the following criteria:

- a) Type 1 diabetes; or
- b) Other condition related diabetes (e.g. Cystic Fibrosis, diabetes in pregnancy, pancreatectomy patients); or
- c) Type 2 diabetes after there has been unacceptable hypoglycaemic events with a 3 month trial of an insulin regimen; or
- d) Type 2 diabetes who require insulin therapy and who require assistance from a carer or healthcare professional to administer their insulin injections.

▲ Inj 100 u per ml, 10 ml	63.00	1	✓	Lantus
▲ Inj 100 u per ml, 3 ml	94.50	5	✓	Lantus
▲ Inj 100 u per ml, 3 ml disposable pen	94.50	5	✓	Lantus SoloStar

Insulin - Rapid Acting Preparations

INSULIN ASPART

▲ Inj 100 u per ml, 3 ml	51.19	5	✓	NovoRapid Penfill
▲ Inj 100 u per ml, 10 ml	30.03	1	✓	NovoRapid

INSULIN GLULISINE

▲ Inj 100 u per ml, 10 ml	27.03	1	✓	Apidra
▲ Inj 100 u per ml, 3 ml	46.07	5	✓	Apidra
▲ Inj 100 u per ml, 3 ml disposable pen	46.07	5	✓	Apidra SoloStar

INSULIN LISPRO

▲ Inj 100 u per ml, 10 ml	34.92	10 ml OP	✓	Humalog
▲ Inj 100 u per ml, 3 ml	59.52	5	✓	Humalog

Alpha Glucosidase Inhibitors

ACARBOSE

* Tab 50 mg	16.50	90	✓	Glucobay
* Tab 100 mg	26.70	90	✓	Glucobay

Oral Hypoglycaemic Agents

GLIBENCLAMIDE

* Tab 5 mg	5.00	100	✓	Daonil
------------------	------	-----	---	---------------

GLICLAZIDE

* Tab 80 mg	22.24	500	✓	Apo-Gliclazide
-------------------	-------	-----	---	-----------------------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLIPIZIDE				
* Tab 5 mg	3.50	100	✓	<u>Minidiab</u>
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg	8.09	500	✓	<u>Apotex</u>
* Tab immediate-release 850 mg	6.67	250	✓	<u>Apotex</u>
PIOGLITAZONE – Special Authority see SA0959 below – Retail pharmacy				
Tab 15 mg	2.61	28	✓	<u>Pizaccord</u>
Tab 30 mg	5.23	28	✓	<u>Pizaccord</u>
Tab 45 mg	7.80	28	✓	<u>Pizaccord</u>

SA0959 Special Authority for Subsidy

Initial application — (Patients with type 2 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has not achieved glycaemic control on maximum doses of metformin or a sulphonylurea or where either or both are contraindicated or not tolerated; or
- 2 Patient is on insulin.

Diabetes Management

Ketone Testing

KETONE BLOOD BETA-KETONE ELECTRODES – Maximum of 20 strip per prescription

Test strip – Not on a BSO	7.07	10 strip OP	✓	<u>Optium Blood Ketone Test Strips</u>
---------------------------------	------	-------------	---	--

SODIUM NITROPRUSSIDE – Maximum of 20 strip per prescription

* Test strip – Not on a BSO	14.14	20 strip OP	✓	<u>Ketostix</u>
-----------------------------------	-------	-------------	---	-----------------

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

a) Maximum of 1 meter per prescription

b)

1) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005 or is prescribed for a pregnant woman with diabetes.

2) Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly.

Meter	6.00	1	✓	<u>CareSens POP</u>
	9.00		✓	<u>CareSens II</u>
			✓	<u>FreeStyle Lite</u>
			✓	<u>On Call Advanced</u>
			✓	<u>Optium Xceed</u>
	19.00		✓	<u>Accu-Chek Performa</u>

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
---	-----	---------------------	-------------------------------------

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

The number of test strips available on a prescription is restricted to 50 unless:

- 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or
- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly.

SensoCard blood glucose test strips are subsidised only if prescribed for a patient who is severely visually impaired and is using a SensoCard Plus Talking Blood Glucose Monitor.

Blood glucose test strips × 50 and lancets × 5	19.10	1 OP	✓ On Call Advanced
	19.60		✓ CareSens
Blood glucose test strips	21.65	50 test OP	✓ Accu-Chek Performa
	10.82	25 test OP	✓ FreeStyle Lite
	21.65	50 test OP	✓ Optium 5 second test
	26.20		✓ Optium 5 second test
			✓ SensoCard

Insulin Syringes and Needles

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.

INSULIN PEN NEEDLES – Maximum of 100 dev per prescription

* 29 g × 12.7 mm	10.50	100	✓ ABM
	3.15	30	✓ B-D Micro-Fine
	10.50	100	✓ B-D Micro-Fine
	11.75		✓ SC Profi-Fine
* 31 g × 5 mm	11.75	100	✓ B-D Micro-Fine
			✓ SC Profi-Fine
* 31 g × 6 mm	10.50	100	✓ ABM
	11.75		✓ Fine Ject
	10.50		
	(26.00)		NovoFine
* 31 g × 8 mm	10.50	100	✓ ABM
	3.15	30	✓ B-D Micro-Fine
	10.50	100	✓ B-D Micro-Fine
	11.75		✓ SC Profi-Fine
* 32 g × 4 mm	10.50	100	✓ B-D Micro-Fine

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription				
* Syringe 0.3 ml with 29 g × 12.7 mm needle	13.00	100	✓	ABM
	1.30	10	✓	DM Ject
	(1.99)			B-D Ultra Fine
	13.00	100	✓	B-D Ultra Fine
* Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	✓	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	✓	B-D Ultra Fine II
			✓	DM Ject
* Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	✓	ABM
	1.30	10	✓	DM Ject
	(1.99)			B-D Ultra Fine
	13.00	100	✓	B-D Ultra Fine
* Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	✓	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	✓	B-D Ultra Fine II
			✓	DM Ject
* Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	✓	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine
	13.00	100	✓	B-D Ultra Fine
			✓	DM Ject
* Syringe 1 ml with 31 g × 8 mm needle	13.00	100	✓	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	✓	B-D Ultra Fine II
			✓	DM Ject

Digestives Including Enzymes

PANCREATIC ENZYME

Tab EC 1,900 BP u lipase, 1,700 BP u amylase, 110 BP u protease	32.46	300	✓	Pancrex V
Tab EC 5,600 BP u lipase, 5,000 BP u amylase, 330 BP u protease	58.44	300	✓	Pancrex V Forte
Cap 8,000 BP u lipase, 9,000 BP u amylase, 430 BP u protease	67.26	300	✓	Pancrex V
Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease	85.00	250	✓	Cotazym ECS
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease	34.93	100	✓	Creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease	94.38	100	✓	Creon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease	94.40	100	✓	Panzytrat

(Cotazym ECS Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease to be delisted 1 May 2011)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
URSODEOXYCHOLIC ACID – Special Authority see SA1003 below – Retail pharmacy				
Cap 300 mg	179.00	100	✓	Actigall

SA1003 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient diagnosed with cholestasis of pregnancy; or
- 2 Both:
 - 2.1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
 - 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).

Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

MUCILAGINOUS LAXATIVES – Only on a prescription

* Dry	6.02	500 g OP	✓ Konsyl-D
	4.58	380 g OP	
	(6.69)		Mucilax
	5.42	450 g OP	
	(12.71)		Isogel
	6.02	500 g OP	
	(16.49)		Normacol
* Dry-original flavour, regular texture only	4.05	336 g OP	
	(12.38)		Metamucil
* Sugar Free	3.31	275 g OP	
	(10.60)		Mucilax

(Mucilax Dry to be delisted 1 February 2011)

(Isogel Dry to be delisted 1 February 2011)

(Normacol Dry to be delisted 1 February 2011)

(Metamucil Dry-original flavour, regular texture only to be delisted 1 February 2011)

MUCILAGINOUS LAXATIVES WITH STIMULANTS

* Dry	2.41	200 g OP	
	(7.69)		Normacol Plus
	6.02	500 g OP	
	(16.49)		Normacol Plus

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Cap 50 mg	3.95	100	✓ Laxofast 50
* Cap 120 mg	5.49	100	✓ Laxofast 120
* Enema conc 18%	5.40	100 ml OP	✓ Coloxyl

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DOCUSATE SODIUM WITH SENNOSIDES				
* Tab 50 mg with total sennosides 8 mg	6.38	200	✓	<u>Laxsol</u>
POLOXAMER – Only on a prescription				
* Oral drops 10%	3.78	30 ml OP	✓	<u>Coloxyl</u>
Osmotic Laxatives				
GLYCEROL				
* Suppos 3.6 g – Only on a prescription	6.00	20	✓	PSM
LACTULOSE – Only on a prescription				
* Oral liq 10 g per 15 ml	6.65	1,000 ml	✓	Duphalac
MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy				
Powder 13.125 g, sachets – Maximum of 60 sach per pre- scription	18.14	30	✓	Movicol
▶SA0891 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated.				
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.				
SODIUM ACID PHOSPHATE – Only on a prescription				
Enema 16% with sodium phosphate 8%	2.50	1	✓	Fleet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription				
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	25.00	50	✓	Micolette
	6.00	12		
	(7.30)			MicroLax
<i>(MicroLax Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml to be delisted 1 January 2011)</i>				
Stimulant Laxatives				
BISACODYL – Only on a prescription				
* Tab 5 mg	4.99	200	✓	<u>Lax-Tab</u>
* Suppos 5 mg	3.00	6	✓	<u>Dulcolax</u>
* Suppos 10 mg	3.00	6	✓	<u>Dulcolax</u>
DANTHRON WITH POLOXAMER – Only on a prescription				
Note: Only for the prevention or treatment of constipation in the terminally ill.				
Oral liq 25 mg with poloxamer 200 mg per 5 ml	9.50	300 ml	✓	Pinorax
Oral liq 75 mg with poloxamer 1 g per 5 ml	13.95	300 ml	✓	Pinorax Forte
SENNA – Only on a prescription				
* Tab, standardised	0.43	20		
	(1.72)			Senokot
	2.17	100		
	(6.16)			Senokot

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

Metabolic Disorder Agents

Gaucher's Disease

IMIGLUCERASE – Special Authority see SA0473 below – Retail pharmacy

Inj 40 iu per ml, 200 iu vial	1,072.00	1	✓	Cerezyme
Inj 40 iu per ml, 400 iu vial	2,144.00	1	✓	Cerezyme S29

▶SA0473 Special Authority for Subsidy

Special Authority approved by the Gaucher's Treatment Panel

Notes: Subject to a budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Gaucher's Treatment Panel	Phone: (04) 460 4990
PHARMAC, PO Box 10 254	Facsimile: (04) 916 7571
Wellington	Email: gaucherpanel@pharmac.govt.nz

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE				
Soln 0.15%	3.60	200 ml		
	(7.14)		Difflam	
	9.00	500 ml		
	(15.36)		Difflam	
CHLORHEXIDINE GLUCONATE				
Mouthwash 0.2%	3.87	200 ml OP	✓	Rivacol
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE				
* Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06	15 g OP		
	(5.62)			Bonjela
SODIUM CARBOXYMETHYLCELLULOSE				
With pectin and gelatin paste	17.20	56 g OP	✓	Stomahesive
	1.52	5 g OP		
	(3.60)			Orabase
	4.55	15 g OP		
	(7.90)			Orabase
With pectin and gelatin powder	8.48	28 g OP		
	(10.95)			Stomahesive
TRIAMCINOLONE ACETONIDE				
0.1% in Dental Paste USP	4.38	5 g OP	✓	Oracort

Oropharyngeal Anti-infectives

AMPHOTERICIN B				
Lozenges 10 mg	5.86	20	✓	Fungilin
MICONAZOLE				
Oral gel 20 mg per g	8.70	40 g OP	✓	Daktarin
NYSTATIN				
Oral liq 100,000 u per ml	3.19	24 ml OP	✓	Nilstat

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formula refer, page 176

HYDROGEN PEROXIDE

* Soln 10 vol – Maximum of 200 ml per prescription..... 1.28 100 ml ✓ PSM

THYMOL GLYCERIN

* Compound, BPC 9.15 500 ml ✓ PSM

Vitamins

Vitamin A

VITAMIN A WITH VITAMINS D AND C

Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg
per 10 drops 4.50 10 ml OP ✓ Vitadol C

Vitamin B

HYDROXOCOBALAMIN

* Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO 6.15 3 ✓ ABM
Hydroxocobalamin

PYRIDOXINE HYDROCHLORIDE

a) No more than 100 mg per dose

b) Only on a prescription

* Tab 25 mg – No patient co-payment payable 3.06 90 ✓ Healtheries

* Tab 50 mg 17.63 500 ✓ Apo-Pyridoxine

THIAMINE HYDROCHLORIDE – Only on a prescription

* Tab 50 mg 5.62 100 ✓ Apo-Thiamine

VITAMIN B COMPLEX

* Tab, strong, BPC 4.70 500 ✓ B-PlexADE
(12.10) Apo-B-Complex

(Apo-B-Complex Tab, strong, BPC to be delisted 1 February 2011)

Vitamin C

ASCORBIC ACID

a) No more than 100 mg per dose

b) Only on a prescription

* Tab 100 mg 13.80 500 ✓ Vitala-C
(17.25) Apo-Ascorbic Acid

(Apo-Ascorbic Acid Tab 100 mg to be delisted 1 January 2011)

Vitamin D

ALFACALCIDOL

Cap 0.25 µg 26.32 100 ✓ One-Alpha

Cap 1 µg 87.98 100 ✓ One-Alpha

Oral drops 2 µg per ml 60.68 20 ml OP ✓ One-Alpha

CALCITRIOL

* Cap 0.25 µg 3.03 30 ✓ Airflow

* Cap 0.5 µg 5.62 30 ✓ Airflow

* Oral liq 1 µg per ml 39.40 10 ml OP ✓ Rocaltrol solution

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CHOLECALCIFEROL				
* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription	7.76	12	✓	Cal-d-Forte

Vitamin E

ALPHA TOCOPHERYL ACETATE – Special Authority see SA0915 below – Retail pharmacy

Water solubilised soln 156 iu/ml, with calibrated dropper 18.30 50 ml OP ✓ **Micelle E***(Micelle E Water solubilised soln 156 iu/ml, with calibrated dropper to be delisted 1 June 2011)***▶SA0915 Special Authority for Subsidy****Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Cystic fibrosis patient; or
- 2 Both:
 - 2.1 Infant or child with liver disease or short gut syndrome; and
 - 2.2 Requires vitamin supplementation.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.**Multivitamin Preparations**

MULTIVITAMINS – Special Authority see SA1036 below – Retail pharmacy

Powder 72.00 200 g OP ✓ **Paediatric Seravit****▶SA1036 Special Authority for Subsidy****Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.

VITAMINS

* Tab (BPC cap strength)	8.00	1,000	✓	MultiADE
	14.80		✓	Healtheries
				Multi-vitamin
				tablets

* Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy	23.40	60	✓	Vitabdeck
---	-------	----	---	------------------

▶SA1002 Special Authority for Subsidy**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome.

Minerals**Calcium**

CALCIUM CARBONATE

* Tab eff 1.75 g (1 g elemental)	6.54	30	✓	Calsource
* Tab 1.25 g (500 mg elemental)	9.08	250	✓	Calci-Tab 500
* Tab 1.5 g (600 mg elemental)	10.18	250	✓	Calci-Tab 600

CALCIUM GLUCONATE

* Inj 10%, 10 ml	21.40	10	✓	Mayne
------------------------	-------	----	---	--------------

‡ safety cap

* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Fluoride				
SODIUM FLUORIDE				
Tab 1.1 mg (0.5 mg elemental)	4.00	100	✓	PSM
Iodine				
POTASSIUM IODATE				
Tab 268 µg (150 µg elemental)	7.55	90	✓	NeuroKare
Iron				
FERROUS FUMARATE				
Tab 200 mg (65 mg elemental)	4.35	100	✓	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID				
Tab 310 mg (100 mg elemental) with folic acid 350 µg	4.75	60	✓	Ferro-F-Tabs
FERROUS SULPHATE				
* Tab long-acting 325 mg (105 mg elemental)	1.01 (4.26) 5.06 (15.58)	30 150		Ferro-Gradumet
*‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	10.30	500 ml	✓	<u>Ferodan</u>
FERROUS SULPHATE WITH FOLIC ACID				
* Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg	1.80 (3.73)	30		Ferrograd-Folic
IRON POLYMALTOSE				
Inj 50 mg per ml, 2 ml	20.95	5	✓	<u>Ferrum H</u>
Magnesium				
For magnesium hydroxide mixture refer, page 176				
MAGNESIUM SULPHATE				
Inj 49.3%, 5 ml	26.60	10	✓	Mayne
Zinc				
ZINC SULPHATE				
* Cap 137.4 mg (50 mg elemental)	10.00	100	✓	<u>Zincaps</u>
Agents Used in the Treatment of Poisonings				
CHARCOAL				
* Tab 300 mg	7.13	100	✓	Red Seal
* Oral liq 50 g per 250 ml	43.50	250 ml OP	✓	Carbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				
IPECACUANHA				
* Tincture	41.20 (43.40)	500 ml		PSM

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	Calcium Disodium Versenate

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Antianaemics

Hypoplastic and Haemolytic

►SA0922 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Both:
 - 1.1 patient in chronic renal failure; and
 - 1.2 Haemoglobin ≤ 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 patient is not diabetic; and
 - 2.1.2 glomerular filtration rate ≤ 30ml/min; or
 - 2.2 Both:
 - 2.2.1 patient is diabetic; and
 - 2.2.2 glomerular filtration rate ≤ 45ml/min; or
 - 2.3 patient is on haemodialysis or peritoneal dialysis.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockcroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l)

GFR (ml/min) (female) = Estimated GFR (male) × 0.85

ERYTHROPOIETIN ALPHA – Special Authority see SA0922 above – Retail pharmacy

Inj human recombinant 1,000 iu prefilled syringe	48.68	6	✓ Eprex
Inj human recombinant 2,000 iu, prefilled syringe	120.18	6	✓ Eprex
Inj human recombinant 3,000 iu, prefilled syringe	166.87	6	✓ Eprex
Inj human recombinant 4,000 iu, prefilled syringe	193.13	6	✓ Eprex
Inj human recombinant 5,000 iu, prefilled syringe	243.26	6	✓ Eprex
Inj human recombinant 6,000 iu, prefilled syringe	291.92	6	✓ Eprex
Inj human recombinant 10,000 iu, prefilled syringe	395.18	6	✓ Eprex

ERYTHROPOIETIN BETA – Special Authority see SA0922 above – Retail pharmacy

Inj 2,000 iu, prefilled syringe	120.18	6	✓ NeoRecormon
Inj 3,000 iu, prefilled syringe	166.87	6	✓ NeoRecormon
Inj 4,000 iu, prefilled syringe	193.13	6	✓ NeoRecormon
Inj 5,000 iu, prefilled syringe	243.26	6	✓ NeoRecormon
Inj 6,000 iu, prefilled syringe	291.29	6	✓ NeoRecormon
Inj 10,000 iu, prefilled syringe	395.18	6	✓ NeoRecormon

Megaloblastic

FOLIC ACID

* Tab 0.8 mg	19.80	1,000	✓ Apo-Folic Acid
* Tab 5 mg	10.21	500	✓ Apo-Folic Acid
Oral liq 50 µg per ml	21.05	25 ml OP	✓ Biomed

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local Sclerosants				
SODIUM TETRADECYL SULPHATE				
* Inj 0.5% 2 ml	23.20 (45.52)	5		Fibro-vein
* Inj 1% 2 ml	25.00 (48.98)	5		Fibro-vein
* Inj 3% 2 ml	28.50 (55.91)	5		Fibro-vein
TRANEXAMIC ACID				
Tab 500 mg	32.92	100	✓	Cyklokapron
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO	8.00	5	✓	Konaktion MM
May be administered orally.				
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	✓	Konaktion MM
May be administered orally.				
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN				
* Tab 100 mg	14.00	990	✓	Ethics Aspirin EC
CLOPIDOGREL				
Tab 75 mg	5.06 16.25 5.06 (73.38)	28 90 28	✓ ✓	Arrow-Clopidogrel Apo-Clopidogrel
<i>(Arrow-Clopidogrel Tab 75 mg to be delisted 1 February 2011)</i>				
<i>(Plavix Tab 75 mg to be delisted 1 February 2011)</i>				
DIPYRIDAMOLE				
* Tab 25 mg	8.36	84	✓	Persantin
* Tab long-acting 150 mg	11.52	60	✓	Pytazen SR
Heparin and Antagonist Preparations				
ENOXAPARIN SODIUM – Special Authority see SA0975 on the next page – Retail pharmacy				
Inj 20 mg	39.20	10	✓	Clexane
Inj 40 mg	52.30	10	✓	Clexane
Inj 60 mg	78.85	10	✓	Clexane
Inj 80 mg	105.12	10	✓	Clexane
Inj 100 mg	135.20	10	✓	Clexane
Inj 120 mg	168.00	10	✓	Clexane
Inj 150 mg	192.00	10	✓	Clexane

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

SA0975 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing warfarin treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml	11.44	10	✓ Pfizer
	46.30	50	✓ Pfizer
	13.36	10	✓ Mayne
	66.80	50	✓ Mayne
Inj 1,000 iu per ml, 35 ml	16.00	1	✓ Mayne
Inj 5,000 iu per ml, 1 ml	14.20	5	✓ Mayne
Inj 5,000 iu per ml, 5 ml	118.50	50	✓ Pfizer
Inj 25,000 iu per ml, 0.2 ml	9.50	5	✓ Mayne

HEPARINISED SALINE

* Inj 10 iu per ml, 5 ml32.50 50 ✓ Pfizer

PROTAMINE SULPHATE

* Inj 10 mg per ml, 5 ml22.40 10
(86.54) Artex

Oral Anticoagulants

RIVAROXABAN – Special Authority see SA1066 on the next page – Retail pharmacy

Tab 10 mg	153.00	15	✓ Xarelto
	306.00	30	✓ Xarelto

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

* Tab 1 mg	3.46	50	✓ Coumadin
	5.69	100	✓ Marevan
* Tab 2 mg	4.31	50	✓ Coumadin
* Tab 3 mg	8.00	100	✓ Marevan
* Tab 5 mg	5.93	50	✓ Coumadin
	9.64	100	✓ Marevan

Fluids and Electrolytes

Intravenous Administration

DEXTROSE

* Inj 50%, 10 ml – Up to 5 inj available on a PSO	22.75	5	✓ Biomed
* Inj 50%, 90 ml – Up to 5 inj available on a PSO	11.25	1	✓ Biomed

POTASSIUM CHLORIDE

* Inj 75 mg per ml, 10 ml	26.00	50	✓ AstraZeneca
---------------------------	-------	----	---------------

SODIUM BICARBONATE

Inj 8.4%, 50ml	19.95	1	✓ Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			
Inj 8.4%, 100 ml	20.50	1	✓ Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			

SODIUM CHLORIDE

Inj 0.9% – Up to 2000 ml available on a PSO	3.06	500 ml	✓ Baxter
	4.06	1,000 ml	✓ Baxter

Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)

Inj 23.4%, 20 ml	31.25	5	✓ Biomed
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO	11.50	50	✓ AstraZeneca
	15.50		✓ Pfizer
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO	11.50	50	✓ AstraZeneca
	15.50		✓ Pfizer
Inj 0.9%, 20 ml	4.72	6	✓ Pharmacia
	11.79	30	✓ Pharmacia
	8.41	20	✓ Multichem

(AstraZeneca Inj 0.9%, 5 ml to be delisted 1 April 2011)

(AstraZeneca Inj 0.9%, 10 ml to be delisted 1 April 2011)

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Specialist				
Infusion	CBS	1 OP	✓	TPN
WATER				
1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye drops.				
Purified for inj, 5 ml – Up to 5 inj available on a PSO	9.20	50	✓	Multichem
	10.51		✓	AstraZeneca
Purified for inj, 10 ml – Up to 5 inj available on a PSO	10.20	50	✓	Multichem
	11.32		✓	AstraZeneca
Purified for inj, 20 ml – Up to 5 inj available on a PSO	5.00	20	✓	Multichem
<i>(AstraZeneca Purified for inj, 5 ml to be delisted 1 April 2011)</i>				
<i>(AstraZeneca Purified for inj, 10 ml to be delisted 1 April 2011)</i>				

Oral Administration

CALCIUM POLYSTYRENE SULPHONATE				
Powder	169.85	300 g OP	✓	Calcium Resonium
COMPOUND ELECTROLYTES				
Powder for soln for oral use 5 g – Up to 10 sach available on a PSO	2.86	10	✓	Enerlyte
DEXTRROSE WITH ELECTROLYTES				
Soln with electrolytes	6.60	1,000 ml OP	✓	Pedialyte - Bubblegum
	6.75		✓	Pedialyte - Fruit
			✓	Pedialyte - Plain
POTASSIUM BICARBONATE				
Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg	82.50	100	✓	Phosphate-Sandoz
For phosphate supplementation				
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26	60		Chlorvescent
	(11.85)			
* Tab long-acting 600 mg	7.00	200	✓	Span-K
SODIUM BICARBONATE				
Cap 840 mg	8.52	100	✓	Sodibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	89.10	450 g OP	✓	Resonium-A

Lipid Modifying Agents

Fibrates

BEZAFIBRATE				
* Tab 200 mg	9.75	90	✓	Fibalip
* Tab long-acting 400 mg	5.70	30	✓	Bezalip Retard
GEMFIBROZIL				
Tab 600 mg	14.00	60	✓	Lipazil

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Lipid Modifying Agents

ACIPIMOX				
* Cap 250 mg	18.75	30	✓	Olbetam
NICOTINIC ACID				
* Tab 50 mg	5.08	100	✓	Apo-Nicotinic Acid
* Tab 500 mg	17.60	100	✓	Apo-Nicotinic Acid

Resins

CHOLESTYRAMINE WITH ASPARTAME				
Sachets 4 g with aspartame	19.25 (52.68)	50		Questran-Lite
COLESTIPOL HYDROCHLORIDE				
Sachets 5 g	16.17	30	✓	Colestid

HMG CoA Reductase Inhibitors (Statins)

Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

ATORVASTATIN – See prescribing guideline above

* Tab 10 mg	18.32	30	✓	Lipitor
* Tab 20 mg	26.70	30	✓	Lipitor
* Tab 40 mg	37.02	30	✓	Lipitor
* Tab 80 mg	110.50	30	✓	Lipitor

PRAVASTATIN – Special Authority see SA0932 below – Retail pharmacy

See prescribing guideline above

Tab 10 mg	27.46	30	✓	Pravachol
Tab 20 mg	42.58	30	✓	Pravachol
Tab 40 mg	65.31	30	✓	Pravachol

SA0932 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater; and
- 2 Confirmed HIV infection; and
- 3 Patient is being treated with an HIV protease inhibitor.

SIMVASTATIN – See prescribing guideline above

* Tab 10 mg	2.05	90	✓	Arrow-Simva 10mg
* Tab 20 mg	3.00	90	✓	Arrow-Simva 20mg
* Tab 40 mg	5.35	90	✓	Arrow-Simva 40mg
* Tab 80 mg	11.65	90	✓	Arrow-Simva 80mg

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Special Authority see SA1045 on the next page – Retail pharmacy

Tab 10 mg	57.60	30	✓	Ezetrol
-----------------	-------	----	---	---------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

▶SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN – Special Authority see SA1046 below – Retail pharmacy

Tab 10 mg with simvastatin 10 mg	69.00	30	✓ Vytorin
Tab 10 mg with simvastatin 20 mg	75.00	30	✓ Vytorin
Tab 10 mg with simvastatin 40 mg	103.50	30	✓ Vytorin
Tab 10 mg with simvastatin 80 mg	123.00	30	✓ Vytorin

▶SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Iron Overload

DEFERIPRONE – Special Authority see SA1042 below – Retail pharmacy

Tab 500 mg	533.17	100	✓ Ferriprox
Oral liq 100 mg per 1 ml	266.59	250 ml OP	✓ Ferriprox

▶SA1042 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia.

Note: For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.

DESFERIOXAMINE MESYLATE

* Inj 500 mg	99.00	10	✓ Mayne
--------------------	-------	----	---------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Alpha Adrenoceptor Blockers				
DOXAZOSIN MESYLATE				
* Tab 2 mg	22.85	500	✓	Apo-Doxazosin
* Tab 4 mg	30.26	500	✓	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg	7.82	30	✓	Dibenyline S29
	26.05	100	✓	Dibenyline S29
PHENTOLAMINE MESYLATE				
* Inj 10 mg per ml, 1 ml	17.97	5		Regitine
	(31.65)			
PRAZOSIN HYDROCHLORIDE				
* Tab 1 mg	5.53	100	✓	Apo-Prazo
* Tab 2 mg	7.00	100	✓	Apo-Prazo
* Tab 5 mg	11.70	100	✓	Apo-Prazo
TERAZOSIN HYDROCHLORIDE				
* Tab 1 mg	1.50	28	✓	Arrow
	(2.50)			Apo-Terazosin
* Tab 7 × 1 mg and 7 × 2 mg	0.74	14 OP	✓	Hytrin Starter Pack
* Tab 2 mg	0.80	28	✓	Arrow
	14.29	500		
	(23.30)			Apo-Terazosin
* Tab 5 mg	1.00	28	✓	Arrow
	17.86	500		
	(29.00)			Apo-Terazosin

(Apo-Terazosin Tab 1 mg to be delisted 1 January 2011)

(Hytrin Starter Pack Tab 7 × 1 mg and 7 × 2 mg to be delisted 1 January 2011)

(Apo-Terazosin Tab 2 mg to be delisted 1 January 2011)

(Apo-Terazosin Tab 5 mg to be delisted 1 January 2011)

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Agents Affecting the Renin-Angiotensin System

Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". **Definition of Congestive Heart Failure** At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

ACE Inhibitors

CAPTOPRIL			
* Tab 12.5 mg	2.00	100	✓ m-Captopril
	10.40	500	✓ Apo-Captopril
* Tab 25 mg	2.40	100	✓ m-Captopril
	13.40	500	✓ Apo-Captopril
* Tab 50 mg	3.50	100	✓ m-Captopril
	19.00	500	✓ Apo-Captopril
*‡ Oral liq 5 mg per ml	94.99	95 ml OP	✓ Capoten
Oral liquid restricted to children under 12 years of age.			
CILAZAPRIL			
* Tab 0.5 mg	0.95	30	✓ Zapril
	(2.20)		Inhibace
* Tab 2.5 mg	2.06	30	✓ Zapril
	1.92	28	
	(4.10)		Inhibace
* Tab 5 mg	3.28	30	✓ Zapril
	3.06	28	
	(6.01)		Inhibace
<i>(Inhibace Tab 0.5 mg to be delisted 1 March 2011)</i>			
<i>(Inhibace Tab 2.5 mg to be delisted 1 March 2011)</i>			
<i>(Inhibace Tab 5 mg to be delisted 1 March 2011)</i>			
ENALAPRIL – Brand switch fee payable - see page 171 for details			
* Tab 5 mg	1.98	90	✓ Arrow-Enalapril
* Tab 10 mg	2.44	90	✓ Arrow-Enalapril
* Tab 20 mg	3.24	90	✓ Arrow-Enalapril
LISINOPRIL			
* Tab 5 mg	2.06	30	✓ Arrow-Lisinopril
* Tab 10 mg	2.36	30	✓ Arrow-Lisinopril
* Tab 20 mg	2.87	30	✓ Arrow-Lisinopril
PERINDOPRIL			
* Tab 2 mg – Higher subsidy of \$18.50 per 30 tab with En-			
dorsement.....	3.00	30	
	(18.50)		Coversyl
* Tab 4 mg – Higher subsidy of \$25.00 per 30 tab with En-			
dorsement.....	4.05	30	
	(25.00)		Coversyl

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
QUINAPRIL				
* Tab 5 mg	1.60	30	✓	Accupril
* Tab 10 mg	1.75	30	✓	Accupril
* Tab 20 mg	2.35	30	✓	Accupril
TRANDOLAPRIL				
* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with En- dorsement.....	3.06 (18.67)	28		Gopten
* Cap 2 mg – Higher subsidy of \$27.00 per 28 cap with En- dorsement.....	4.43 (27.00)	28		Gopten

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 12.5 mg	5.36	28	✓	Inhibace Plus
ENALAPRIL WITH HYDROCHLOROTHIAZIDE				
* Tab 20 mg with hydrochlorothiazide 12.5 mg	3.32 (8.70)	30		Co-Renitec
QUINAPRIL WITH HYDROCHLOROTHIAZIDE				
* Tab 10 mg with hydrochlorothiazide 12.5 mg	3.37	30	✓	Accuretic 10
* Tab 20 mg with hydrochlorothiazide 12.5 mg	4.57	30	✓	Accuretic 20

Angiotension II Antagonists

CANDESARTAN – Special Authority see SA0933 below – Retail pharmacy				
* Tab 4 mg – No more than 1.5 tab per day	16.22	30	✓	Atacand
* Tab 8 mg – No more than 1.5 tab per day	19.30	30	✓	Atacand
* Tab 16 mg – No more than 1 tab per day	23.54	30	✓	Atacand
* Tab 32 mg – No more than 1 tab per day	38.50	30	✓	Atacand

SA0933 | Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient with congestive heart failure; and
 - 1.2 Either:
 - 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or
 - 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or
- 2 All of the following:
 - 2.1 Patient with raised blood pressure; and
 - 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and
 - 2.3 Either:
 - 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or
 - 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LOSARTAN – Special Authority see SA0911 below – Retail pharmacy				
* Tab 12.5 mg	17.40	30	✓	Cozaar
* Tab 25 mg	21.76	30	✓	Cozaar
* Tab 50 mg	23.10	30	✓	Cozaar
Tab 50 mg with hydrochlorothiazide 12.5 mg	30.00	30	✓	Hyzaar
* Tab 100 mg	35.40	30	✓	Cozaar

►SA0911 Special Authority for Subsidy

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
- 2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

Initial application — (Patient had an approval for Losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 115

AMIODARONE HYDROCHLORIDE

▲ Tab 100 mg – Retail pharmacy-Specialist	18.65	30	✓	Aratac
▲ Tab 200 mg – Retail pharmacy-Specialist	30.52	30	✓	Cordarone-X
Inj 50 mg per ml, 3 ml – Up to 5 inj available on a PSO	60.84	10	✓	Aratac
			✓	Cordarone-X
			✓	Cordarone-X

DIGOXIN

* Tab 62.5 µg – Up to 30 tab available on a PSO	6.94	250	✓	Lanoxin PG
* Tab 250 µg – Up to 30 tab available on a PSO	15.13	250	✓	Lanoxin
*‡ Oral liq 50 µg per ml	16.60	60 ml	✓	Lanoxin

DISOPYRAMIDE PHOSPHATE

▲ Cap 100 mg	15.00	100		
	(23.87)			Rythmodan
▲ Cap 150 mg	26.21	100	✓	Rythmodan

FLECAINIDE ACETATE – Retail pharmacy-Specialist

▲ Tab 50 mg	45.82	60	✓	Tambacor
▲ Tab 100 mg	80.92	60	✓	Tambacor
▲ Cap long-acting 100 mg	45.82	30	✓	Tambacor CR
▲ Cap long-acting 200 mg	80.92	30	✓	Tambacor CR
Inj 10 mg per ml, 15 ml	52.45	5	✓	Tambacor

MEXILETINE HYDROCHLORIDE

▲ Cap 50 mg	23.52	100	✓	Mexitil
▲ Cap 200 mg	55.05	100	✓	Mexitil

PROPafenone Hydrochloride – Retail pharmacy-Specialist

▲ Tab 150 mg	40.90	50	✓	Rytmonorm
--------------------	-------	----	---	-----------

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Antihypotensives

MIDODRINE – Special Authority see SA0934 below – Retail pharmacy

Tab 2.5 mg	53.00	100	✓ Gutron
Tab 5 mg	79.00	100	✓ Gutron

SA0934 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Notes: Treatment should be started with small doses and titrated upwards as necessary.

Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta Adrenoceptor Blockers

ATENOLOL

* Tab 50 mg	6.18	500	✓ Pacific Atenolol
	12.36	1,000	✓ <u>Atenolol Tablet USP</u>
* Tab 100 mg	10.73	500	✓ Pacific Atenolol
	21.46	1,000	✓ <u>Atenolol Tablet USP</u>

CARVEDILOL

Tab 6.25 mg	21.00	30	✓ Dilatrend
Tab 12.5 mg	27.00	30	✓ Dilatrend
Tab 25 mg	33.75	30	✓ Dilatrend

CELIPROLOL

* Tab 200 mg	19.00	180	✓ Celol
--------------------	-------	-----	---------

LABETALOL

* Tab 50 mg	8.23	100	✓ Hybloc
* Tab 100 mg	10.06	100	✓ Hybloc
* Tab 200 mg	17.55	100	✓ Hybloc
* Tab 400 mg	34.44	100	✓ Hybloc
* Inj 5 mg per ml, 20 ml	59.06	5	
	(88.60)		Trandate

(Hybloc Tab 400 mg to be delisted 1 June 2011)

METOPROLOL SUCCINATE

* Tab long-acting 23.75 mg	2.18	30	✓ Betaloc CR
			✓ Metoprolol - AFT CR
* Tab long-acting 47.5 mg	2.74	30	✓ Betaloc CR
			✓ Metoprolol - AFT CR
* Tab long-acting 95 mg	4.71	30	✓ Betaloc CR
			✓ Metoprolol - AFT CR
* Tab long-acting 190 mg	8.51	30	✓ Betaloc CR
			✓ Metoprolol - AFT CR

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METOPROLOL TARTRATE				
* Tab 50 mg	16.50	100	✓	Lopresor
* Tab 100 mg	21.80	60	✓	Lopresor
* Tab long-acting 200 mg	18.40	28	✓	Slow-Lopresor
* Inj 1 mg per ml 5 ml	24.08	5		
	(34.00)			Betaloc

NADOLOL				
* Tab 40 mg	14.97	100	✓	Apo-Nadolol
* Tab 80 mg	22.19	100	✓	Apo-Nadolol

PINDOLOL				
* Tab 5 mg	5.40	100	✓	Apo-Pindolol
* Tab 10 mg	9.19	100	✓	Apo-Pindolol
* Tab 15 mg	13.80	100	✓	Apo-Pindolol

PROPRANOLOL				
* Tab 10 mg	3.55	100	✓	Cardinol
* Tab 40 mg	4.65	100	✓	Cardinol
* Cap long-acting 160 mg	16.06	100	✓	Cardinol LA

SOTALOL				
* Tab 80 mg	27.50	500	✓	Mylan
* Tab 160 mg	10.50	100	✓	Mylan
* Inj 10 mg per ml, 4 ml	41.34	5	✓	Sotacor

TIMOLOL MALEATE				
* Tab 10 mg	10.55	100	✓	Apo-Timol

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers (DHP CCBs)

AMLODIPINE				
* Tab 5 mg	7.33	100	✓	Apo-Amlodipine
* Tab 10 mg	11.79	100	✓	Apo-Amlodipine

FELODIPINE				
* Tab long-acting 2.5 mg – No more than 1 tab per day	10.38	30	✓	Plendil ER
* Tab long-acting 5 mg	10.73	90	✓	Felo 5 ER
* Tab long-acting 10 mg	15.60	90	✓	Felo 10 ER

ISRADIPINE				
Cap long-acting 2.5 mg	7.50	30	✓	Dynacirc-SRO
Cap long-acting 5 mg	7.85	30	✓	Dynacirc-SRO

NIFEDIPINE				
* Tab long-acting 10 mg	17.72	60	✓	Adalat 10
* Tab long-acting 20 mg	7.30	100	✓	Nyefax Retard
* Tab long-acting 30 mg	8.56	30	✓	Adefin XL
	10.70		✓	Arrow-Nifedipine XR
	5.50			
	(19.90)			Adalat Oros
* Tab long-acting 60 mg	12.28	30	✓	Adefin XL
	15.35		✓	Arrow-Nifedipine XR
	8.00			
	(29.50)			Adalat Oros

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE

* Tab 30 mg	4.60	100	✓	<u>Dilzem</u>
* Tab 60 mg	8.50	100	✓	<u>Dilzem</u>
* Cap long-acting 120 mg	4.34	30	✓	<u>Cardizem CD</u>
* Cap long-acting 180 mg	6.50	30	✓	<u>Cardizem CD</u>
* Cap long-acting 240 mg	8.67	30	✓	<u>Cardizem CD</u>

PERHEXILINE MALEATE – Special Authority see SA0256 below – Retail pharmacy

* Tab 100 mg	62.90	100	✓	<u>Pexsig</u>
--------------	-------	-----	---	---------------

▶SA0256 Special Authority for Subsidy

Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Refractory angina; and
- 2 Patient is already on maximal anti-anginal therapy.

Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

VERAPAMIL HYDROCHLORIDE

* Tab 40 mg	7.01	100	✓	<u>Isoptin</u>
* Tab 80 mg	11.74	100	✓	<u>Isoptin</u>
* Tab long-acting 120 mg	15.20	250	✓	<u>Verpamil SR</u>
* Tab long-acting 240 mg	25.00	250	✓	<u>Verpamil SR</u>
* Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO	7.54	5	✓	<u>Isoptin</u>

Centrally Acting Agents

CLONIDINE

* TDDS 2.5 mg, 100 µg per day – Only on a prescription	23.30	4	✓	<u>Catapres-TTS-1</u>
* TDDS 5 mg, 200 µg per day – Only on a prescription	32.80	4	✓	<u>Catapres-TTS-2</u>
* TDDS 7.5 mg, 300 µg per day – Only on a prescription	41.20	4	✓	<u>Catapres-TTS-3</u>

CLONIDINE HYDROCHLORIDE

* Tab 150 µg	33.00	100	✓	<u>Catapres</u>
* Inj 150 µg per ml, 1 ml	15.45	5	✓	<u>Catapres</u>

METHYLDOPA

* Tab 125 mg	12.00	100	✓	<u>Prodopa</u>
* Tab 250 mg	13.10	100	✓	<u>Prodopa</u>
* Tab 500 mg	20.85	100	✓	<u>Prodopa</u>

Diuretics

Loop Diuretics

BUMETANIDE

* Tab 1 mg	16.36	100	✓	<u>Burinex</u>
* Inj 500 µg per ml, 4 ml	7.95	5	✓	<u>Burinex</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FUROSEMIDE				
* Tab 40 mg – Up to 30 tab available on a PSO.....	10.75	1,000	✓	Diurin 40
* Tab 500 mg	25.00	50	✓	Urex Forte
*† Oral liq 10 mg per ml	10.66	30 ml OP	✓	Lasix
* Infusion 10 mg per ml, 25 ml	48.14	5	✓	Lasix
* Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO	1.30	5	✓	Frusemide-Clarix
	13.00	50		
	(29.50)			Mayne

(Mayne Inj 10 mg per ml, 2 ml to be delisted 1 February 2011)

Potassium Sparing Diuretics

AMILORIDE				
† Oral liq 1 mg per ml	26.20	25 ml OP	✓	Biomed
SPIRONOLACTONE				
* Tab 25 mg	4.60	100	✓	Spirotone
* Tab 100 mg	15.15	100	✓	Spirotone
† Oral liq 5 mg per ml	26.80	25 ml OP	✓	Biomed

Potassium Sparing Combination Diuretics

AMILORIDE WITH FRUSEMIDE				
* Tab 5 mg with frusemide 40 mg	8.63	28	✓	Frumil
AMILORIDE WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	✓	Moduretic
	13.00	500	✓	Amizide

(Amizide Tab 5 mg with hydrochlorothiazide 50 mg to be delisted 1 April 2011)

Thiazide and Related Diuretics

BENDROFLUAZIDE				
* Tab 2.5 mg – Up to 150 tab available on a PSO.....	7.58	500	✓	Arrow- Bendrofluzide
May be supplied on a PSO for reasons other than emergency.				
* Tab 5 mg	11.75	500	✓	Arrow- Bendrofluzide
CHLOROTHIAZIDE				
† Oral liq 50 mg per ml	22.60	25 ml OP	✓	Biomed
CHLORTHALIDONE				
* Tab 25 mg	8.00	50	✓	Hygroton
INDAPAMIDE				
* Tab 2.5 mg	2.95	90	✓	Dapa-Tabs
	3.25	100	✓	Napamide

(Napamide Tab 2.5 mg to be delisted 1 January 2011)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Nitrates				
GLYCERYL TRINITRATE				
* Tab 600 µg – Up to 100 tab available on a PSO.....	8.00	100 OP	✓	<u>Lycinate</u>
* Oral pump spray 400 µg per dose – Up to 250 dose available on a PSO.....	5.16	250 dose OP	✓	<u>Nitrolingual Pumpspray</u>
* TDDS 5 mg	16.56	30	✓	<u>Nitroderm TTS</u>
* TDDS 10 mg	19.60	30	✓	<u>Nitroderm TTS</u>
ISOSORBIDE MONONITRATE				
* Tab 20 mg	18.00	100	✓	<u>Ismo 20</u>
* Tab long-acting 40 mg	14.84	30	✓	<u>Corangin</u>
* Tab long-acting 60 mg	3.94	90	✓	<u>Duride</u>
Sympathomimetics				
ADRENALINE				
Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO	4.98	5	✓	<u>Aspen Adrenaline</u>
	5.25		✓	<u>Mayne</u>
Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO	27.00	5	✓	<u>Mayne</u>
ISOPRENALINE HYDROCHLORIDE				
* Inj 200 µg per ml, 1 ml	36.80	25		Isuprel
	(135.00)			
Vasodilators				
AMYL NITRITE				
* Ampoule, 0.3 ml crushable	62.92	12		Baxter
	(73.40)			
HYDRALAZINE				
* Inj 20 mg per ml, 1 ml	25.90	5	✓	<u>Apresoline</u>
OXYPENTIFYLLINE				
Tab 400 mg	36.94	50		Trental 400
	(42.26)			
PAPAVERINE HYDROCHLORIDE				
* Inj 12 mg per ml, 10 ml	73.12	5	✓	<u>Mayne</u>
Endothelin Receptor Antagonists				
▶SA0967 Special Authority for Subsidy				
Special Authority approved by the Pulmonary Arterial Hypertension Panel				
Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:				
The Coordinator, PAH Panel				
PHARMAC, PO Box 10-254, WELLINGTON				
Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz				
AMBRISENTAN – Special Authority see SA0967 above – Retail pharmacy				
Tab 5 mg	4,585.00	30	✓	<u>Volibris</u>
Tab 10 mg	4,585.00	30	✓	<u>Volibris</u>
BOSENTAN – Special Authority see SA0967 above – Retail pharmacy				
Tab 62.5 mg	4,585.00	60	✓	<u>Tracleer</u>
Tab 125 mg	4,585.00	60	✓	<u>Tracleer</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Phosphodiesterase Type 5 Inhibitors

▶SA0968 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

SILDENAFIL – Special Authority see SA0968 above – Retail pharmacy

Tab 25 mg	52.00	4	✓ Viagra
Tab 50 mg	59.50	4	✓ Viagra
Tab 100 mg	68.00	4	✓ Viagra

Prostacyclin Analogues

▶SA0969 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

ILOPROST – Special Authority see SA0969 above – Retail pharmacy

Nebuliser soln 10 µg per ml, 2 ml	1,185.00	30	✓ Ventavis
---	----------	----	------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 82

ADAPALENE

a) Maximum of 30 g per prescription			
b) Only on a prescription			
Crn 0.1%	22.89	30 g OP	✓ Differin
Gel 0.1%	22.89	30 g OP	✓ Differin

ISOTRETINOIN – Special Authority see SA0955 below – Retail pharmacy

Cap 10 mg	48.48	180	✓ Oratane
Cap 20 mg	69.70	180	✓ Oratane

▶SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crn 0.5 mg per g – Maximum of 50 g per prescription	13.90	50 g OP	✓ ReTrieve
---	-------	---------	------------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antibacterials Topical				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 82				
FUSIDIC ACID				
Crm 2%	3.25	15 g OP	✓	Foban
a) Maximum of 15 g per prescription				
b) Only on a prescription				
c) Not in combination				
Oint 2%	3.25	15 g OP	✓	Foban
a) Maximum of 15 g per prescription				
b) Only on a prescription				
c) Not in combination				
HYDROGEN PEROXIDE				
* Crm 1%	8.56	10 g OP	✓	Crystacide
MUPIROCIN				
Oint 2%	6.60 (9.26)	15 g OP		Bactroban
a) Only on a prescription				
b) Not in combination				
SILVER SULPHADIAZINE				
Crm 1%	12.30	50 g OP	✓	Flamazine
a) Up to 250 g available on a PSO				
b) Not in combination				

Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, page 87

AMOROLFINE				
a) Only on a prescription				
b) Not in combination				
Nail soln 5%	37.86 (61.87)	5 ml OP		Loceryl
CICLOPIROXOLAMINE				
a) Only on a prescription				
b) Not in combination				
Crm 1%	1.00 (12.82)	20 g OP		Batrafen
Nail soln 8%	19.85	3.5 ml OP	✓	Batrafen
Soln 1%	4.36 (11.54)	20 ml OP		Batrafen
<i>(Batrafen Crm 1% to be delisted 1 January 2011)</i>				
CLOTRIMAZOLE				
* Crm 1%	0.50	20 g OP	✓	Clomazol
a) Only on a prescription				
b) Not in combination				
* Soln 1%	4.36 (7.55)	20 ml OP		Canesten
a) Only on a prescription				
b) Not in combination				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ECONAZOLE NITRATE				
Crm 1%	1.00 (7.48)	20 g OP		Pevaryl
a) Only on a prescription				
b) Not in combination				
Foaming soln 1%, 10 ml sachets	9.89 (17.23)	3		Pevaryl
a) Only on a prescription				
b) Not in combination				
MICONAZOLE NITRATE				
* Crm 2%	0.42	15 g OP	✓	<u>Multichem</u>
a) Only on a prescription				
b) Not in combination				
* Lotn 2%	4.36 (10.03)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
* Tinct 2%	4.36 (12.10)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
NYSTATIN				
Crm 100,000 u per g	1.00 (7.90)	15 g OP		Mycostatin
a) Only on a prescription				
b) Not in combination				

Antipruritic Preparations

CALAMINE				
a) Only on a prescription				
b) Not in combination				
Crm, aqueous, BP	2.78	100 g	✓	<u>healthE</u>
Lotn, BP	16.70	2,000 ml	✓	<u>API</u>
CROTAMITON				
a) Only on a prescription				
b) Not in combination				
Crm 10%	3.79	20 g OP	✓	<u>Itch-Soothe</u>
MENTHOL – Only in combination				
Only in combination with aqueous cream, 10% urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion				
Crystals	6.50 6.92 29.60	25 g 100 g	✓ ✓ ✓	<u>PSM</u> <u>MidWest</u> <u>MidWest</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

DERMATOLOGICALS

Subsidy
(Manufacturer's Price)
\$ Per Fully
Subsidised ✓ Brand or
Generic
Manufacturer

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 75

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE

Crm 0.05%	2.96 (6.91)	15 g OP	Diprosone
	8.97 (18.36)	50 g OP	Diprosone
Crm 0.05% in propylene glycol base	4.33 (13.83)	30 g OP	Diprosone OV
Oint 0.05%	2.96 (6.51)	15 g OP	Diprosone
	8.97 (17.11)	50 g OP	Diprosone
Oint 0.05% in propylene glycol base	4.33 (13.83)	30 g OP	Diprosone OV

BETAMETHASONE VALERATE

* Crm 0.1%	2.00	50 g OP	✓ Beta Cream
* Oint 0.1%	2.20	50 g OP	✓ Beta Ointment
* Lotn 0.1%	10.05	50 ml OP	✓ Betnovate

CLOBETASOL PROPIONATE

* Crm 0.05%	3.48	30 g OP	✓ Dermol
* Oint 0.05%	3.48	30 g OP	✓ Dermol

CLOBETASONE BUTYRATE

Crm 0.05%	5.38 (7.09)	30 g OP	Eumovate
	16.13 (22.00)	100 g OP	Eumovate

DIFLUCORTOLONE VALERATE

Crm 0.1%	8.97 (15.86)	50 g OP	Nerisone
Fatty oint 0.1%	8.97 (15.86)	50 g OP	Nerisone

HYDROCORTISONE

* Crm 1% – Only on a prescription	3.75	100 g	✓ Pharmacy Health
	12.20	500 g	✓ PSM
* Powder – Only in combination	33.00	25 g	✓ ABM

Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals. Refer, page 172

HYDROCORTISONE BUTYRATE

Lipocream 0.1%	2.30	30 g OP	✓ Locoid Lipocream
	6.85	100 g OP	✓ Locoid Lipocream
Oint 0.1%	6.85	100 g OP	✓ Locoid
Milky emul 0.1%	6.85	100 ml OP	✓ Locoid Crelo

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL				
Lotn 1% with wool fat hydrous 3% and mineral oil – Only on a prescription.....	9.95	250 ml	✓	<u>DP Lotn HC</u>
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1%	4.95	15 g OP	✓	<u>Advantan</u>
Oint 0.1%	4.95	15 g OP	✓	<u>Advantan</u>
MOMETASONE FUROATE				
Crm 0.1%	2.38	15 g OP	✓	<u>m-Mometasone</u>
	4.55	45 g OP	✓	<u>m-Mometasone</u>
Oint 0.1%	2.38	15 g OP	✓	<u>m-Mometasone</u>
	4.55	45 g OP	✓	<u>m-Mometasone</u>
Lotn 0.1%	4.80	30 ml OP	✓	<u>Elocon</u>
TRIAMCINOLONE ACETONIDE				
Crm 0.02%	6.63	100 g OP	✓	<u>Aristocort</u>
Oint 0.02%	6.69	100 g OP	✓	<u>Aristocort</u>

Corticosteroids - Combination

BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a prescription				
Crm 0.1% with clioquinol 3%	3.49	15 g OP		
	(4.90)			Betnovate-C
Oint 0.1% with clioquinol 3%	3.49	15 g OP		
	(4.90)			Betnovate-C
BETAMETHASONE VALERATE WITH FUSIDIC ACID				
Crm 0.1% with fusidic acid 2%	3.49	15 g OP		
	(9.61)			Fucicort
a) Maximum of 15 g per prescription				
b) Only on a prescription				
HYDROCORTISONE BUTYRATE WITH CHLORQUINALDOL – Only on a prescription				
Crm 0.1% with chlorquinaldol 3%	3.49	15 g OP	✓	<u>Locoid C</u>
<i>(Locoid C Crm 0.1% with chlorquinaldol 3% to be delisted 1 March 2011)</i>				
HYDROCORTISONE WITH MICONAZOLE – Only on a prescription				
* Crm 1% with miconazole nitrate 2%	2.10	15 g OP	✓	<u>Micreme H</u>
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription				
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g OP	✓	<u>Pimafucort</u>
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g OP	✓	<u>Pimafucort</u>
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN				
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription	3.49	15 g OP		
	(6.60)			Viaderm KC

Disinfecting and Cleansing Agents

CHLORHEXIDINE GLUCONATE – Subsidy by endorsement				
a) No more than 500 ml per month				
b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.				
* Handrub 1% with ethanol 70%	4.60	500 ml	✓	<u>healthE</u>
* Soln 4%	7.20	500 ml	✓	<u>Orión</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

SODIUM HYPOCHLORITE – Subsidy by endorsement

Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.

* Soln	2.71	2,500 ml	✓	Janola
--------------	------	----------	---	--------

(Janola Soln to be delisted 1 January 2011)

TRICLOSAN – Subsidy by endorsement

a) Maximum of 500 ml per prescription

b)

a) Only if prescribed for a patient identified with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or

b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly

Soln 1%	5.90	500 ml OP	✓	healthE
---------------	------	-----------	---	---------

Dusting Powders

DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement

Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly.

Powder 2%	6.81	50 g OP		Prantal
	(13.54)			

(Prantal Powder 2% to be delisted 1 January 2011)

Barrier Creams and Emollients

Barrier Creams

ZINC

Crm BP	6.55	500 g		PSM
	(12.00)			

(PSM Crm BP to be delisted 1 January 2011)

ZINC AND CASTOR OIL

Oint BP	5.11	500 g	✓	PSM
---------------	------	-------	---	-----

Emollients

AQUEOUS CREAM

* Crm	2.28	500 g	✓	AFT
-------------	------	-------	---	-----

CETOMACROGOL

* Crm BP	3.15	500 g	✓	PSM
----------------	------	-------	---	-----

EMULSIFYING OINTMENT

* Oint BP	3.69	500 g	✓	AFT
-----------------	------	-------	---	-----

GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription

* Lotn 5% with paraffin liq 5% and cetyl alcohol 2%	1.40	250 ml		QV
	(8.10)			

(QV Lotn 5% with paraffin liq 5% and cetyl alcohol 2% to be delisted 1 January 2011)

OIL IN WATER EMULSION

* Crm	2.80	500 g	✓	healthE Fatty Cream
-------------	------	-------	---	---------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OILY CREAM				
* Crm BP	2.80	500 g		
	(13.60)			David Craig
	(15.40)			PSM
<i>(David Craig Crm BP to be delisted 1 January 2011)</i>				
<i>(PSM Crm BP to be delisted 1 January 2011)</i>				
UREA				
* Crm 10%	3.07	100 g OP	✓	Nutraplus
WOOL FAT WITH MINERAL OIL – Only on a prescription				
* Lotn hydrous 3% with mineral oil	1.40	250 ml OP		
	(3.50)			DP Lotion
	5.60	1,000 ml		
	(10.90)			DP Lotion
	1.40	250 ml OP		
	(3.50)			Hydroderm Lotion
	5.60	1,000 ml		
	(9.54)			Hydroderm Lotion
	(20.53)			Alpha-Keri Lotion
	1.40	250 ml OP		
	(7.73)			BK Lotion
	5.60	1,000 ml		
	(23.91)			BK Lotion

Other Dermatological Bases

PARAFFIN				
White soft – Only in combination	3.58	500 g		
	(7.78)			IPW
	20.20	2,500 g	✓	IPW
	3.58	500 g		
	(8.69)			PSM

Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Minor Skin Infections				
POVIDONE IODINE				
Oint 10%	3.27	25 g OP	✓	Betadine
a) Maximum of 100 g per prescription				
b) Only on a prescription				
Antiseptic soln 10%	0.19	15 ml		Betadine
	(3.27)			
	1.28	100 ml		Betadine
	(6.01)			
	6.20	500 ml	✓	Betadine
	51.06	4,500 ml	✓	Betadine
	1.28	100 ml		
	(4.20)			Riodine
	6.20	500 ml	✓	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol	1.63	100 ml		Betadine Skin Prep
	(3.60)			
	10.00	500 ml	✓	Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol	1.63	100 ml		Orion
	(6.04)			
	8.13	500 ml		Orion
	(18.63)			

Parasiticial Preparations

GAMMA BENZENE HEXACHLORIDE				
Crn 1%	3.50	50 g OP	✓	Benhex
MALATHION				
Liq 0.5%	3.79	200 ml OP	✓	A-Lices
	(4.99)			Derbac-M
Shampoo 1%	2.83	30 ml OP	✓	A-Lices
<i>(Derbac-M Liq 0.5% to be delisted 1 January 2011)</i>				
PERMETHRIN				
Lotn 5%	3.65	30 ml OP	✓	A-Scabies

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see SA0954 below – Retail pharmacy				
Cap 10 mg	75.80	100	✓	Neotigason
Cap 25 mg	162.96	100	✓	Neotigason

►SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:

- 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement

continued. . .

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or				
3.2 Patient is male.				
Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:				
All of the following:				
1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and				
2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and				
3 Either:				
3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or				
3.2 Patient is male.				
CALCIPOTRIOL				
Crm 50 µg per g	20.20	30 g OP	✓	Daivonex
	56.32	100 g OP	✓	Daivonex
Oint 50 µg per g	20.20	30 g OP	✓	Daivonex
	56.32	100 g OP	✓	Daivonex
Soln 50 µg per ml	20.22	30 ml OP	✓	Daivonex
	33.79	60 ml OP	✓	Daivonex
COAL TAR				
Soln BP – Only in combination	12.95	200 ml	✓	Midwest
Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 172				
With or without other dermatological galenicals.				
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR				
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%	3.43	30 g OP		
	(4.35)			Egopsoryl TA
	6.59	75 g OP		
	(8.00)			Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR				
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	✓	Coco-Scalp
SALICYLIC ACID				
Powder – Only in combination	15.00	500 g	✓	ABM
	18.88	250 g	✓	PSM
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible, refer, page 172				
2) With or without other dermatological galenicals.				
3) Maximum 20 g or 20 ml per prescription when prescribed with white soft paraffin or collodion flexible.				
SULPHUR				
Precipitated – Only in combination	6.35	100 g	✓	Midwest
	6.50		✓	ABM
	(9.25)			PSM
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 172				
2) With or without other dermatological galenicals.				

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TAR WITH CADE OIL				
Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound	9.70	350 ml		
	(29.60)			Polytar Emollient
<i>(Polytar Emollient Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound to be delisted 1 January 2011)</i>				
TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN – Only on a prescription				
* Soln 2.3% with triethanolamine lauryl sulphate and fluo- cein sodium	2.90	500 ml	✓	<u>Pinetarsol</u>
	5.54	1,000 ml	✓	<u>Pinetarsol</u>

Scalp Preparations

BETAMETHASONE VALERATE				
* Scalp app 0.1%	7.22	100 ml OP	✓	<u>Beta Scalp</u>
CLOBETASOL PROPIONATE				
* Scalp app 0.05%	6.36	30 ml OP	✓	<u>Dermol</u>
HYDROCORTISONE BUTYRATE				
Scalp lotn 0.1%	3.65	100 ml OP	✓	<u>Locoid</u>
KETOCONAZOLE				
Shampoo 2%	3.48	100 ml OP	✓	<u>Sebizole</u>
a) Maximum of 100 ml per prescription				
b) Only on a prescription				

Sunscreens

SUNSCREENS, PROPRIETARY – Subsidy by endorsement

Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.

Crm	2.55	100 g OP		
	(5.89)			Hamilton Sunscreen
	1.28	50 g OP		
	(5.50)			Aquasun Oil Free Faces SPF30+
Lotn	2.55	100 ml OP	✓	<u>Marine Blue Lotion SPF 30+</u>
	5.10	200 ml OP	✓	<u>Marine Blue Lotion SPF 30+</u>
	3.19	125 ml OP		
	(6.94)			Aquasun 30+

Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 64

IMIQUIMOD – Special Authority see SA0923 on the next page – Retail pharmacy

Crm 5%	110.40	12	✓	<u>Aldara</u>
--------------	--------	----	---	---------------

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

►SA0923 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
Any of the following:

- 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
- 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
- 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

Notes: Superficial basal cell carcinoma

- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.

External anogenital warts

- Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Inadequate response to initial treatment for anogenital warts; or
- 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or
- 3 Inadequate response to initial treatment for superficial basal cell carcinoma.

Note: Every effort should be made to biopsy the lesion to confirm that it is a superficial basal cell carcinoma.

PODOPHYLLOTOXIN

Soln 0.5%	33.60	3.5 ml OP	✓ Condyline
a) Maximum of 3.5 ml per prescription			
b) Only on a prescription			

Other Skin Preparations

Antineoplastics

FLUOROURACIL SODIUM

Crm 5%	26.49	20 g OP	✓ Efudix
--------------	-------	---------	-----------------

Topical Analgesia

For aspirin & chloroform application refer, page 176

CAPSAICIN – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075%	12.50	45 g OP	✓ Zostrix HP
------------------	-------	---------	---------------------

Wound Management Products

HYDROGEN PEROXIDE

* Soln 20 vol – Maximum of 500 ml per prescription.....	0.63	100 ml	
	(2.35)		PSM
	3.13	500 ml	
	(7.00)		PSM

(PSM Soln 20 vol to be delisted 1 January 2011)

MAGNESIUM SULPHATE

Paste	2.98	80 g	
	(4.90)		PSM

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Contraceptives - Non-hormonal				
Condoms				
CONDOMS				
* 49 mm – Up to 144 dev available on a PSO.....	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
			✓	MarquisTantiliza
			✓	Shield 49
* 52 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Marquis Selecta
			✓	Marquis Sensolite
			✓	Marquis Supalite
* 52 mm extra strength – Up to 144 dev available on a PSO.....	13.36	144	✓	Marquis Protecta
* 53 mm – Up to 144 dev available on a PSO.....	1.11	12	✓	Shield Blue
	13.36	144	✓	Shield Blue
	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
			✓	Marquis Black
			✓	Marquis Titillata
* 53 mm (chocolate) – Up to 144 dev available on a PSO.....	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
* 53 mm (strawberry) – Up to 144 dev available on a PSO.....	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
* 53 mm extra strength – Up to 144 dev available on a PSO.....	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
* 54 mm, shaped – Up to 144 dev available on a PSO.....	1.12	12		
	(1.24)			Lifestyles Flared
	13.36	144		
	(14.84)			Lifestyles Flared
* 55 mm – Up to 144 dev available on a PSO.....	1.11	12	✓	Gold Knight
	13.36	144	✓	Gold Knight
			✓	Marquis Conformata
* 56 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Durex Select
				Flavours
* 56 mm extra strength – Up to 144 dev available on a PSO.....	13.36	144	✓	Durex Extra Safe
* 56 mm, shaped – Up to 144 dev available on a PSO.....	1.11	12	✓	Durex Confidence
	13.36	144	✓	Durex Confidence
* 60 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Shield XL
Spermicidal Agents				
APPLICATOR				
When ordered with a spermicide.				
* Applicator – Up to 1 dev available on a PSO.....	4.34	1	✓	Ortho
<i>(Ortho Applicator to be delisted 1 January 2011)</i>				
NONOXYNOL-9				
Jelly 2% – Up to 108 g available on a PSO.....	10.95	108 g OP	✓	Gynol II
<i>(Gynol II Jelly 2% to be delisted 1 January 2011)</i>				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Contraceptive Devices				
DIAPHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO.				
* 55 mm	42.90	1	✓	Ortho Coil
* 60 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 65 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 70 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 75 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 80 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 85 mm	42.90	1	✓	Ortho All-flex Ortho Coil
* 90 mm	42.90	1	✓	Ortho All-flex Ortho Coil
<i>(Ortho Coil 55 mm to be delisted 1 January 2011)</i>				
<i>(Ortho All-flex 60 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 60 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 65 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 70 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 75 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 80 mm to be delisted 1 January 2011)</i>				
<i>(Ortho All-flex 85 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 85 mm to be delisted 1 January 2011)</i>				
<i>(Ortho All-flex 90 mm to be delisted 1 January 2011)</i>				
<i>(Ortho Coil 90 mm to be delisted 1 January 2011)</i>				
INTRA-UTERINE DEVICE				
a) Up to 40 dev available on a PSO				
b) Only on a PSO				
* IUD	39.50	1	✓	Multiload Cu 375 Multiload Cu 375 SL

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

GENITO-URINARY SYSTEM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLLOESTRADIOL WITH DESOGESTREL

* Tab 20 µg with desogestrel 150 µg	6.62	63	
	(16.50)		Mercilon 21
a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA0500 on the preceding page			
b) Up to 63 tab available on a PSO			
* Tab 20 µg with desogestrel 150 µg and 7 inert tab	6.62	84	
	(16.50)		Mercilon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 on the preceding page			
b) Up to 84 tab available on a PSO			
* Tab 30 µg with desogestrel 150 µg	6.62	63	
	(16.50)		Marvelon 21
a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA0500 on the preceding page			
b) Up to 63 tab available on a PSO			
* Tab 30 µg with desogestrel 150 µg and 7 inert tab	6.62	84	
	(16.50)		Marvelon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 on the preceding page			
b) Up to 84 tab available on a PSO			

ETHINYLLOESTRADIOL WITH LEVONORGESTREL

* Tab 50 µg with levonorgestrel 125 µg and 7 inert tab – Up to 84 tab available on a PSO	9.45	84	✓ Microgynon 50 ED
* Tab 30 µg with levonorgestrel 150 µg	6.62	63	
	(16.50)		Microgynon 30
a) Higher subsidy of \$15.00 per 63 tab with Special Authority see SA0500 on the preceding page			
b) Up to 63 tab available on a PSO			
* Tab 30 µg with levonorgestrel 150 µg and 7 inert tab	6.62	84	✓ Levlen ED ✓ Monofeme
	(14.49)		Nordette 28
	(16.50)		Microgynon 30 ED
a) Higher subsidy of up to \$15.00 per 84 tab with Special Authority see SA0500 on the preceding page			
b) Up to 84 tab available on a PSO			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETHINYLLOESTRADIOL WITH NORETHISTERONE				
* Tab 35 µg with norethisterone 1 mg – Up to 63 tab available on a PSO	6.62	63	✓	Brevinor 1/21
* Tab 35 µg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	✓	Brevinor 1/28
* Tab 35 µg with norethisterone 500 µg – Up to 63 tab available on a PSO	6.62	63	✓	Brevinor 21
* Tab 35 µg with norethisterone 500 µg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	✓	Norimin
NORETHISTERONE WITH MESTRANOL				
* Tab 1 mg with mestranol 50 µg and 7 inert tab	6.62 (13.80)	84		Norinyl-1/28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 on page 69				
b) Up to 84 tab available on a PSO				

Combined Oral Contraceptives - Other

ETHINYLLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 µg with levonorgestrel 100 µg and 7 inert tab – Up to 84 tab available on a PSO	6.62 (16.50) (16.50)	84		Loette Microgynon 20 ED

Progestogen-only Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

* Tab 30 µg	6.62 (16.50)	84		Microlut
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above				
b) Up to 84 tab available on a PSO				
* Subdermal implant (2 × 75 mg rods)	133.65	1	✓	Jadelle

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MEDROXYPROGESTERONE ACETATE				
* Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO	7.15	1	✓	Depo-Provera
NORETHISTERONE				
* Tab 350 µg – Up to 84 tab available on a PSO.....	7.15	84	✓	Noriday 28

Emergency Contraceptives

LEVONORGESTREL				
* Tab 1.5 mg	12.50	1	✓	Postinor-1
a) Maximum of 2 tab per prescription				
b) Up to 5 tab available on a PSO				

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions “contraceptive” (code “O”) when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- \$3.00 prescription charge (patient co-payment) will apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

* Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs	4.91	84	✓	Ginet 84
--	------	----	---	-----------------

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

.....	8.43	100 g OP		
	(24.00)			Aci-Jel

CLOTTRIMAZOLE

* Vaginal crm 1% with applicators	1.30	35 g OP	✓	Clomazol
* Vaginal crm 2% with applicators	2.50	20 g OP	✓	Clomazol

MICONAZOLE NITRATE

* Vaginal crm 2% with applicator	2.75	40 g OP		
	(3.70)			Micreme

NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓	Nilstat
--	------	---------	---	----------------

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE

Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO	11.60	5	✓	Mayne
--	-------	---	---	--------------

METHYLERGOMETRINE

Inj 200 µg per ml, 1 ml – Up to 10 inj available on a PSO	9.28	10	✓	Hospira ^{S29}
<i>(Hospira ^{S29} Inj 200 µg per ml, 1 ml to be delisted 1 March 2011)</i>				

OESTRIOL

* Crm 1 mg per g with applicator	6.30	15 g OP	✓	Ovestin
* Pessaries 500 µg	6.53	15	✓	Ovestin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OXYTOCIN – Up to 5 inj available on a PSO				
Inj 5 iu per ml, 1 ml	5.94	5	✓	<u>Syntocinon</u>
Inj 10 iu per ml, 1 ml	7.48	5	✓	<u>Syntocinon</u>
Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml	10.12	5	✓	<u>Syntometrine</u>

Pregnancy Tests - hCG Urine

PREGNANCY TESTS - HCG URINE

- a) Up to 200 test available on a PSO
- b) Only on a PSO

Cassette	22.80	40 test OP	✓	<u>Innovacon hCG One Step Pregnancy Test</u>
----------------	-------	------------	---	--

Urinary Agents

For urinary tract infections refer to INFECTIONS, Antibacterials, page 95

5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see SA0928 below – Retail pharmacy

Tab 5 mg	19.20	30	✓	<u>Fintral</u>
----------------	-------	----	---	----------------

▶SA0928 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 below – Retail pharmacy

Cap 400 µg	5.98	30	✓	<u>Tamsulosin-Rex</u>
------------------	------	----	---	-----------------------

▶SA1032 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Other Urinary Agents

OXYBUTYNIN

* Tab 5 mg	44.79	500	✓	<u>Apo-Oxybutynin</u>
* Oral liq 5 mg per 5 ml	50.40	473 ml OP	✓	<u>Apo-Oxybutynin</u>

SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets	2.71	28	✓	<u>Ural</u>
-------------------------------	------	----	---	-------------

SOLIFENACIN SUCCINATE – Special Authority see SA0998 on the next page – Retail pharmacy

Tab 5 mg	56.50	30	✓	<u>Vesicare</u>
Tab 10 mg	56.50	30	✓	<u>Vesicare</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

GENITO-URINARY SYSTEM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

▶SA0998 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has overactive bladder and a documented intolerance of oxybutynin.

Detection of Substances in Urine

ORTHO-TOLIDINE

* Compound diagnostic sticks	7.50	50 test OP	
	(8.25)		Hemastix

TETRABROMOPHENOL

* Blue diagnostic strips	7.02	100 test OP	
	(13.92)		Albustix

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
Anabolic Agents			
NANDROLONE DECANOATE – Retail pharmacy-Specialist			
Inj 50 mg per ml, 1 ml	21.16	1	✓ Deca-Durabolin Orgaject S29
Corticosteroids and Related Agents for Systemic Use			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE			
* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml	19.20 (33.60)	5	Celestone Chronodose
DEXAMETHASONE			
* Tab 1 mg – Retail pharmacy-Specialist	16.08	100	✓ Douglas
Up to 30 tab available on a PSO			
* Tab 4 mg – Retail pharmacy-Specialist	61.89	100	✓ Douglas
Up to 30 tab available on a PSO			
Oral liq 1 mg per ml – Retail pharmacy-Specialist	39.90	25 ml OP	✓ Biomed
Oral liq prescriptions:			
1) Must be written by a Paediatrician or Paediatric Cardiologist; or			
2) On the recommendation of a Paediatrician or Paediatric Cardiologist.			
DEXAMETHASONE SODIUM PHOSPHATE			
* Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO	21.50	5	✓ Hospira
* Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO	31.00	5	✓ Hospira
FLUDROCORTISONE ACETATE			
* Tab 100 µg	7.62	100	✓ Florinef
HYDROCORTISONE			
* Tab 5 mg	8.35	100	✓ Douglas
* Tab 20 mg	20.95	100	✓ Douglas
* Inj 50 mg per ml, 2 ml	3.99	1	✓ Solu-Cortef
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
METHYLPREDNISOLONE – Retail pharmacy-Specialist			
* Tab 4 mg	48.57	100	✓ Medrol
* Tab 100 mg	166.52	20	✓ Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml	6.03	1	✓ Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE			
Inj 40 mg per ml with lignocaine 1 ml	6.03	1	✓ Depo-Medrol with Lidocaine
METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy-Specialist			
Inj 40 mg per ml, 1 ml	151.40	25	✓ Solu-Medrol
Inj 62.5 mg per ml, 2 ml	412.59	25	✓ Solu-Medrol
Inj 500 mg	20.80	1	✓ Solu-Medrol
Inj 1 g	42.57	1	✓ Solu-Medrol
PREDNISOLONE SODIUM PHOSPHATE			
* Oral liq 5 mg per ml – Up to 30 ml available on a PSO	9.95	30 ml OP	✓ Redipred
Restricted to children under 12 years of age.			

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PREDNISONE				
* Tab 1 mg	10.68	500	✓	<u>Apo-Prednisone</u>
* Tab 2.5 mg	12.09	500	✓	<u>Apo-Prednisone</u>
* Tab 5 mg – Up to 30 tab available on a PSO.....	11.09	500	✓	<u>Apo-Prednisone</u>
* Tab 20 mg	29.03	500	✓	<u>Apo-Prednisone</u>
TETRACOSACTRIN				
* Inj 250 µg	177.18	10	✓	<u>Synacthen</u>
* Inj 1 mg per ml, 1 ml	26.88	1	✓	<u>Synacthen Depot</u>
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml	11.11	5	✓	<u>Kenacort-A</u>
Inj 40 mg per ml, 1 ml	28.09	5	✓	<u>Kenacort-A40</u>

Sex Hormones Non Contraceptive

Androgen Agonists and Antagonists

CYPROTERONE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg	21.10	50	✓	<u>Siterone</u>
Tab 100 mg	41.50	50	✓	<u>Siterone</u>
TESTOSTERONE				
Transdermal patch, 2.5 mg per day	80.00	60	✓	<u>Androderm</u>
TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist				
Inj long-acting 100 mg per ml, 10 ml	61.41	1	✓	<u>Depo-Testosterone</u>
TESTOSTERONE ESTERS – Retail pharmacy-Specialist				
Inj 250 mg per ml, 1 ml	12.98	1	✓	<u>Sustanon Ampoules</u>
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist				
Cap 40 mg	79.92	100	✓	<u>Arrow-Testosterone</u>

Hormone Replacement Therapy - Systemic

▶SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria:

Any of the following:

- 1 acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy - patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Oestrogens				
OESTRADIOL – See prescribing guideline on the preceding page				
* Tab 1 mg	4.12 (10.55)	28 OP		Estrofem
* Tab 2 mg	4.12 (10.55)	28 OP		Estrofem
* TDDS 25 µg per day	3.01 (10.86)	8		Estraderm TTS 25
a) Higher subsidy of \$10.86 per 8 patch with Special Authority see SA1018 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 3.9 mg (releases 50 µg of oestradiol per day)	4.12 (13.18) (32.50)	4		Climara 50 Femtran 50
a) Higher subsidy of \$13.18 per 4 patch with Special Authority see SA1018 on the preceding page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 50 µg per day	4.12 (13.18) (13.18)	8		Estraderm TTS 50 Estradot 50 µg
a) Higher subsidy of \$13.18 per 8 patch with Special Authority see SA1018 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 7.8 mg (releases 100 µg of oestradiol per day)	7.05 (16.14) (35.00)	4		Climara 100 Femtran 100
a) Higher subsidy of \$16.14 per 4 patch with Special Authority see SA1018 on the preceding page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 100 µg per day	7.05 (16.14)	8		Estraderm TTS 100
a) Higher subsidy of \$16.14 per 8 patch with Special Authority see SA1018 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
OESTRADIOL VALERATE – See prescribing guideline on the preceding page				
* Tab 1 mg	8.24	56	✓	Progynova
* Tab 2 mg	8.24	56	✓	Progynova
OESTROGENS – See prescribing guideline on the preceding page				
* Conjugated, equine tab 300 µg	3.01 (11.48)	28		Premarin
* Conjugated, equine tab 625 µg	4.12 (11.48)	28		Premarin

Progestogens

MEDROXYPROGESTERONE ACETATE – See prescribing guideline on the preceding page

* Tab 2.5 mg	3.09	30	✓	Provera
* Tab 5 mg	13.06	100	✓	Provera
* Tab 10 mg	6.85	30	✓	Provera

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Progestogen and Oestrogen Combined Preparations				
OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on page 76				
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40	28 OP		
	(14.52)			Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40	28 OP		
	(14.52)			Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6)	5.40	28 OP		
	(14.52)			Trisequans
OESTROGENS WITH MEDROXYPROGESTERONE – See prescribing guideline on page 76				
* Tab 625 µg conjugated equine with 2.5 mg medroxyproges- terone acetate tab (28)	5.40	28 OP		
	(22.96)			Premia 2.5 Continuous
* Tab 625 µg conjugated equine with 5 mg medroxyproges- terone acetate tab (28)	5.40	28 OP		
	(22.96)			Premia 5 Continuous

Other Oestrogen Preparations

ETHINYLOESTRADIOL				
* Tab 10 µg	17.60	100	✓	NZ Medical and Scientific
OESTRIOL				
* Tab 2 mg	7.00	30	✓	Ovestin

Other Progestogen Preparations

DYDROGESTERONE				
Tab 10 mg	15.40	28		
	(16.75)			Duphaston
<i>(Duphaston Tab 10 mg to be delisted 1 June 2011)</i>				
LEVONORGESTREL				
* Levonorgestrel - releasing intrauterine system 20µg/24 hr – Special Authority see SA0782 below – Retail pharmacy	269.50	1	✓	Mirena

SA0782 Special Authority for Subsidy

Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
 - 3.1 serum ferritin level < 16 µg/l (within the last 12 months); or
 - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
 - 1.2 Previous insertion was removed or expelled within 3 months of insertion; and
- 2 Applicant to state date of the previous insertion.

MEDROXYPROGESTERONE ACETATE

* Tab 100 mg – Retail pharmacy-Specialist	96.50	100	✓ Provera
* Tab 200 mg – Retail pharmacy-Specialist	70.50	30	✓ Provera

NORETHISTERONE

* Tab 5 mg – Up to 30 tab available on a PSO.....	25.00	100	✓ Primolut N
---	-------	-----	--------------

Thyroid and Antithyroid Agents

CARBIMAZOLE

* Tab 5 mg	10.80	100	✓ Neo-Mercazole
------------------	-------	-----	-----------------

LEVOTHYROXINE

* Tab 50 µg	1.71	28	✓ Goldshield
	45.00	1,000	✓ Synthroid
	64.28		✓ Eltroxin

‡ Safety cap for extemporaneously compounded oral liquid preparations.

* Tab 100 µg	1.78	28	✓ Goldshield
	46.75	1,000	✓ Synthroid
	66.78		✓ Eltroxin

‡ Safety cap for extemporaneously compounded oral liquid preparations.

* Tab 25 µg	43.24	1,000	✓ Synthroid
-------------------	-------	-------	-------------

‡ Safety cap for extemporaneously compounded oral liquid preparations.

Trophic Hormones

Growth Hormones

►SA0755 Special Authority for Subsidy

Special Authority approved by the Growth Hormone Committee

Notes: Subject to budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

NZGHC Coordinator

PHARMAC, PO Box 10-254, WELLINGTON

Tel: 0800 808 476, Fax: (09) 929 3221, Email: growthhormone@pharmac.govt.nz

SOMATROPIN – Special Authority see SA0755 above

* Inj cartridge 16 iu (5.3 mg)	160.00	1	✓ Genotropin
* Inj cartridge 36 iu (12 mg)	360.00	1	✓ Genotropin

‡ safety cap

* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GnRH Analogues				
GOSERELIN ACETATE				
Inj 3.6 mg	200.00	1	✓	Zoladex
Inj 10.8 mg	500.00	1	✓	Zoladex
LEUPRORELIN				
Inj 3.75 mg	221.60	1	✓	Lucrin Depot
Inj 3.75 mg prefilled syringe	221.60	1	✓	Lucrin Depot PDS
Inj 7.5 mg	166.20	1	✓	Eligard
Inj 11.25 mg	591.68	1	✓	Lucrin Depot
Inj 11.25 mg prefilled syringe	591.68	1	✓	Lucrin Depot PDS
Inj 22.5 mg	443.76	1	✓	Eligard
Inj 30 mg	591.68	1	✓	Eligard
Inj 30 mg prefilled syringe	1,109.40	1	✓	Lucrin Depot PDS
Inj 45 mg	832.05	1	✓	Eligard

Vasopressin Agonists

DESMOPRESSIN				
▲ Nasal drops 100 µg per ml – Retail pharmacy-Specialist.....	39.03	2.5 ml OP	✓	Minirin
▲ Nasal spray 10 µg per dose – Retail pharmacy-Specialist	29.94	6 ml OP	✓	Desmopressin- PH&T
Inj 4 µg per ml, 1 ml – Special Authority see SA0090 below – Retail pharmacy	67.18	10	✓	Minirin

►SA0090 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE				
Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1031 below.....	16.50	2	✓	Arrow-Cabergoline
	66.00	8	✓	Arrow-Cabergoline
	16.50	2	✓	Dostinex
	66.00	8	✓	Dostinex

►SA1031 Special Authority for Waiver of Rule

Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid without further renewal unless notified where the patient has pathological hyperprolactinemia.

Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

CLOMIPHENE CITRATE				
Tab 50 mg	2.50	5	✓	Phenate
	29.84	10	✓	Serophene
<i>(Phenate Tab 50 mg to be delisted 1 February 2011)</i>				
DANAZOL – Retail pharmacy-Specialist				
Cap 100 mg	68.33	100	✓	Azol
Cap 200 mg	97.83	100	✓	Azol

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
GESTRINONE – Retail pharmacy-Specialist			
Cap 2.5 mg	101.87	8 OP	✓ Dimetriose
METYRAPONE			
Cap 250 mg – Retail pharmacy-Specialist	238.00	50	✓ Metopirone

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Anthelmintics				
MEBENDAZOLE – Only on a prescription				
Tab 100 mg	17.28	24	✓	De-Worm
Oral liq 100 mg per 5 ml	2.18	15 ml		
	(7.17)			Vermox

Antibacterials

- a) For topical antibacterials, refer to DERMATOLOGICALS, page 58
 b) For anti-infective eye preparations, refer to SENSORY ORGANS, page 166

Cephalosporins and Cephamycins

CEFACLOR MONOHYDRATE				
Cap 250 mg	28.90	100	✓	Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml	3.53	100 ml	✓	Ranbaxy-Cefaclor
CEFAZOLIN SODIUM – Subsidy by endorsement				
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 500 mg	5.00	5	✓	Hospira
Inj 1 g	8.00	5	✓	Hospira
CEFOTIXIM SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement				
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 1 g	55.00	5	✓	Mayne
CEFTRIAOXONE SODIUM – Subsidy by endorsement				
a) Up to 5 inj available on a PSO				
b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly.				
Inj 500 mg	2.70	1	✓	Veracol
	2.57			
	(3.99)			AFT
Inj 1 g	10.49	5	✓	Aspen Ceftriaxone
	2.10	1		
	(5.40)			AFT
<i>(AFT Inj 500 mg to be delisted 1 February 2011)</i>				
<i>(AFT Inj 1 g to be delisted 1 January 2011)</i>				
CEFUROXIME AXETIL – Subsidy by endorsement				
Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Tab 250 mg	29.40	50	✓	Zinnat
CEFUROXIME SODIUM				
Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement.....				
	20.97	10	✓	Mayne
Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement.....				
	10.71	5	✓	Zinacef
Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement.....				
	4.04	1	✓	Zinacef
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
CEPHALEXIN MONOHYDRATE			
Cap 500 mg	8.90	20	✓ Cephalexin ABM
Grans for oral liq 125 mg per 5 ml	8.50	100 ml	✓ Cefalexin Sandoz
Grans for oral liq 250 mg per 5 ml	11.50	100 ml	✓ Cefalexin Sandoz

Macrolides

AZITHROMYCIN – Subsidy by endorsement; can be waived by Special Authority see SA0964 below

- a) Maximum of 2 tab per prescription; can be waived by Special Authority see SA0964 below
- b) Up to 8 tab available on a PSO
- c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly; can be waived by Special Authority see SA0964.

Tab 500 mg	5.95	2 OP	✓ Arrow-Azithromycin
------------------	------	------	-----------------------------

SA0964 Special Authority for Waiver of Rule

Initial application only from a respiratory specialist or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The applicant is part of multidisciplinary team experienced in the management of cystic fibrosis; and
- 2 The patient has been definitively diagnosed with cystic fibrosis*; and
- 3 The patient has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms as defined by two positive respiratory tract cultures at least three months apart*; and
- 4 The patient has negative cultures for non-tuberculous mycobacteria.

Notes: Caution is advised if using azithromycin as an antibiotic in the treatment of cystic fibrosis patients with pneumonia.

Testing for non-tuberculosis mycobacteria should occur annually.

Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6).

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0988 below

Tab 250 mg	5.53	10	✓ Klacid
	7.75	14	✓ Klamycin
Grans for oral liq 125 mg per 5 ml	23.12	70 ml	✓ Klacid

SA0988 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician.

Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or
- 2 Atypical and drug-resistant mycobacterial infection; or
- 3 All of the following:
 - 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and
 - 3.2 HIV infection; and
 - 3.3 CD4 count ≤ 50 cells/mm³.

Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN ETHYL SUCCINATE

Tab 400 mg – Up to 30 tab available on a PSO.....	16.95	100	✓ E-Myacin
Grans for oral liq 200 mg per 5 ml – Up to 200 ml available on a PSO.....	4.35	100 ml	✓ E-Myacin
Grans for oral liq 400 mg per 5 ml – Up to 200 ml available on a PSO.....	5.85	100 ml	✓ E-Myacin

ERYTHROMYCIN LACTOBIONATE

Inj 1 g	10.93	1	✓ Erythrocin IV
---------------	-------	---	------------------------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ERYTHROMYCIN STEARATE				
Tab 250 mg – Up to 30 tab available on a PSO.....	14.95 (22.29)	100		ERA
Tab 500 mg	29.90 (44.58)	100		ERA
ROXITHROMYCIN				
Tab 150 mg	8.98	50	✓	<u>Arrow-</u> <u>Roxithromycin</u>
Tab 300 mg	16.48	50	✓	<u>Arrow-</u> <u>Roxithromycin</u>
Penicillins				
AMOXYCILLIN				
Cap 250 mg – Up to 30 cap available on a PSO.....	16.18 (17.30)	500	✓	<u>Alphamox</u> Apo-Amoxi
Cap 500 mg	26.50 (27.25)	500	✓	<u>Alphamox</u> Apo-Amoxi
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO.....	1.55	100 ml	✓	<u>Ospamox</u>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO.....	1.10	100 ml	✓	<u>Ospamox</u>
Drops 125 mg per 1.25 ml	4.00	30 ml OP	✓	<u>Ospamox Paediatric</u> <u>Drops</u>
Inj 250 mg	12.42	10	✓	<u>Ibiamox</u>
Inj 500 mg	14.24	10	✓	<u>Ibiamox</u>
Inj 1 g – Up to 5 inj available on a PSO.....	21.62	10	✓	<u>Ibiamox</u>
<i>(Apo-Amoxi Cap 250 mg to be delisted 1 March 2011)</i>				
<i>(Apo-Amoxi Cap 500 mg to be delisted 1 March 2011)</i>				
AMOXYCILLIN CLAVULANATE				
Tab amoxicillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO	25.10	100	✓	<u>Synermox</u>
Grans for oral liq amoxicillin 125 mg with potassium clavu- lanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO.....	2.20	100 ml	✓	<u>Curam</u>
Grans for oral liq amoxicillin 250 mg with potassium clavu- lanate 62.5 mg per 5 ml – Up to 200 ml available on a PSO.....	3.85	100 ml	✓	<u>Curam</u>
BENZATHINE BENZYL PENICILLIN				
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO.....	315.00	10	✓	<u>Bicillin LA</u>
BENZYL PENICILLIN SODIUM (PENICILLIN G)				
Inj 1 mega u – Up to 5 inj available on a PSO.....	10.49	10	✓	<u>Sandoz</u>

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
FLUCLOXACILLIN SODIUM			
Cap 250 mg – Up to 30 cap available on a PSO	32.00	250	✓ <u>AFT</u>
Cap 500 mg	110.00	500	✓ <u>AFT</u>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO	3.12	100 ml	✓ <u>AFT</u>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO	3.55	100 ml	✓ <u>AFT</u>
Inj 250 mg	9.00	10	✓ <u>Flucloxin</u>
Inj 500 mg	10.40	10	✓ <u>Flucloxin</u>
Inj 1 g – Up to 5 inj available on a PSO	14.00	10	✓ <u>Flucloxin</u>
PHENOXYMETHYLPENICILLIN (PENICILLIN V)			
Cap potassium salt 250 mg – Up to 30 cap available on a PSO	9.71	50	✓ <u>Cilicaine VK</u>
Cap potassium salt 500 mg	11.70	50	✓ <u>Cilicaine VK</u>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO	1.68	100 ml	✓ <u>AFT</u>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO	1.78	100 ml	✓ <u>AFT</u>
PROCAINE PENICILLIN			
Inj 1.5 mega u – Up to 5 inj available on a PSO	50.86	5	✓ <u>Cilicaine</u>
Tetracyclines			
DOXYCYCLINE HYDROCHLORIDE			
* Tab 50 mg – Up to 30 tab available on a PSO	2.90 (6.00)	30	Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO	8.10	250	✓ <u>Doxine</u>
MINOCYCLINE HYDROCHLORIDE			
* Tab 50 mg	5.79 (12.05)	60	Mino-tabs
* Cap 100 mg	19.32 (52.04)	100	Minomycin
Other Antibiotics			
For topical antibiotics, refer to DERMATOLOGICALS, page 58			
CIPROFLOXACIN			
Tab 250 mg – Up to 5 tab available on a PSO	3.35	30	✓ <u>ReX Medical</u>
Tab 500 mg – Up to 5 tab available on a PSO	4.90	30	✓ <u>ReX Medical</u>
Tab 750 mg – Retail pharmacy-Specialist	7.54	30	✓ <u>ReX Medical</u>
CLINDAMYCIN			
Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip- tion; can be waived by endorsement - Retail pharmacy - Specialist	11.39	16	✓ <u>Dalacin C</u>
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy- Specialist	16.00	1	✓ <u>Dalacin C</u>
CO-TRIMOXAZOLE			
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO	17.00	500	✓ <u>Trisul</u>
* Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO	2.15	100 ml	✓ <u>Deprim</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement				
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 150 mg	65.00	1	✓	Colistin-Link
FUSIDIC ACID				
Tab 250 mg – Retail pharmacy-Specialist	34.50	12	✓	Fucidin
Inj 500 mg sodium fusidate per 10 ml – Retail pharmacy-Specialist – Subsidy by endorsement.....	12.87 (17.80)	1		Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement	8.56	5	✓	Mayne
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Inj 40 mg per ml, 2 ml – Subsidy by endorsement	9.00	10	✓	Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
MOXIFLOXACIN – Special Authority see SA1065 below – Retail pharmacy				
Tab 400 mg	52.00	5	✓	Avelox
►SA1065 Special Authority for Subsidy				
Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:				
Either:				
1 Both:				
1.1 Active tuberculosis*; and				
1.2 Any of the following:				
1.2.1 Documented resistance to one or more first-line medications; or				
1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or				
1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or				
1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or				
1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or				
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*.				
Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6).				
Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
TOBRAMYCIN				
Inj 40 mg per ml, 2 ml – Subsidy by endorsement	34.50	5	✓	Mayne
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
TRIMETHOPRIM				
* Tab 300 mg – Up to 30 tab available on a PSO.....	8.69	50	✓	TMP
VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement				
Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudomembranous colitis or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Inj 50 mg per ml, 10 ml	5.04	1	✓	Pacific

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antifungals				
a) For topical antifungals refer to DERMATOLOGICALS, page 58				
b) For topical antifungals refer to GENITO URINARY, page 72				
FLUCONAZOLE – Retail pharmacy-Specialist				
Cap 50 mg	6.82	28	✓	Pacific
Cap 150 mg	1.30	1	✓	Pacific
Cap 200 mg	19.05	28	✓	Pacific
ITRACONAZOLE – Retail pharmacy-Specialist				
Cap 100 mg	4.25	15	✓	Itrazole
	23.70		✓	Sporanox
KETOCONAZOLE				
Tab 200 mg – Retail pharmacy-Specialist	38.12	30	✓	Nizoral
NYSTATIN				
Tab 500,000 u	14.16	50	✓	Nilstat
Cap 500,000 u	12.81	50	✓	Nilstat
TERBINAFINE				
Tab 250 mg	25.50	100	✓	Apo-Terbinafine

Antimalarials

HYDROXYCHLOROQUINE SULPHATE				
* Tab 200 mg	22.50	100	✓	Plaquenil

Antitrichomonal Agents

METRONIDAZOLE				
Tab 200 mg – Up to 30 tab available on a PSO.....	9.50	100	✓	Trichozole
Tab 400 mg	17.50	100	✓	Trichozole
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	✓	Flagyl-S
Suppos 500 mg	24.48	10	✓	Flagyl
ORNIDAZOLE				
Tab 500 mg	12.38	10	✓	Tiberal

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

DAPSONE – No patient co-payment payable				
Tab 25 mg	95.00	100	✓	Dapsone S29
Tab 100 mg	110.00	100	✓	Dapsone S29
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable				
Tab 100 mg	48.01	56	✓	Myambutol
Tab 400 mg	49.34	56	✓	Myambutol
ISONIAZID – Retail pharmacy-Specialist				
No patient co-payment payable				
* Tab 100 mg	20.00	100	✓	PSM
* Tab 100 mg with rifampicin 150 mg	90.04	100	✓	Rifinah
* Tab 150 mg with rifampicin 300 mg	179.57	100	✓	Rifinah

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PYRAZINAMIDE – Retail pharmacy-Specialist				
No patient co-payment payable				
* Tab 500 mg	59.00	100	✓	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				
No patient co-payment payable				
* Cap 150 mg	213.19	30	✓	Mycobutin
RIFAMPICIN – Retail pharmacy-Specialist				
No patient co-payment payable				
* Tab 600 mg	114.40	30	✓	Rifadin
* Cap 150 mg	58.66	100	✓	Rifadin
* Cap 300 mg	122.36	100	✓	Rifadin
* Oral liq 100 mg per 5 ml	12.66	60 ml	✓	Rifadin

Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 166

Hepatitis B Treatment

ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy				
Tab 10 mg	670.00	30	✓	Hepsera

▶SA0829 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:
- 2 Patient has raised serum ALT ($> 1 \times$ ULN); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient is cirrhotic; and
 - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
 - 5.2 Both:
 - 5.2.1 Patient is not cirrhotic; and
 - 5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT ($> 1 \times$ ULN); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and
- iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines.

Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR – Special Authority see SA0977 on the next page – Retail pharmacy				
Tab 0.5 mg	400.00	30	✓	Baraclude

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

►SA0977 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 patient has $\geq 2,000$ IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE – Special Authority see SA0832 below – Retail pharmacy

Tab 100mg	143.00	28	✓ Zeffix
Oral liq 5 mg per ml	90.00	240 ml	✓ Zeffix

►SA0832 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 All of the following:
 - 1.1.1 HBsAg positive for more than 6 months; and
 - 1.1.2 HBeAg positive or HBV DNA positive defined as $> 100,000$ copies per ml by quantitative PCR at a reference laboratory; and
 - 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or
 - 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or
 - 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
 - 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 2 All of the following:
 - 2.1 No continuing alcohol abuse or intravenous drug use; and
 - 2.2 Not coinfecting with HCV or HDV; and
 - 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and
 - 2.4 No history of hypersensitivity to lamivudine; and
 - 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance.

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- Renewal for patients who have maintained continuous treatment and response to lamivudine
- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or
 - Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine
 - 2 All of the following:
 - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
 - 2.2 Patient is cirrhotic; and
Documented resistance to lamivudine, defined as:
 - 2.3 Patient has raised serum ALT ($> 1 \times \text{ULN}$); and
 - 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 2.5 Detection of M204I or M204V mutation; or
 - Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil
 - 3 All of the following:
 - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and
Documented resistance to adefovir, defined as:
 - 3.2 Patient has raised serum ALT ($> 1 \times \text{ULN}$); and
 - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

* Tab dispersible 200 mg	1.98	25	✓ Lovir
* Tab dispersible 400 mg	6.64	56	✓ Lovir
* Tab dispersible 800 mg	7.38	35	✓ Lovir

VALACICLOVIR – Special Authority see SA0957 below – Retail pharmacy

Tab 500 mg	102.72	30	✓ Valtrex
------------------	--------	----	-----------

►SA0957 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1047 on the next page

Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1025 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1025, page 92

Tab 300 mg	531.00	30	✓ Viread
------------------	--------	----	----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

►SA1047 Special Authority for Waiver of Rule

Initial application — (Confirmed Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Initial application — (Pregnant) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent Pregnancy) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Antiretrovirals

▶SA1025 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 350 cells/mm³.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Either:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

continued...

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

continued...

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Either:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA1025 on the preceding page – Retail pharmacy

Tab 50 mg	158.33	30	✓ Stocrin
Tab 200 mg	474.99	90	✓ Stocrin
Tab 600 mg	474.99	30	✓ Stocrin

ETRAVIRINE – Special Authority see SA1025 on the preceding page – Retail pharmacy

Tab 100 mg	770.00	120	✓ Intence
------------------	--------	-----	-----------

NEVIRAPINE – Special Authority see SA1025 on the preceding page – Retail pharmacy

Tab 200 mg	319.80	60	✓ <u>Viramune</u>
Oral suspension 10 mg per ml	134.55	240 ml	✓ <u>Viramune</u> <u>Suspension</u>

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA1025 on the preceding page – Retail pharmacy

Tab 300 mg	458.00	60	✓ Ziagen
Oral liq 20 mg per ml	100.00	240 ml OP	✓ Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority see SA1025 on the preceding page – Retail pharmacy

Note: Kivexa counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 600 mg with lamivudine 300 mg	630.00	30	✓ Kivexa
---	--------	----	----------

DIDANOSINE [DDI] – Special Authority see SA1025 on the preceding page – Retail pharmacy

Cap 125 mg	115.05	30	✓ Videx EC
Cap 200 mg	184.08	30	✓ Videx EC
Cap 250 mg	230.10	30	✓ Videx EC
Cap 400 mg	368.16	30	✓ Videx EC

EMTRICITABINE – Special Authority see SA1025 on the preceding page – Retail pharmacy

Cap 200 mg	307.20	30	✓ Emtriva
------------------	--------	----	-----------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LAMIVUDINE – Special Authority see SA1025 on page 92 – Retail pharmacy				
Tab 150 mg	153.60	60	✓	3TC
Oral liq 10 mg per ml	50.00	240 ml OP	✓	3TC
STAVUDINE [D4T] – Special Authority see SA1025 on page 92 – Retail pharmacy				
Cap 20 mg	317.10	60	✓	Zerit
Cap 30 mg	377.80	60	✓	Zerit
Cap 40 mg	503.80	60	✓	Zerit
Powder for oral soln 1 mg per ml	100.76	200 ml OP	✓	Zerit
ZIDOVUDINE [AZT] – Special Authority see SA1025 on page 92 – Retail pharmacy				
Cap 100 mg	145.00	100	✓	Retrovir
Oral liq 10 mg per ml	29.00	200 ml OP	✓	Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1025 on page 92 – Retail pharmacy				
Combivir counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.				
Tab 300 mg with lamivudine 150 mg	667.20	60	✓	Combivir

Protease Inhibitors

ATAZANAVIR SULPHATE – Special Authority see SA1025 on page 92 – Retail pharmacy				
Cap 150 mg	568.34	60	✓	Reyataz
Cap 200 mg	757.79	60	✓	Reyataz
DARUNAVIR – Special Authority see SA1025 on page 92 – Retail pharmacy				
Tab 300 mg	1,190.00	120	✓	Prezista
Tab 400 mg	837.50	60	✓	Prezista
INDINAVIR – Special Authority see SA1025 on page 92 – Retail pharmacy				
Cap 200 mg	519.75	360	✓	Crixivan
Cap 400 mg	519.75	180	✓	Crixivan
LOPINAVER WITH RITONAVIR – Special Authority see SA1025 on page 92 – Retail pharmacy				
Tab 100 mg with ritonavir 25 mg	183.75	60	✓	Kaletra
Tab 200 mg with ritonavir 50 mg	735.00	120	✓	Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml	735.00	300 ml OP	✓	Kaletra
RITONAVIR – Special Authority see SA1025 on page 92 – Retail pharmacy				
Cap 100 mg	121.27	84	✓	Norvir
Oral liq 80 mg per ml	103.98	90 ml OP	✓	Norvir

Strand Transfer Inhibitors

RALTEGRAVIR POTASSIUM – Special Authority see SA1025 on page 92 – Retail pharmacy				
Tab 400 mg	1,350.00	60	✓	Isentress

Antiretrovirals - Additional Therapies

HIV Fusion Inhibitors

ENFUVIRTIDE – Special Authority see SA0845 on the next page – Retail pharmacy				
Powder for inj 90 mg per ml × 60	2,380.00	1	✓	Fuzeon

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

➔SA0845 Special Authority for Subsidy

Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

- 1) Diagnosis
 - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
 - PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
 - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
 - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging $> 1.5 \times$ upper limit of normal. (ALT is the preferable enzyme); or
 - Liver biopsy showing significant inflammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes).

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia ($< 2.0 \times 10^9$) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist				
See prescribing guideline on the preceding page				
Inj 3 m iu prefilled syringe	31.32	1	✓	Roferon-A
Inj 6 m iu prefilled syringe	62.64	1	✓	Roferon-A
Inj 9 m iu prefilled syringe	93.96	1	✓	Roferon-A
INTERFERON ALPHA-2B – PCT – Retail pharmacy-Specialist				
See prescribing guideline on the preceding page				
Inj 18 m iu, 1.2 ml multidose pen	187.92	1	✓	Intron-A
Inj 30 m iu, 1.2 ml multidose pen	313.20	1	✓	Intron-A
Inj 60 m iu, 1.2 ml multidose pen	626.40	1	✓	Intron-A
PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA0952 below – Retail pharmacy				
See prescribing guideline on the preceding page				
Inj 135 µg prefilled syringe	362.00	1	✓	Pegasys
	1,448.00	4	✓	Pegasys
Inj 180 µg prefilled syringe	450.00	1	✓	Pegasys
	1,800.00	4	✓	Pegasys
Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112	1,799.68	1 OP	✓	Pegasys RBV Combination Pack
Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168	1,975.00	1 OP	✓	Pegasys RBV Combination Pack
Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112	2,059.84	1 OP	✓	Pegasys RBV Combination Pack
Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168	2,190.00	1 OP	✓	Pegasys RBV Combination Pack

►SA0952 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist.

Approvals valid for 48 weeks for applications meeting the following criteria:

Either:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist.

Approvals valid for 6 months where patient has chronic hepatitis C, genotype 2 or 3 infection.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 48 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log₁₀ IU/ml; and
- 5 Either:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 5.1 HBeAg positive; or
- 5.2 serum HBV DNA \geq 2,000 units/ml and significant fibrosis (\geq Metavir Stage F2); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes:

- Approved dose is 180 μ g once weekly.
- The recommended dose of Pegylated Interferon-alpha 2a is 180 μ g once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 μ g once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alpha 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE

* Tab 1 g	18.40	100		
	(38.10)			Hiprex

NITROFURANTOIN

* Tab 50 mg	22.20	100	✓	Nifuran
* Tab 100 mg	37.50	100	✓	Nifuran

NORFLOXACIN

Tab 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement - Retail pharmacy - Specialist.....	22.50	100	✓	Arrow-Norfloxacine
---	-------	-----	---	--------------------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Vaccines

Influenza vaccine

INFLUENZA VACCINE – Hospital pharmacy [Xpharm]

A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health:

- a) all people 65 years of age and over;
- b) people under 65 years of age with:
 - i) the following cardiovascular disease:
 - 1) ischaemic heart disease,
 - 2) congestive heart disease,
 - 3) rheumatic heart disease,
 - 4) congenital heart disease, or
 - 5) cerebo-vascular disease;
 - ii) the following chronic respiratory disease:
 - 1) asthma, if on a regular preventative therapy, or
 - 2) other chronic respiratory disease with impaired lung function;
 - iii) diabetes;
 - iv) chronic renal disease;
 - v) any cancer, excluding basal and squamous skin cancers if not invasive;
 - vi) the following other conditions:
 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies, or
 - g) children on long term aspirin.
- c) people under 65 years of age who are:
 - i) pregnant; or
 - ii) morbidly obese
- d) children aged over 6 months and under 5 years who are from high deprivation backgrounds

The following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease,

B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.

D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder.

Inj	9.00	1	✓ Fluvax
	90.00	10	✓ Influvac
			✓ Vaxigrip

(Fluvax Inj to be delisted 1 January 2011)

(Influvac Inj to be delisted 1 January 2011)

(Vaxigrip Inj to be delisted 1 January 2011)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Anticholinesterases

NEOSTIGMINE

Inj 2.5 mg per ml, 1 ml	20.30	50	✓	AstraZeneca
-------------------------------	-------	----	---	-------------

PYRIDOSTIGMINE BROMIDE

▲ Tab 60 mg	40.08	100	✓	Mestinon
-------------------	-------	-----	---	----------

Anti-inflammatory Non Steroidal Drugs (NSAIDs)

►SA1038 Special Authority for Manufacturers Price

Note: Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 September 2010.

DICLOFENAC SODIUM

* Tab EC 25 mg	1.63	50	✓	<u>Diclofenac Sandoz</u>
* Tab 50 mg dispersible – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy	1.50	20		
	(8.00)			Voltaren D
* Tab EC 50 mg	2.13	50	✓	<u>Diclofenac Sandoz</u>
* Tab long-acting 75 mg	32.80	500	✓	<u>Diclax SR</u>
* Tab long-acting 100 mg	63.22	500	✓	<u>Diclax SR</u>
* Inj 25 mg per ml, 3 ml	12.00	5	✓	<u>Voltaren</u>
Up to 5 inj available on a PSO				
* Suppos 12.5 mg	1.85	10	✓	<u>Voltaren</u>
* Suppos 25 mg	2.22	10	✓	<u>Voltaren</u>
* Suppos 50 mg	3.84	10	✓	<u>Voltaren</u>
Up to 10 supp available on a PSO				
* Suppos 100 mg	6.36	10	✓	<u>Voltaren</u>

IBUPROFEN – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy

* Tab 200 mg	16.00	1,000	✓	<u>Ethics Ibuprofen</u>
* Tab 400 mg	1.07	30		
	(4.56)			Brufen
* Tab 600 mg	1.60	30		
	(6.84)			Brufen
* Tab long-acting 800 mg	9.12	30	✓	<u>Brufen Retard</u>
*‡ Oral liq 100 mg per 5 ml	2.69	200 ml	✓	<u>Fenpaed</u>

KETOPROFEN – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy

* Cap long-acting 100 mg	6.72	100		
	(21.56)			Oruvail 100
* Cap long-acting 200 mg	13.44	100		
	(43.12)			Oruvail 200

MEFENAMIC ACID – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy

* Cap 250 mg	0.50	20		
	(5.60)			Ponstan
	2.50	100		
	(18.33)			Ponstan

NAPROXEN

* Tab 250 mg	23.70	500	✓	<u>Noflam 250</u>
* Tab 500 mg	24.88	250	✓	<u>Noflam 500</u>
* Tab long-acting 750 mg	18.00	90	✓	<u>Naprosyn SR 750</u>
* Tab long-acting 1,000 mg	21.00	90	✓	<u>Naprosyn SR 1000</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
NAPROXEN SODIUM				
* Tab 275 mg	5.69	120	✓	Sonaflam
* Tab 550 mg	9.95	100	✓	Synflex
SULINDAC – Additional subsidy by Special Authority see SA1038 on the preceding page – Retail pharmacy				
* Tab 100 mg	5.32	100		
	(12.00)			Daclin
* Tab 200 mg	6.72	100		
	(20.00)			Daclin
	3.36	50		
	(15.87)			Clinoril
TENOXCAM				
* Tab 20 mg	23.75	100	✓	Tilcotil
* Inj 20 mg	9.95	1	✓	AFT
TIAPROFENIC ACID – Additional subsidy by Special Authority see SA1038 on the preceding page – Retail pharmacy				
* Tab 300 mg	4.03	60		
	(19.26)			Surgam

NSAIDs Other

INDOMETHACIN				
* Cap long-acting 75 mg	13.30	100	✓	Rheumacin SR
* Suppos 100 mg	14.50	30	✓	Arthrexin
<i>(Rheumacin SR Cap long-acting 75 mg to be delisted 1 February 2011)</i>				
MELOXICAM – Special Authority see SA1034 below – Retail pharmacy				
Tab 7.5 mg	11.50	30	✓	Arrow-Meloxicam

►SA1034 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
- 2 The patient has haemophilic arthropathy; and
- 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

PIROXICAM				
* Tab dispersible 10 mg	3.25	50	✓	Piram-D
* Tab dispersible 20 mg	5.50	100	✓	Piram-D
<i>(Piram-D Tab dispersible 10 mg to be delisted 1 April 2011)</i>				
<i>(Piram-D Tab dispersible 20 mg to be delisted 1 April 2011)</i>				

Antirheumatoid Agents

AURANOFIN				
Tab 3 mg	68.99	60	✓	Ridaura
LEFLUNOMIDE				
Tab 10 mg	55.00	30	✓	AFT-Leflunomide
	79.27		✓	Arava
Tab 20 mg	76.00	30	✓	AFT-Leflunomide
	108.60		✓	Arava
Tab 100 mg	54.44	3	✓	Arava

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PENICILLAMINE				
Tab 125 mg	61.93	100	✓	D-Penamime
Tab 250 mg	98.98	100	✓	D-Penamime
SODIUM AUROTHIOMALATE				
Inj 10 mg per 0.5 ml	76.87	10	✓	Myocrisin
Inj 20 mg per 0.5 ml	113.17	10	✓	Myocrisin
Inj 50 mg per 0.5 ml	217.23	10	✓	Myocrisin

Tumour Necrosis Factor (TNF) Inhibitors

ADALIMUMAB – Special Authority see SA1059 below – Retail pharmacy				
Inj 40 mg per 0.8 ml prefilled pen	1,799.92	2	✓	HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe	1,799.92	2	✓	Humira

SA1059 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
 - 2.5.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
- 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
- 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years - Male: 7.0 cm; Female: 5.5 cm
- 25-34 years - Male: 7.5 cm; Female: 5.5 cm
- 35-44 years - Male: 6.5 cm; Female: 4.5 cm
- 45-54 years - Male: 6.0 cm; Female: 5.0 cm
- 55-64 years - Male: 5.5 cm; Female: 4.0 cm
- 65-74 years - Male: 4.0 cm; Female: 4.0 cm
- 75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
 - 2.2.2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

- 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
- 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 50% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

ETANERCEPT – Special Authority see SA1060 below – Retail pharmacy

Inj 25 mg	949.96	4	✓ Enbrel
Inj 50 mg autoinjector	1,899.92	4	✓ Enbrel

SA1060 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose); and
- 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15 mg/m² weekly or at the maximum tolerated dose) in combination with one other disease-modifying agent; and

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

6 Both:

6.1 Either:

6.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 active, swollen, tender joints; or

6.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

6.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Either:

2.5.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or

2.5.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

2 All of the following:

2.1 Either:

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2 All of the following:

- 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
- 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and

2.5 Either:

- 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or
- 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:

2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or

2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a named specialist or rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

3.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a rheumatologist; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 50% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Calcium Homeostasis

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis).

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause - glucocorticosteroid therapy).

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \leq -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM – Special Authority see SA1039 on the preceding page – Retail pharmacy			
Tab 70 mg	35.91	4	✓ Fosamax
ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 on the preceding page – Retail pharmacy			
Tab 70 mg with cholecalciferol 5,600 iu	35.91	4	✓ Fosamax Plus

Alendronate for Paget's Disease

▶SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy			
Tab 40 mg	133.00	30	✓ Fosamax

Other Treatments

CALCITONIN			
* Inj 100 iu per ml, 1 ml	110.00	5	✓ <u>Miacalcic</u>
ETIDRONATE DISODIUM			
* Tab 200 mg	23.95	100	✓ <u>Arrow-Etidronate</u>

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PAMIDRONATE DISODIUM				
Inj 3 mg per ml, 5 ml	18.75	1	✓	Pamisol
Inj 3 mg per ml, 10 ml	37.50	1	✓	Pamisol
Inj 6 mg per ml, 10 ml	75.00	1	✓	Pamisol
Inj 9 mg per ml, 10 ml	112.50	1	✓	Pamisol
ZOLEDRONIC ACID – Special Authority see SA1035 below – Retail pharmacy				
Soln for infusion 5 mg in 100 ml	600.00	100 ml	✓	Aclasta

SA1035 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis); and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy); and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient may not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient may not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score ≤ -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria); and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu per ml	18.32	10	
	(243.24)		Hyalase

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Hyperuricaemia and Antigout				
ALLOPURINOL				
* Tab 100 mg	5.44	250	✓	<u>Apo-Allopurinol</u>
* Tab 300 mg	4.03	100	✓	<u>Apo-Allopurinol</u>
COLCHICINE				
* Tab 500 µg	9.60	100	✓	<u>Colgout</u>
PROBENECID				
* Tab 500 mg	55.00	100	✓	<u>Probenecid-AFT</u>

Muscle Relaxants

BACLOFEN				
* Tab 10 mg	4.75	100	✓	<u>Pacifen</u>
DANTROLENE SODIUM				
* Cap 25 mg	32.96	100	✓	<u>Dantrium</u>
* Cap 50 mg	51.70	100	✓	<u>Dantrium</u>
ORPHENADRINE CITRATE				
Tab 100 mg	18.54	100	✓	<u>Norflex</u>
QUININE SULPHATE				
* Tab 200 mg	15.95 (17.20)	250		Q 200
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
* Tab 300 mg	54.06	500	✓	<u>Q 300</u>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders				
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE				
▲ Cap 100 mg	47.81	60	✓	<u>Symmetrel</u>
APOMORPHINE HYDROCHLORIDE				
▲ Inj 10 mg per ml, 2 ml	110.00	5	✓	<u>Apomine</u>
BROMOCRIPTINE MESYLATE				
* Tab 2.5 mg	32.08	100	✓	<u>Apo-Bromocriptine</u>
* Cap 5 mg	60.43	100	✓	<u>Apo-Bromocriptine S29</u>
ENTACAPONE				
▲ Tab 200 mg	116.00	100	✓	<u>Comtan</u>
LEVODOPA WITH BENSERAZIDE				
* Tab dispersible 50 mg with benserazide 12.5 mg	10.00	100	✓	<u>Madopar Dispersible</u>
* Cap 50 mg with benserazide 12.5 mg	8.00	100	✓	<u>Madopar 62.5</u>
* Cap 100 mg with benserazide 25 mg	12.50	100	✓	<u>Madopar 125</u>
* Cap long-acting 100 mg with benserazide 25 mg	17.00	100	✓	<u>Madopar HBS</u>
* Cap 200 mg with benserazide 50 mg	25.00	100	✓	<u>Madopar 250</u>
LEVODOPA WITH CARBIDOPA				
* Tab 100 mg with carbidopa 25 mg	10.00	50	✓	<u>Sindopa</u>
	20.00	100	✓	<u>Sinemet</u>
* Tab long-acting 200 mg with carbidopa 50 mg	47.50	100	✓	<u>Sinemet CR</u>
* Tab 250 mg with carbidopa 25 mg	40.00	100	✓	<u>Sinemet</u>
LISURIDE HYDROGEN MALEATE				
▲ Tab 200 µg	27.50	30	✓	<u>Dopergin</u>
PERGOLIDE				
▲ Tab 0.25 mg	48.00	100	✓	<u>Permax</u>
▲ Tab 1 mg	170.00	100	✓	<u>Permax</u>
ROPINIROLE HYDROCHLORIDE				
▲ Tab 0.25 mg	6.20	84	✓	<u>Ropin</u>
▲ Tab 1 mg	15.95	84	✓	<u>Ropin</u>
▲ Tab 2 mg	24.95	84	✓	<u>Ropin</u>
▲ Tab 5 mg	38.00	84	✓	<u>Ropin</u>
SELEGILINE HYDROCHLORIDE				
* Tab 5 mg	16.06	100	✓	<u>Apo-Selegiline</u>
			✓	<u>Apo-Selegiline S29 S29</u>
TOLCAPONE				
▲ Tab 100 mg	128.75	100	✓	<u>Tasmar</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Anticholinergics				
BENZTROPINE MESYLATE				
Tab 2 mg	7.99	60	✓	Benztrop
Inj 1 mg per ml, 2 ml	36.35	5	✓	Cogentin
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
ORPHENADRINE HYDROCHLORIDE				
Tab 50 mg	31.93	250	✓	Disipal
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	✓	Kemadrin

Agents for Essential Tremor, Chorea and Related Disorders

TETRABENAZINE				
Tab 25 mg	243.00	112	✓	Xenazine 25

Anaesthetics

Local

LIGNOCAINE				
Gel 2%, 10 ml urethral syringe – Up to 5 each available on a PSO	43.26	10	✓	Pfizer
LIGNOCAINE HYDROCHLORIDE				
Viscous solution 2%	55.00	200 ml	✓	Xylocaine Viscous
Inj 0.5%, 5 ml – Up to 5 inj available on a PSO	44.10	50	✓	Xylocaine
Inj 1%, 5 ml – Up to 5 inj available on a PSO	35.00	50	✓	Xylocaine
Inj 2%, 5 ml – Up to 5 inj available on a PSO	23.00	50	✓	Xylocaine
Inj 1%, 20 ml – Up to 5 inj available on a PSO	20.00	5	✓	Xylocaine
Inj 2%, 20 ml – Up to 5 inj available on a PSO	15.00	5	✓	Xylocaine
LIGNOCAINE WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Up to 5 each available on a PSO	43.26	10	✓	Pfizer
LIGNOCAINE WITH PRILOCAINE – Special Authority see SA0906 below – Retail pharmacy				
Crn 2.5% with prilocaine 2.5%	45.00	30 g OP	✓	EMLA
Crn 2.5% with prilocaine 2.5% (5 g tubes)	45.00	5	✓	EMLA

►SA0906 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Analgesics

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 99

Non-Opioid Analgesics

ASPIRIN

* Tab EC 300 mg	2.00	100		
	(8.10)			Aspec 300
* Tab dispersible 300 mg – Up to 30 tab available on a PSO	2.00	100	✓	<u>Ethics Aspirin</u>

NEFOPAM HYDROCHLORIDE

Tab 30 mg	23.40	90	✓	<u>Acupan</u>
-----------------	-------	----	---	---------------

PARACETAMOL

* Tab 500 mg – Up to 30 tab available on a PSO.....	9.60	1,000	✓	<u>Pharmacare</u>
*‡ Oral liq 120 mg per 5 ml	6.80	1,000 ml	✓	<u>Paracare Junior</u>
a) Up to 200 ml available on a PSO				
b) Not in combination				
*‡ Oral liq 250 mg per 5 ml	7.00	1,000 ml	✓	<u>Paracare Double Strength</u>
a) Up to 100 ml available on a PSO				
b) Not in combination				
* Suppos 125 mg	7.49	20	✓	<u>Panadol</u>
* Suppos 250 mg	14.40	20	✓	<u>Panadol</u>
* Suppos 500 mg	20.50	50	✓	<u>Paracare</u>

TRAMADOL HYDROCHLORIDE

Cap 50 mg	6.95	100	✓	<u>Arrow-Tramadol</u>
-----------------	------	-----	---	-----------------------

Opioid Analgesics

BUPRENORPHINE HYDROCHLORIDE – Only on a controlled drug form

Inj 0.3 mg per ml, 1 ml	7.42	5		
	(9.38)			Temgesic

CODEINE PHOSPHATE

Tab 15 mg	5.39	100	✓	<u>PSM</u>
Tab 30 mg	8.25	100	✓	<u>PSM</u>
Tab 60 mg	17.76	100	✓	<u>PSM</u>

DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg	27.27	60	✓	<u>DHC Continus</u>
-----------------------------	-------	----	---	---------------------

FENTANYL – Special Authority see SA0935 on the next page – Retail pharmacy

a) Only on a controlled drug form				
b) No patient co-payment payable				
Transdermal patch, matrix 25 µg per hour	55.23	5	✓	<u>Durogesic</u>
Transdermal patch, matrix 50 µg per hour	100.52	5	✓	<u>Durogesic</u>
Transdermal patch, matrix 75 µg per hour	139.18	5	✓	<u>Durogesic</u>
Transdermal patch, matrix 100 µg per hour	171.22	5	✓	<u>Durogesic</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SA0935 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:				
Both:				
1 Patient is terminally ill and is opioid-responsive; and				
2 Either:				
2.1 is unable to take oral medication; or				
2.2 is intolerant to morphine, or morphine is contraindicated.				
Renewal from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.				
FENTANYL CITRATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Inj 50 µg per ml, 2 ml	6.10	5	✓	Hospira
Inj 50 µg per ml, 10 ml	15.65	5	✓	Hospira
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).				
d) For methadone hydrochloride oral liquid refer, page 176				
Tab 5 mg	1.85	10	✓	Methatabs
‡ Oral liq 2 mg per ml	5.95	200 ml	✓	Biodone
‡ Oral liq 5 mg per ml	5.55	200 ml	✓	Biodone Forte
‡ Oral liq 10 mg per ml	8.95	200 ml	✓	Biodone Extra Forte
Inj 10 mg per ml, 1 ml	61.00	10	✓	AFT
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
‡ Oral liq 1 mg per ml	8.84	200 ml	✓	RA-Morph
‡ Oral liq 2 mg per ml	11.62	200 ml	✓	RA-Morph
‡ Oral liq 5 mg per ml	14.65	200 ml	✓	RA-Morph
‡ Oral liq 10 mg per ml	21.55	200 ml	✓	RA-Morph
MORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab immediate-release 10 mg	2.80	10	✓	Sevredol
Tab long-acting 10 mg	1.80	10	✓	LA-Morph
Tab immediate-release 20 mg	5.52	10	✓	Sevredol
Tab long-acting 30 mg	3.60	10	✓	LA-Morph
Tab long-acting 60 mg	7.20	10	✓	LA-Morph
Tab long-acting 100 mg	8.50	10	✓	LA-Morph
Cap long-acting 10 mg	2.22	10	✓	m-Eslon
Cap long-acting 30 mg	3.20	10	✓	m-Eslon
Cap long-acting 60 mg	6.90	10	✓	m-Eslon
Cap long-acting 100 mg	8.05	10	✓	m-Eslon
Cap long-acting 200 mg	17.00	10	✓	m-Eslon
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.17	5	✓	Mayne
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.50	5	✓	Mayne
Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.70	5	✓	Mayne
Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.98	5	✓	Mayne

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
MORPHINE TARTRATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Inj 80 mg per ml, 1.5 ml	30.00	5	✓	<u>Hospira</u>
Inj 80 mg per ml, 5 ml	75.00	5	✓	<u>Hospira</u>
OXYCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab controlled-release 5 mg	7.51	20	✓	<u>OxyContin</u>
Tab controlled-release 10 mg	11.14	20	✓	<u>OxyContin</u>
Tab controlled-release 20 mg	18.93	20	✓	<u>OxyContin</u>
Tab controlled-release 40 mg	33.29	20	✓	<u>OxyContin</u>
Tab controlled-release 80 mg	58.03	20	✓	<u>OxyContin</u>
Cap 5 mg	2.83	20	✓	<u>OxyNorm</u>
Cap 10 mg	5.58	20	✓	<u>OxyNorm</u>
Cap 20 mg	9.77	20	✓	<u>OxyNorm</u>
‡ Oral liq 5 mg per 5 ml	11.20	250 ml	✓	<u>OxyNorm</u>
Inj 10 mg per ml, 1 ml	14.40	5	✓	<u>OxyNorm</u>
Inj 10 mg per ml, 2 ml	28.80	5	✓	<u>OxyNorm</u>

Prescribing Guideline

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.

PARACETAMOL WITH CODEINE

* Tab paracetamol 500 mg with codeine phosphate 8 mg	2.45	100	✓	<u>ParaCode</u>
--	------	-----	---	-----------------

PETHIDINE HYDROCHLORIDE

a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab 50 mg	3.20	10	✓	<u>PSM</u>
Tab 100 mg	4.20	10	✓	<u>PSM</u>
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.20	5	✓	<u>Mayne</u>
Inj 50 mg per ml, 1.5 ml – Up to 5 inj available on a PSO	4.35	5	✓	<u>Mayne</u>
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.50	5	✓	<u>Mayne</u>

Antidepressants

Cyclic and Related Agents

AMITRIPTYLINE

Tab 10 mg	2.77	50	✓	<u>Amirol</u>
Tab 25 mg	3.40	100	✓	<u>Amitrip</u>
Tab 50 mg	5.20	100	✓	<u>Amitrip</u>

CLOMIPRAMINE HYDROCHLORIDE

Tab 10 mg	12.60	100	✓	<u>Apo-Clomipramine</u>
Tab 25 mg	8.68	100	✓	<u>Apo-Clomipramine</u>

DOTHIEPIN HYDROCHLORIDE

Tab 75 mg	8.75	100	✓	<u>Dopress</u>
Cap 25 mg	4.75	100	✓	<u>Dopress</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DOXEPIH HYDROCHLORIDE				
Cap 10 mg	5.24	100	✓	Anten
Cap 25 mg	5.46	100	✓	Anten
Cap 50 mg	7.34	100	✓	Anten
IMIPRAMINE HYDROCHLORIDE				
Tab 10 mg	5.48	50	✓	Tofranil
Tab 25 mg	8.80	50	✓	Tofranil
MAPROTILINE HYDROCHLORIDE				
Tab 25 mg	25.06	100	✓	Ludiomil
Tab 75 mg	21.01	30	✓	Ludiomil
MIANSERIN HYDROCHLORIDE – Special Authority see SA1048 below – Retail pharmacy				
Tab 30 mg	24.86	30	✓	Tolvon

►SA1048 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Both:

1.1 Depression; and

1.2 Either:

1.2.1 Co-existent bladder neck obstruction; or

1.2.2 Cardiovascular disease; or

2 Both:

2.1 The patient has a severe major depressive episode; and

2.2 Either:

2.2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or

2.2.2 Both:

2.2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and

2.2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

NORTRIPTYLINE HYDROCHLORIDE

Tab 10 mg	5.94	100	✓	Norpress
Tab 25 mg	14.44	180	✓	Norpress

Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

PHENELZINE SULPHATE

Tab 15 mg	95.00	100	✓	Nardil
-----------------	-------	-----	---	---------------

TRANLYCYPROMINE SULPHATE

Tab 10 mg	22.94	50	✓	Parnate
-----------------	-------	----	---	----------------

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE

Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.

Tab 150 mg	69.23	500	✓	Apo-Moclobemide
Tab 300 mg	31.33	100	✓	Apo-Moclobemide

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	3.78	84	✓	Arrow-Citalopram
ESCITALOPRAM				
Tab 10 mg	2.65	28	✓	Loxalate
Tab 20 mg	4.20	28	✓	Loxalate
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement	2.50	30	✓	Fluox
Subsidised by endorsement				
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or				
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.				
* Cap 20 mg	2.70	84	✓	Fluox
PAROXETINE HYDROCHLORIDE				
Tab 20 mg	2.38	30	✓	Loxamine
SERTRALINE				
Tab 50 mg	5.40	90	✓	Arrow-Sertraline
Tab 100 mg	9.60	90	✓	Arrow-Sertraline

Other Antidepressants

MIRTAZAPINE – Special Authority see SA0994 below – Retail pharmacy				
Tab 30 mg	22.00	30	✓	Avanza
Tab 45 mg	35.00	30	✓	Avanza

SA0994 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has a severe major depressive episode; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

VENLAFAXINE – Special Authority see SA1061 on the next page – Retail pharmacy				
Cap 37.5 mg	18.64	28	✓	Efexor XR
Cap 75 mg	37.27	28	✓	Efexor XR
Cap 150 mg	45.68	28	✓	Efexor XR

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 The patient has 'treatment-resistant' depression; and

2 Either:

2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or

2.2 Both:

2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and

2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM

Inj 1 mg per ml, 1 ml	19.00	5	✓ Rivotril
-----------------------------	-------	---	------------

DIAZEPAM

Inj 5 mg per ml, 2 ml – Subsidy by endorsement	9.24	5	✓ Mayne
--	------	---	---------

a) Up to 5 inj available on a PSO

b) Only on a PSO

Rectal tubes 5 mg – Up to 5 tube available on a PSO	25.05	5	✓ Stesolid
---	-------	---	------------

Rectal tubes 10 mg – Up to 5 tube available on a PSO	30.50	5	✓ Stesolid
--	-------	---	------------

PARALDEHYDE

* Inj 5 ml	1,500.00	5	✓ AFT
------------------	----------	---	-------

PHENYTOIN SODIUM

* Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	69.24	5	✓ Mayne
---	-------	---	---------

* Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO	77.27	5	✓ Mayne
---	-------	---	---------

Control of Epilepsy

CARBAMAZEPINE

* Tab 200 mg	14.53	100	✓ Tegretol
--------------------	-------	-----	------------

* Tab long-acting 200 mg	16.98	100	✓ Tegretol CR
--------------------------------	-------	-----	---------------

* Tab 400 mg	34.58	100	✓ Tegretol
--------------------	-------	-----	------------

* Tab long-acting 400 mg	39.17	100	✓ Tegretol CR
--------------------------------	-------	-----	---------------

*‡ Oral liq 100 mg per 5 ml	26.37	250 ml	✓ Tegretol
-----------------------------------	-------	--------	------------

CLOBAZAM

Tab 10 mg	9.12	50	✓ Frisium
-----------------	------	----	-----------

‡ Safety cap for extemporaneously compounded oral liquid preparations.

CLONAZEPAM

Tab 500 µg	6.26	100	✓ Paxam
------------------	------	-----	---------

Tab 2 mg	11.15	100	✓ Paxam
----------------	-------	-----	---------

‡ Oral drops 2.5 mg per ml	7.38	10 ml OP	✓ Rivotril
----------------------------------	------	----------	------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETHOSUXIMIDE				
* Cap 250 mg	32.90	200	✓	Zarontin
*‡ Oral liq 250 mg per 5 ml	11.96	200 ml	✓	Zarontin
GABAPENTIN – Special Authority see SA1009 below – Retail pharmacy				
▲ Cap 100 mg	7.16	100	✓	Nupentin
▲ Cap 300 mg	11.50	100	✓	Nupentin
▲ Cap 400 mg	14.75	100	✓	Nupentin

▶SA1009 Special Authority for Subsidy

Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin; or
- 2 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents, or seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.				
Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.				
GABAPENTIN (NEURONTIN) – Special Authority see SA0973 below – Retail pharmacy				
▲ Tab 600 mg	67.50	100	✓	Neurontin
▲ Cap 100 mg	13.26	100	✓	Neurontin
▲ Cap 300 mg	39.76	100	✓	Neurontin
▲ Cap 400 mg	53.01	100	✓	Neurontin
▶SA0973 Special Authority for Subsidy				
Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.				
LAMOTRIGINE				
▲ Tab dispersible 2 mg	6.74	30	✓	Lamictal
▲ Tab dispersible 5 mg	9.64	30	✓	Lamictal
	15.00	56	✓	Arrow-Lamotrigine
▲ Tab dispersible 25 mg	19.38	56	✓	Logem
	20.40		✓	Arrow-Lamotrigine
			✓	Mogine
	29.09		✓	Lamictal
▲ Tab dispersible 50 mg	32.97	56	✓	Logem
	34.70		✓	Arrow-Lamotrigine
			✓	Mogine
	47.89		✓	Lamictal
▲ Tab dispersible 100 mg	56.91	56	✓	Logem
	59.90		✓	Arrow-Lamotrigine
			✓	Mogine
	79.16		✓	Lamictal
LEVETIRACETAM				
Tab 250 mg	24.03	60	✓	Levetiracetam-Rex
Tab 500 mg	28.71	60	✓	Levetiracetam-Rex
Tab 750 mg	45.23	60	✓	Levetiracetam-Rex
PHENOBARBITONE				
For phenobarbitone oral liquid refer, page 176				
* Tab 15 mg	25.00	500	✓	PSM
* Tab 30 mg	26.00	500	✓	PSM
PHENYTOIN SODIUM				
* Tab 50 mg	42.09	200	✓	Dilantin Infatab
* Cap 30 mg	19.13	200	✓	Dilantin
* Cap 100 mg	17.21	200	✓	Dilantin
*‡ Oral liq 30 mg per 5 ml	19.16	500 ml	✓	Dilantin
PRIMIDONE				
* Tab 250 mg	17.25	100	✓	Apo-Primidone

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM VALPROATE				
* Tab 100 mg	13.65	100	✓	Epilim Crushable
* Tab 200 mg EC	27.44	100	✓	Epilim
* Tab 500 mg EC	52.24	100	✓	Epilim
*‡ Oral liq 200 mg per 5 ml	20.48	300 ml	✓	Epilim S/F Liquid
			✓	Epilim Syrup
			✓	Epilim IV
* Inj 100 mg per ml, 4 ml	41.50	1		
TOPIRAMATE				
▲ Tab 25 mg	11.07	60	✓	Arrow-Topiramate
	26.04		✓	Topamax
▲ Tab 50 mg	18.81	60	✓	Arrow-Topiramate
	44.26		✓	Topamax
▲ Tab 100 mg	31.99	60	✓	Arrow-Topiramate
	75.25		✓	Topamax
▲ Tab 200 mg	55.19	60	✓	Arrow-Topiramate
	129.85		✓	Topamax
▲ Sprinkle cap 15 mg	20.84	60	✓	Topamax
▲ Sprinkle cap 25 mg	26.04	60	✓	Topamax
VIGABATRIN – Special Authority see SA1010 below – Retail pharmacy				
▲ Tab 500 mg	119.30	100	✓	Sabril

SA1010 Special Authority for Subsidy

Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Patient has infantile spasms; or

1.2 Both:

1.2.1 Patient has epilepsy; and

1.2.2 Either:

1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or

2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Note: Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 99

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE			
Tab 1 mg with caffeine 100 mg	31.00	100	✓ Cafergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL			
Tab 5 mg with paracetamol 500 mg	6.77	60	✓ Paramax
RIZATRIPTAN BENZOATE			
Wafer 10 mg	25.32	3	✓ Maxalt Melt
SUMATRIPTAN			
Tab 50 mg	1.55	4	✓ Arrow-Sumatriptan
	38.83	100	✓ Arrow-Sumatriptan
Tab 100 mg	1.55	2	✓ Arrow-Sumatriptan
	77.66	100	✓ Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml – Retail pharmacy-Specialist	80.00	2 OP	✓ Imigran
Maximum of 10 inj per prescription			

Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 51

CLONIDINE HYDROCHLORIDE			
* Tab 25 µg	19.25	100	✓ Dixarit
PIZOTIFEN			
* Tab 500 µg	21.10	100	✓ Sandomigran

Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, page 27

APREPITANT – Special Authority see SA0987 on the next page – Retail pharmacy

Cap 2 × 80 mg and 1 × 125 mg	116.00	3 OP	✓ Emend Tri-Pack
------------------------------------	--------	------	-------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
►SA0987 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.				
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.				
BETAHISTINE DIHYDROCHLORIDE				
* Tab 16 mg	9.26	84	✓	Vergo 16
CYCLIZINE HYDROCHLORIDE				
Tab 50 mg	1.59	10	✓	Nausicalm
CYCLIZINE LACTATE				
Inj 50 mg per ml, 1 ml	14.95	5	✓	Nausicalm Valoid (AFT)
<i>(Valoid (AFT) Inj 50 mg per ml, 1 ml to be delisted 1 March 2011)</i>				
DOMPERIDONE				
* Tab 10 mg	7.99	100	✓	Motilium
HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 below – Retail pharmacy				
Patch 1.5 mg	11.95	2	✓	Scopoderm TTS

►SA0939 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:				
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and				
2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and				
3 The applicant must specify the underlying malignancy or chronic disease.				
Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
HYOSCINE HYDROBROMIDE				
* Inj 400 µg per ml, 1 ml	6.66	5	✓	Mayne
METOCLOPRAMIDE HYDROCHLORIDE				
* Tab 10 mg	5.15	100	✓	Metamide
* Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO	4.50	10	✓	Pfizer
ONDANSETRON				
a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below				
b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below				
c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below.				
d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria.				
Tab 4 mg	5.10	30	✓	Dr Reddy's Ondansetron
	17.18	10	✓	Zofran
Tab disp 4 mg	17.18	10	✓	Zofran Zydis
Tab 8 mg	1.70	10	✓	Dr Reddy's Ondansetron
	33.89	20	✓	Zofran
Tab disp 8 mg	20.43	10	✓	Zofran Zydis

►SA0887 Special Authority for Waiver of Rule				
Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.				
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.				

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PROCHLORPERAZINE				
* Tab 3 mg buccal	5.97 (15.00)	50		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO.....	16.85	500	✓	Antinaus
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	25.81	10	✓	Stemetil
* Suppos 25 mg	23.87	5	✓	Stemetil
PROMETHAZINE THEOCLATE				
* Tab 25 mg	1.20 (6.24)	10		Avomine
TROPISETRON				
a) Maximum of 6 cap per prescription				
b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month.				
Cap 5 mg	77.41	5	✓	Navoban

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE				
Tab 100 mg	22.52	30	✓	Solian
Tab 200 mg	97.03	60	✓	Solian
Tab 400 mg	185.44	60	✓	Solian
Oral liq 100 mg per ml	55.44	60 ml	✓	Solian
ARIPIRAZOLE – Special Authority see SA0920 below – Retail pharmacy				
Tab 10 mg	123.54	30	✓	Abilify
Tab 15 mg	175.28	30	✓	Abilify
Tab 20 mg	213.42	30	✓	Abilify
Tab 30 mg	260.07	30	✓	Abilify

►SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CHLORPROMAZINE HYDROCHLORIDE				
Tab 10 mg – Up to 30 tab available on a PSO.....	12.36	100	✓	Largactil
Tab 25 mg – Up to 30 tab available on a PSO.....	13.02	100	✓	Largactil
Tab 100 mg – Up to 30 tab available on a PSO.....	30.61	100	✓	Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO.....	25.66	10	✓	Largactil
CLOZAPINE – Hospital pharmacy [HP4]				
Tab 25 mg	13.37	50	✓	Clozaril
	26.74	100	✓	Clozaril
	6.69	50	✓	Clopine
	13.37	100	✓	Clopine
Tab 50 mg	8.67	50	✓	Clopine
	17.33	100	✓	Clopine
Tab 100 mg	34.65	50	✓	Clozaril
	69.30	100	✓	Clozaril
	17.33	50	✓	Clopine
	34.65	100	✓	Clopine
Tab 200 mg	34.65	50	✓	Clopine
	69.30	100	✓	Clopine
Suspension 50 mg per ml	17.33	100 ml	✓	Clopine
HALOPERIDOL				
Tab 500 µg – Up to 30 tab available on a PSO.....	5.42	100	✓	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO.....	8.20	100	✓	Serenace
Tab 5 mg – Up to 30 tab available on a PSO.....	25.84	100	✓	Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO.....	19.87	100 ml	✓	Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	18.74	10	✓	Serenace
LEVOMEPROMAZINE				
Tab 25 mg	16.93	100	✓	Nozinan
Tab 100 mg	43.96	100	✓	Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	✓	Nozinan
LITHIUM CARBONATE				
Tab 250 mg	36.10	500	✓	Lithicarb
Tab 400 mg	13.50	100	✓	Lithicarb
Tab long-acting 400 mg	17.65	100	✓	Priadel
Cap 250 mg	7.73	100	✓	Douglas
OLANZAPINE – Special Authority see SA0741 below – Retail pharmacy				
Tab 2.5 mg	51.07	28	✓	Zyprexa
Tab 5 mg	101.21	28	✓	Zyprexa
Tab 10 mg	204.49	28	✓	Zyprexa

SA0741 Special Authority for Subsidy

Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Patient presents with first episode schizophrenia or related psychoses; or
- 2 Both:
 - 2.1 Patient suffering from schizophrenia and related psychoses or acute mania in bipolar disorder who is likely to benefit from antipsychotic treatment; and
 - 2.2 Either:
 - 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or			
3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection.			
Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.			
Note: Initial prescriptions to be written by psychiatrists or psychiatric registrars and subsequent prescriptions can be written by General Practitioners.			
PERICYAZINE			
Tab 2.5 mg	12.49	100	✓ Neulactil
Tab 10 mg	44.45	100	✓ Neulactil
QUETIAPINE			
Tab 25 mg	7.00	60	✓ Dr Reddy's Quetiapine
	16.78	90	✓ Seroquel
Tab 100 mg	14.00	60	✓ Quetapel
	32.59	90	✓ Dr Reddy's Quetiapine
Tab 200 mg	24.00	60	✓ Seroquel
	56.70	90	✓ Quetapel
Tab 300 mg	40.00	60	✓ Dr Reddy's Quetiapine
	95.40	90	✓ Seroquel
			✓ Quetapel

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RISPERIDONE				
Tab 0.5 mg	3.51	60	✓	Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓	Ridal
	5.20	20	✓	Risperdal
Tab 1 mg	6.00	60	✓	Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓	Ridal
	30.77	60	✓	Risperdal
Tab 2 mg	11.00	60	✓	Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓	Ridal
	61.53	60	✓	Risperdal
Tab 3 mg	15.00	60	✓	Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓	Ridal
	92.32	60	✓	Risperdal
Tab 4 mg	20.00	60	✓	Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓	Ridal
	123.05	30 ml	✓	Risperdal
Oral liq 1 mg per ml	18.35	30 ml	✓	Apo-Risperidone ✓ Risperon ✓ Risperdal
	45.92			
TRIFLUOPERAZINE HYDROCHLORIDE				
Tab 1 mg	9.83	100	✓	Stelazine
Tab 2 mg	14.64	100	✓	Stelazine
Tab 5 mg	16.66	100	✓	Stelazine
ZIPRASIDONE – Subsidy by endorsement				
Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.				
Cap 20 mg	87.88	60	✓	Zeldox
Cap 40 mg	164.78	60	✓	Zeldox
Cap 60 mg	247.17	60	✓	Zeldox
Cap 80 mg	329.56	60	✓	Zeldox
ZUCLOPENTHIXOL HYDROCHLORIDE				
Tab 10 mg	31.45	100	✓	Clopixol
Depot Injections				
FLUPENTHIXOL DECANOATE				
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO	13.14	5	✓	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO	20.90	5	✓	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	40.87	5	✓	Fluanxol

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUPHENAZINE DECANOATE				
Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO	17.60	5	✓	Modecate
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO	27.90	5	✓	Modecate
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	154.50	5	✓	Modecate
HALOPERIDOL DECANOATE				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	28.39	5	✓	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	55.90	5	✓	Haldol Concentrate
PIPTHIAZINE PALMITATE				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	178.48	10	✓	Pipartil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	353.32	10	✓	Pipartil
RISPERIDONE – Special Authority see SA0926 below – Retail pharmacy				
Microspheres for injection 25 mg	175.00	1	✓	Risperdal Consta
Microspheres for injection 37.5 mg	230.00	1	✓	Risperdal Consta
Microspheres for injection 50 mg	280.00	1	✓	Risperdal Consta

►SA0926 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had less than 12 months treatment with risperidone microspheres; and
- 1.2 There is no clinical reason to discontinue treatment; or

- 2 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres.

Note: Risperidone microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone microspheres.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO 19.80 5 ✓ Clopixol

Orodispersible Antipsychotics

OLANZAPINE – Special Authority see SA0739 below – Retail pharmacy

Wafer 5 mg 102.19 28 ✓ Zyprexa Zydys
 Wafer 10 mg 204.37 28 ✓ Zyprexa Zydys

►SA0739 Special Authority for Subsidy

Initial application only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient meets the current criteria for standard olanzapine tablets; and
- 2 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; or the patient is non-adherent to oral therapy with standard olanzapine tablets; and
- 3 The patient is under direct supervision for administration of medicine.

Renewal only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners.

RISPERIDONE – Special Authority see SA0927 below – Retail pharmacy

Orally-disintegrating tablets 0.5 mg	21.42	28	✓	Risperdal Quicklet
Orally-disintegrating tablets 1 mg	42.84	28	✓	Risperdal Quicklet
Orally-disintegrating tablets 2 mg	85.71	28	✓	Risperdal Quicklet

SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

Anxiolytics

ALPRAZOLAM

Tab 250 µg	3.15	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 500 µg	4.10	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 1 mg	7.25	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

BUSPIRONE HYDROCHLORIDE – Special Authority see SA0863 below – Retail pharmacy

Tab 5 mg	28.00	100	✓	Pacific Buspirone
Tab 10 mg	17.00	100	✓	Pacific Buspirone

SA0863 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 For use only as an anxiolytic; and
- 2 Other agents are contraindicated or have failed.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DIAZEPAM				
Tab 2 mg	11.44	500	✓	Arrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 5 mg	13.71	500	✓	Arrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
LORAZEPAM				
Tab 1 mg	16.42	250	✓	Ativan
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 2.5 mg	11.17	100	✓	Ativan
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
OXAZEPAM				
Tab 10 mg	1.98 (5.89)	100		Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 15 mg	2.45 (8.13)	100		Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

Multiple Sclerosis Treatments

►SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstacordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 - 5.5 with 2+ relapses:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

- experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
- b) EDSS score 2.0 with 3+ relapses:
- experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
- a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- 7) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) pregnancy and/or lactation; or
- 4) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- 6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 on the preceding page

Inj 20 mg prefilled syringe 1,089.25 28 ✓ Copaxone

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INTERFERON BETA-1-ALPHA – Special Authority see SA1062 on page 134				
Inj 6 million iu prefilled syringe	1,329.65	4	✓	Avonex
Inj 6 million iu per vial	1,329.65	4	✓	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA1062 on page 134				
Inj 8 million iu per 1 ml	1,322.89	15	✓	Betaferon

Sedatives and Hypnotics

LORMETAZEPAM

Tab 1 mg	3.11	30		Noctamid
	(23.50)			

‡ Safety cap for extemporaneously compounded oral liquid preparations.

MIDAZOLAM

Note: Midazolam injection will be funded if prescribed for intranasal administration for use in palliative care. Note that only the Hypnovel brand is currently indicated for intranasal administration.

Tab 7.5 mg	10.38	100		Hypnovel
	(25.00)			

‡ Safety cap for extemporaneously compounded oral liquid preparations.

Inj 1 mg per ml, 5 ml	10.75	10	✓	Hypnovel
	(14.73)			Pfizer

Inj 5 mg per ml, 3 ml	11.90	5	✓	Hypnovel
	(19.64)			Pfizer

NITRAZEPAM

Tab 5 mg	2.00	100		Nitrados
	(4.98)			

‡ Safety cap for extemporaneously compounded oral liquid preparations.

TEMAZEPAM

Tab 10 mg	0.83	25	✓	Normison
-----------------	------	----	---	----------

‡ Safety cap for extemporaneously compounded oral liquid preparations.

TRIAZOLAM

Tab 125 µg	5.10	100		Hypam
	(6.50)			

‡ Safety cap for extemporaneously compounded oral liquid preparations.

Tab 250 µg	4.10	100		Hypam
	(7.20)			

‡ Safety cap for extemporaneously compounded oral liquid preparations.

ZOPICLONE

Tab 7.5 mg	21.02	500	✓	Apo-Zopiclone
------------------	-------	-----	---	---------------

Stimulants/ADHD Treatments

Stimulants/ADHD treatments

ATOMOXETINE – Special Authority see SA0951 on the next page – Retail pharmacy

Cap 10 mg	107.03	28	✓	Strattera
Cap 18 mg	107.03	28	✓	Strattera
Cap 25 mg	107.03	28	✓	Strattera
Cap 40 mg	107.03	28	✓	Strattera
Cap 60 mg	107.03	28	✓	Strattera
Cap 80 mg	139.11	28	✓	Strattera
Cap 100 mg	139.11	28	✓	Strattera

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

►SA0951 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

DEXAMPHETAMINE SULPHATE – Special Authority see SA0907 below – Retail pharmacy

Only on a controlled drug form

Tab 5 mg	16.50	100	✓ PSM
----------------	-------	-----	-------

►SA0907 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Both:
 - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 3.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients 5 or over - patient has had an approval for dexamphetamine for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (ADHD in patients under 5 - patient has had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Initial application — (Narcolepsy - patient has had an approval for dexamphetamine for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for dexamphetamine for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexamphetamine for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA0908 below – Retail pharmacy

Only on a controlled drug form

Tab immediate-release 5 mg	3.20	30	✓ Rubifen
Tab immediate-release 10 mg	3.00	30	✓ Ritalin
			✓ Rubifen
Tab immediate-release 20 mg	7.85	30	✓ Rubifen
Tab sustained-release 20 mg	10.95	30	✓ Rubifen SR
	50.00	100	✓ Ritalin SR

SA0908 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

3.2 Both:

3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and

3.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients 5 or over - patient has had an approval for methylphenidate for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

2.1 Applicant is a paediatrician or psychiatrist; or

2.2 Both:

2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and

2.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (ADHD in patients under 5 - patient has had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Initial application — (Narcolepsy - patient has had an approval for methylphenidate for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

2.1 Applicant is a paediatrician or psychiatrist; or

2.2 Both:

2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and

2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for methylphenidate for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA0924 below – Retail pharmacy				
Only on a controlled drug form				
Tab extended-release 18 mg	58.96	30	✓	Concerta
Tab extended-release 27 mg	65.44	30	✓	Concerta
Tab extended-release 36 mg	71.93	30	✓	Concerta
Tab extended-release 54 mg	86.24	30	✓	Concerta
Cap modified-release 10 mg	19.50	30	✓	Ritalin LA
Cap modified-release 20 mg	25.50	30	✓	Ritalin LA
Cap modified-release 30 mg	31.90	30	✓	Ritalin LA
Cap modified-release 40 mg	38.25	30	✓	Ritalin LA

►SA0924 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Both:
 - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 3.2.2 Provide name of the recommending specialist; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg	7.71	90	✓	Donepezil-Rex
* Tab 10 mg	14.06	90	✓	Donepezil-Rex

Treatments for Opioid Overdose

NALOXONE HYDROCHLORIDE

a) Up to 5 inj available on a PSO				
b) Only on a PSO				
* Inj 400 µg per ml, 1 ml	33.00	5	✓	Mayne

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Treatments for Substance Dependence

BUPROPION HYDROCHLORIDE				
Tab modified-release 150 mg	65.00	30	✓	Zyban
DISULFIRAM				
Tab 200 mg	24.30	100	✓	Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 below – Retail pharmacy				
Tab 50 mg	180.00	30	✓	ReVia

▶SA0909 | Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

The patient may not have had more than 1 prior approval in the last 12 months.

VARENICLINE TARTRATE – Special Authority see SA1054 below – Retail pharmacy

Tab 1 mg	67.74	28	✓	Champix
		56	✓	Champix
Tab 0.5 mg × 11 and 1 mg × 14	60.48	1 OP	✓	Champix

▶SA1054 | Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

NERVOUS SYSTEM

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 3 The patient has not used varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant.

Note: The patient may not have had more than 1 prior approval in the past 12 months.

Nicotine Gum

NICOTINE

- a) Maximum of 768 piece per prescription
- b) Maximum of 384 piece per dispensing
- c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks.
- d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria.

Gum 2 mg (Fruit)	14.97	96 OP	✓ <u>Habitrol</u>
	23.41		✓ <u>Nicotinell</u>
Gum 2 mg (Mint)	14.97	96 OP	✓ <u>Habitrol</u>
	23.41		✓ <u>Nicotinell</u>
Gum 4 mg (Fruit)	20.02	96 OP	✓ <u>Habitrol</u>
	23.41		✓ <u>Nicotinell</u>
Gum 4 mg (Mint)	20.02	96 OP	✓ <u>Habitrol</u>
	23.41		✓ <u>Nicotinell</u>

(Nicotinell Gum 2 mg (Fruit) to be delisted 1 January 2011)

(Nicotinell Gum 2 mg (Mint) to be delisted 1 January 2011)

(Nicotinell Gum 4 mg (Fruit) to be delisted 1 January 2011)

(Nicotinell Gum 4 mg (Mint) to be delisted 1 January 2011)

Nicotine Lozenge

NICOTINE

- a) Maximum of 432 loz per prescription
- b) Maximum of 216 loz per dispensing
- c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks.
- d) The maximum of 216 loz per dispensing cannot be waived via Access Exemption Criteria.

Lozenge 1 mg	11.08	36 OP	✓ <u>Habitrol</u>
Lozenge 2 mg	11.08	36 OP	✓ <u>Habitrol</u>

Nicotine Patch

NICOTINE

- a) Maximum of 56 patch per prescription
- b) Maximum of 28 patch per dispensing
- c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks.
- d) The maximum of 28 patch per dispensing cannot be waived via Access Exemption Criteria.

Patch 7 mg	10.53	7 OP	✓ <u>Habitrol</u>
Patch 14 mg	11.63	7 OP	✓ <u>Habitrol</u>
Patch 21 mg	12.32	7 OP	✓ <u>Habitrol</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	47.89	100	✓	Myleran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml	20.00	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 15 ml	22.50	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 45 ml	50.00	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 100 ml	105.00	1	✓	Carboplatin Ebewe
Inj 1 mg for ECP	0.15	1 mg	✓	Baxter
CARMUSTINE – PCT only – Specialist				
Inj 100 mg	204.13	1	✓	BICNU
Inj 100 mg for ECP	204.13	100 mg OP	✓	Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	22.35	25	✓	Leukeran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	15.00	1	✓	Cisplatin Ebewe
	19.00		✓	Mayne
Inj 1 mg per ml, 100 ml	21.00	1	✓	Cisplatin Ebewe
	38.00		✓	Mayne
Inj 1 mg for ECP	0.27	1 mg	✓	Baxter
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	25.71	50	✓	Cycloblastin
Inj 1 g – PCT – Retail pharmacy-Specialist	23.65	1	✓	Endoxan
	127.80	6	✓	Cytosan
Inj 2 g – PCT only – Specialist	47.30	1	✓	Endoxan
Inj 1 mg for ECP – PCT only – Specialist	0.03	1 mg	✓	Baxter
IFOSFAMIDE – PCT only – Specialist				
Inj 1 g	96.00	1	✓	Holoxan
Inj 2 g	180.00	1	✓	Holoxan
Inj 1 mg for ECP	0.10	1 mg	✓	Baxter
LOMUSTINE – PCT only – Specialist				
Cap 10 mg	132.59	20	✓	CeeNU
Cap 40 mg	399.15	20	✓	CeeNU
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist	31.31	25	✓	Alkeran
Inj 50 mg – PCT only – Specialist	52.15	1	✓	Alkeran
OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 on the next page				
Inj 50 mg	55.00	1	✓	Oxaliplatin Ebewe
	200.00		✓	Eloxatin
Inj 100 mg	110.00	1	✓	Oxaliplatin Ebewe
	400.00		✓	Eloxatin
Inj 1 mg for ECP	1.20	1 mg	✓	Baxter

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	✓

▶SA0900 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has metastatic colorectal cancer; and
 - 1.2 To be used for first or second line use as part of a combination chemotherapy regimen; or
- 2 Both:
 - 2.1 The patient has stage III (Duke's C) colorectal* cancer; and
 - 2.2 Adjuvant oxaliplatin to be given in combination with a fluoropyrimidine (fluorouracil or capecitabine).

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with * are Unapproved Indications, oxaliplatin is indicated for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour.

THIOTEPA – PCT only – Specialist

Inj 15 mg	CBS	1	✓ Bedford ^{s29}
-----------------	-----	---	--------------------------

Antimetabolites

CALCIUM FOLINATE

Tab 15 mg – PCT – Retail pharmacy-Specialist.....	63.89	10	✓ Mayne
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist.....	17.10	5	✓ Mayne
Inj 50 mg – PCT – Retail pharmacy-Specialist.....	24.50	5	✓ <u>Calcium Folate</u> Ebewe
Inj 100 mg – PCT only – Specialist.....	9.75	1	✓ Calcium Folate Ebewe
Inj 300 mg – PCT only – Specialist.....	30.00	1	✓ Calcium Folate Ebewe
Inj 1 g – PCT only – Specialist.....	90.00	1	✓ Calcium Folate Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	0.10	1 mg	✓ Baxter

CAPECITABINE – Retail pharmacy-Specialist – Special Authority see SA1049 below

Tab 150 mg	115.00	60	✓ Xeloda
Tab 500 mg	705.00	120	✓ Xeloda

▶SA1049 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has advanced gastrointestinal malignancy; or
- 2 The patient has metastatic breast cancer; or
- 3 The patient has stage III (Duke's stage C) colorectal*# cancer and undergone surgery; or
- 4 Both:
 - 4.1 The patient has stage II (Dukes' stage B) colorectal* cancer and has undergone surgery; and
 - 4.2 Any of the following:
 - 4.2.1 The patient has stage T4 disease; or
 - 4.2.2 The patient has vascular invasion; or

continued...

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
4.2.3 Fewer than 10 lymph nodes were examined at resection; or			
5 All of the following:			
5.1 The patient has locally advanced (clinically or radiologically staged T3/T4: N0,1,2) rectal cancer; and			
5.2 Surgery is planned; and			
5.3 Capecitabine to be given prior to surgery (neoadjuvant); and			
5.4 Capecitabine to be given at a maximum dose of 825 mg/m ² twice daily in combination with radiation therapy for a maximum of 6 weeks; or			
6 Both:			
6.1 The patient has poor venous access or needle phobia*; and			
6.2 The patient requires a substitute for single agent fluoropyrimidine*.			
Note: Indications marked with * are Unapproved Indications, # capecitabine is approved for stage III (Duke's stage C) colon cancer.			
Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:			
Either:			
1 The patient requires continued therapy; or			
2 The tumour has relapsed and requires re-treatment.			
CLADRIBINE – PCT only – Specialist			
Inj 2 mg per ml, 5 ml	873.00	1	✓ Litak S29
Inj 1 mg per ml, 10 ml	5,249.72	7	✓ Leustatin
Inj 10 mg for ECP	749.96	10 mg OP	✓ Baxter
CYTARABINE			
Inj 100 mg – PCT – Retail pharmacy-Specialist	76.00	5	✓ Pfizer
	80.00		✓ Mayne
Inj 500 mg – PCT – Retail pharmacy-Specialist	18.15	1	✓ Pfizer
	95.36	5	✓ Mayne
Inj 1 g – PCT – Retail pharmacy-Specialist	37.00	1	✓ Pfizer
	42.65		✓ Mayne
Inj 2 g – PCT – Retail pharmacy-Specialist	31.00	1	✓ Pfizer
	34.47		✓ Mayne
Inj 1 mg for ECP – PCT only – Specialist	0.27	10 mg	✓ Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist	15.20	100 mg OP	✓ Baxter
FLUDARABINE PHOSPHATE – PCT only – Specialist			
Tab 10 mg	867.00	20	✓ Fludara Oral
Inj 50 mg	1,430.00	5	✓ Fludara
Inj 50 mg for ECP	286.00	50 mg OP	✓ Baxter
FLUOROURACIL SODIUM			
Inj 50 mg per ml, 10 ml – PCT only – Specialist	26.25	5	✓ Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist	7.50	1	✓ Fluorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist	13.55	1	✓ Mayne
Inj 50 mg per ml, 50 ml – PCT only – Specialist	18.00	1	✓ Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist	34.50	1	✓ Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.77	100 mg	✓ Baxter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1012 on the next page			
Inj 1 g	62.50	1	✓ Gemcitabine Ebewe
	349.20		✓ Gemzar
Inj 200 mg	12.50	1	✓ Gemcitabine Ebewe
	78.00		✓ Gemzar
Inj 1 mg for ECP	0.07	1 mg	✓ Baxter

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
---	----------------------------	--

►SA1012 Special Authority for Subsidy

Initial application — (Hodgkin's Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has Hodgkin's Disease*; and
- 2 Any of the following:
 - 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and
- 3 Gemcitabine to be given for a maximum of 6 treatment cycles.

Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has T-cell Lymphoma*; and
- 2 Gemcitabine to be given for a maximum of 6 treatment cycles.

Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or
- 2 The patient has advanced malignant mesothelioma; or
- 3 The patient has advanced pancreatic carcinoma; or
- 4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or
- 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic).

Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

IRINOTECAN – PCT only – Specialist – Special Authority see SA0878 below

Inj 20 mg per ml, 2 ml	41.00	1	<ul style="list-style-type: none"> ✓ Camptosar ✓ Irinotecan-Rex
Inj 20 mg per ml, 5 ml	100.00	1	<ul style="list-style-type: none"> ✓ Camptosar ✓ Irinotecan-Rex
Inj 1 mg for ECP	1.04	1 mg	<ul style="list-style-type: none"> ✓ Baxter

►SA0878 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic colorectal cancer; and
- 2 Either:
 - 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or
 - 2.2 As single agent chemotherapy in fluoropyrimidine-relapsed disease.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

MERCAPTOPURINE – PCT – Retail pharmacy-Specialist

Tab 50 mg	47.06	25	<ul style="list-style-type: none"> ✓ Purinethol
-----------------	-------	----	--

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
METHOTREXATE			
* Tab 2.5 mg – PCT – Retail pharmacy-Specialist.....	5.22	30	✓ Methoblastin
* Tab 10 mg – PCT – Retail pharmacy-Specialist.....	40.93	50	✓ Methoblastin
* Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist.....	23.65	5	✓ Mayne
* Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist.....	48.00	5	✓ Hospira
* Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist.....	90.00	1	✓ Hospira
* Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist.....	25.00	1	✓ Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist.....	125.00	1	✓ Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist.....	0.09	1 mg	✓ Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist.....	4.73	5 mg OP	✓ Baxter
THIOGUANINE – PCT – Retail pharmacy-Specialist			
Tab 40 mg.....	97.16	25	✓ Lanvis

Other Cytotoxic Agents

AMSACRINE – PCT only – Specialist			
Inj 75 mg.....	CBS	6	✓ Amsidine S29
ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA0879 below			
Cap 0.5 mg.....	CBS	100	✓ Agrylin S29 ✓ Teva S29

▶SA0879 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has primary thrombocythaemia; and
- 2 Either:
 - 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or
 - 2.2 is intolerant or refractory to hydroxyurea or interferon.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.

ARSENIC TRIOXIDE – PCT only – Specialist			
Inj 10 mg.....	4,817.00	10	✓ AFT S29
BLEOMYCIN SULPHATE – PCT only – Specialist			
Inj 15,000 iu.....	120.00	1	✓ DBL Bleomycin Sulfate
Inj 1,000 iu for ECP.....	9.28	1,000 iu	✓ Baxter
COLASPASE (L-ASPARAGINASE) – PCT only – Specialist			
Inj 10,000 iu.....	102.32	1	✓ Leunase
Inj 10,000 iu for ECP.....	102.32	10,000 iu OP	✓ Baxter
DACARBAZINE – PCT only – Specialist			
Inj 200 mg.....	48.00	1	✓ Hospira
Inj 200 mg for ECP.....	48.00	200 mg OP	✓ Baxter
DACTINOMYCIN (ACTINOMYCIN D) – PCT only – Specialist			
Inj 0.5 mg.....	13.52	1	✓ Cosmegen
Inj 0.5 mg for ECP.....	13.52	0.5 mg OP	✓ Baxter

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DAUNORUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 10 ml	118.72	1	✓	Pfizer ^{§29}
Inj 5 mg per ml, 4 ml	99.00	1	✓	Mayne
Inj 20 mg for ECP	118.72	20 mg OP	✓	Baxter
DOCETAXEL – PCT only – Specialist – Special Authority see SA0880 below				
Inj 20 mg	325.00	1	✓	Docetaxel Ebewe
	460.00		✓	Taxotere
Inj 80 mg	1,300.00	1	✓	Docetaxel Ebewe
	1,650.00		✓	Taxotere
Inj 1 mg for ECP	17.55	1 mg	✓	Baxter
►SA0880 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
Any of the following:				
1 Both:				
1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and				
1.2 Either:				
1.2.1 Has not received prior chemotherapy; or				
1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or				
2 The patient has metastatic breast cancer; or				
3 Both:				
3.1 The patient has early breast cancer; and				
3.2 Docetaxel is to be given concurrently with trastuzumab; or				
4 Both:				
4.1 The patient has non small-cell lung cancer; and				
4.2 Either:				
4.2.1 Has advanced disease (stage IIIa or above); or				
4.2.2 Is receiving combined chemotherapy and radiotherapy; or				
5 Both:				
5.1 The patient has small-cell lung cancer*; and				
5.2 Docetaxel is to be used as second-line therapy.				
Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 The patient has metastatic breast cancer, non small-cell lung cancer, or small-cell lung cancer*; and				
2 Either:				
2.1 The patient requires continued therapy; or				
2.2 The tumour has relapsed and requires re-treatment.				
Note: indications marked with * are Unapproved Indications.				
DOXORUBICIN – PCT only – Specialist				
Inj 10 mg	10.00	1	✓	Doxorubicin Ebewe
Inj 50 mg	40.00	1	✓	Doxorubicin Ebewe
Inj 100 mg	80.00	1	✓	Doxorubicin Ebewe
Inj 200 mg	150.00	1	✓	Doxorubicin Ebewe
Inj 1 mg for ECP	0.88	1 mg	✓	Baxter

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
EPIRUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 5 ml	25.00	1	✓ Epirubicin Ebewe
Inj 2 mg per ml, 25 ml	87.50	1	✓ Epirubicin Ebewe
Inj 2 mg per ml, 50 ml	125.00	1	✓ Epirubicin Ebewe
Inj 2 mg per ml, 100 ml	210.00	1	✓ Epirubicin Ebewe
Inj 1 mg for ECP	1.80	1 mg	✓ Baxter
ETOPOSIDE			
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	✓ Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist	340.73	10	✓ Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist	25.00	1	✓ Mayne
	612.20	10	✓ Vepesid
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	✓ Baxter
ETOPOSIDE PHOSPHATE – PCT only – Specialist			
Inj 100 mg (of etoposide base)	40.00	1	✓ Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	✓ Baxter
HYDROXYUREA – PCT – Retail pharmacy-Specialist			
Cap 500 mg	31.76	100	✓ Hydrea
IDARUBICIN HYDROCHLORIDE – PCT only – Specialist			
Cap 5 mg	115.00	1	✓ Zavedos
Cap 10 mg	144.50	1	✓ Zavedos
Inj 5 mg	170.00	1	✓ Zavedos
Inj 10 mg	340.00	1	✓ Zavedos
Inj 1 mg for ECP	37.74	1 mg	✓ Baxter
MESNA – PCT only – Specialist			
Tab 400 mg	210.65	50	✓ Uromitexan
Tab 600 mg	314.40	50	✓ Uromitexan
Inj 100 mg per ml, 4 ml	137.04	15	✓ Uromitexan
Inj 100 mg per ml, 10 ml	314.66	15	✓ Uromitexan
Inj 1 mg for ECP	2.29	100 mg	✓ Baxter
MITOMYCIN C – PCT only – Specialist			
Inj 2 mg	283.00	10	✓ Mitomycin-C ^{S29}
Inj 5 mg	72.75	1	✓ Arrow ^{S29}
Inj 10 mg	808.00	5	✓ Mitomycin-C ^{S29}
Inj 1 mg for ECP	16.13	1 mg	✓ Baxter
MITOZANTRONE – PCT only – Specialist			
Inj 2 mg per ml, 5 ml	110.00	1	✓ Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml	100.00	1	✓ Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml	407.50	1	✓ Onkotrone
Inj 1 mg for ECP	5.65	1 mg	✓ Baxter
PACLITAXEL – PCT only – Specialist			
Inj 30 mg	137.50	5	✓ Paclitaxel Ebewe
Inj 100 mg	91.67	1	✓ Paclitaxel Ebewe
Inj 150 mg	137.50	1	✓ Paclitaxel Ebewe
Inj 300 mg	275.00	1	✓ Paclitaxel Ebewe
Inj 600 mg	550.00	1	✓ Paclitaxel Ebewe
Inj 1 mg for ECP	1.02	1 mg	✓ Baxter
PENTOSTATIN (DEOXYCOFORMYCIN) – PCT only – Specialist			
Inj 10 mg	CBS	1	✓ Nipent ^{S29}

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PROCARBAZINE HYDROCHLORIDE – PCT only – Specialist				
Cap 50 mg	225.00	50	✓	Natulan ^{S29}
TEMOZOLIMIDE – Special Authority see SA1063 below – Retail pharmacy				
Cap 5 mg	50.00	5	✓	Temodal
Cap 20 mg	170.00	5	✓	Temodal
Cap 100 mg	840.00	5	✓	Temodal
Cap 250 mg	2,100.00	5	✓	Temodal
►SA1063 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:				
1 Either:				
1.1 Patient has newly diagnosed glioblastoma multiforme; or				
1.2 Patient has newly diagnosed anaplastic astrocytoma*; and				
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and				
3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m ² .				
Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.				
THALIDOMIDE – PCT only – Specialist – Special Authority see SA0882 below				
Only on a controlled drug form				
Cap 50 mg	490.00	28	✓	Thalidomide Pharmion
►SA0882 Special Authority for Subsidy				
Initial application — (for new patients) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:				
1 The patient has refractory, progressive or relapsed multiple myeloma; and				
2 The patient has received prior chemotherapy.				
Initial application — (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005.				
Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.				
TRETINOIN				
Cap 10 mg	435.90	100	✓	Vesanoid
VINBLASTINE SULPHATE				
Inj 10 mg – PCT – Retail pharmacy-Specialist	27.50	1	✓	Mayne
	137.50	5	✓	Mayne
Inj 1 mg for ECP – PCT only – Specialist	3.05	1 mg	✓	Baxter
VINCRIStINE SULPHATE				
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	108.00	5	✓	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	116.00	5	✓	Hospira
Inj 1 mg for ECP – PCT only – Specialist	15.77	1 mg	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VINORELBINE – PCT only – Specialist – Special Authority see SA1013 below				
Inj 10 mg per ml, 1 ml	24.00	1	✓	Navelbine
	42.00		✓	Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml	120.00	1	✓	Navelbine
	210.00		✓	Vinorelbine Ebewe
Inj 1 mg for ECP	2.71	1 mg	✓	Baxter

►SA1013 Special Authority for Subsidy

Initial application — (Hodgkin's Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has Hodgkin's Disease*; and
- 2 Any of the following:
 - 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and
- 3 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has T-cell Lymphoma*; and
- 2 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has metastatic breast cancer; or
- 2 The patient has non-small cell lung cancer (stage IIIa, or above); or
- 3 All of the following:
 - 3.1 The patient has stage IB-IIIa non-small cell lung cancer; and
 - 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and
 - 3.3 The patient has good performance status (WHO/ECOG grade 0-1).

Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

Protein-tyrosine Kinase Inhibitors

DASATINIB – Special Authority see SA0976 on the next page

Tab 20 mg	3,774.06	60	✓	Sprycel
Tab 50 mg	6,214.20	60	✓	Sprycel
Tab 70 mg	7,692.58	60	✓	Sprycel
Tab 100 mg	6,214.20	30	✓	Sprycel

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Wellington	

Special Authority criteria for CML - access by application

- Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- Subsidised for use as monotherapy only.
- Initial approvals valid seven months.
- Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - complete haematologic response (as characterised by an absolute neutrophil count (ANC) $> 1.5 \times 10^9/L$, platelets $> 100 \times 10^9/L$, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts $< 5\%$ (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) $> 1.0 \times 10^9/L$, platelets $> 20 \times 10^9/L$, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts $< 5\%$ (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts $< 15\%$, BM and PB blasts and promyelocytes $< 30\%$, PB basophils $< 20\%$ and absence of extramedullary disease other than spleen and liver).
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB HYDROCHLORIDE – Retail pharmacy-Specialist – Special Authority see SA1044 below

Tab 100 mg	3,100.00	30	✓ Tarceva
Tab 150 mg	3,950.00	30	✓ Tarceva

►SA1044 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and
- Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
- Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESYLATE – Special Authority see SA0643 on the next page

Tab 100 mg	2,400.00	60	✓ Glivec
------------------	----------	----	----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

➔SA0643 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The CML/GIST Co-ordinator Phone: (04) 460 4990
 PHARMAC Facsimile: (04) 916 7571
 PO Box 10 254 Email: mary.chesterfield@pharmac.govt.nz
 Wellington

Special Authority criteria for CML – access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10⁹/L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10⁹/L, platelets > 20 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 3) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST – access by application

- a) Funded for patients:
 - 1) with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

SUNITINIB – Special Authority see SA1055 on the next page – Retail pharmacy

Cap 12.5 mg	2,315.38	28	✓ Sutent
Cap 25 mg	4,630.77	28	✓ Sutent
Cap 50 mg	9,261.54	28	✓ Sutent

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1055 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Either:
 - 2.1 The patient is sunitinib treatment naive; or
 - 2.2 The patient received sunitinib prior to 1 November 2010 and disease has not progressed; and
- 3 The patient has good performance status (WHO/ECOG grade 0-1); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis based on the NCCN clinical practice guidelines for kidney cancer; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

NCCN clinical practice guidelines for kidney cancer are available at

http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, page 79

BICALUTAMIDE – Special Authority see SA0941 below – Retail pharmacy

Tab 50 mg	27.10	30	✓ Bicalox
-----------------	-------	----	------------------

►SA0941 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the patient has advanced prostate cancer.

FLUTAMIDE – Retail pharmacy-Specialist

Tab 250 mg	55.00	100	✓ Flutamin
------------------	-------	-----	-------------------

MEGESTROL ACETATE – Retail pharmacy-Specialist

Tab 160 mg	57.92	30	✓ Apo-Megestrol
------------------	-------	----	------------------------

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 on the next page – Retail pharmacy

Inj 50 µg per ml, 1 ml	25.65	5	✓ Hospira
	43.50		✓ Sandostatin
Inj 100 µg per ml, 1 ml	48.50	5	✓ Hospira
	81.00		✓ Sandostatin
Inj 500 µg per ml, 1 ml	175.00	5	✓ Hospira
	399.00		✓ Sandostatin
Inj LAR 10 mg prefilled syringe	1,772.50	1	✓ Sandostatin LAR
Inj LAR 20 mg prefilled syringe	2,358.75	1	✓ Sandostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1	✓ Sandostatin LAR

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 µg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TAMOXIFEN CITRATE				
* Tab 10 mg	10.80	100	✓	Genox
* Tab 20 mg	6.66	60	✓	Tamoxifen Sandoz
	11.10	100	✓	Genox

Aromatase Inhibitors

ANASTROZOLE				
Tab 1 mg	26.55	30	✓	Aremed
	29.50		✓	Arimidex
			✓	DP-Anastrozole
EXEMESTANE – Additional subsidy by Special Authority see SA1000 below – Retail pharmacy				
Tab 25 mg	26.55	30		
	(175.00)			Aromasin

SA1000 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria:
All of the following:

- 1 Patient is a postmenopausal woman; and
- 2 Patient has hormone receptor positive breast cancer; and
- 3 Any of the following:
 - 3.1 The patient was receiving funded exemestane prior to 1 February 2010; or
 - 3.2 The patient has advanced breast cancer and a very clear history of intolerance to anastrozole or letrozole; or
 - 3.3 The patient has advanced breast cancer and disease has progressed following treatment with anastrozole or letrozole.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefitting from treatment.

LETROZOLE				
Tab 2.5 mg	26.55	30	✓	Letara

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist				
* Tab 50 mg	18.45	100	✓	Azamun
	(34.90)			Imuprine
* Inj 50 mg	60.00	1	✓	Imuran
<i>(Azamun Tab 50 mg to be delisted 1 January 2011)</i>				
<i>(Imuran Tab 50 mg to be delisted 1 January 2011)</i>				

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 on the next page – Retail pharmacy

Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically.

Tab 500 mg	70.00	50	✓	Cellcept
	85.00		✓	Myaccord
Cap 250 mg	70.00	100	✓	Cellcept
	85.00		✓	Myaccord
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	285.00	165 ml OP	✓	Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

►SA1041 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Transplant recipient; or
- 2 Both:
 - Patients with diseases where
 - 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.2 Either:
 - Patients with diseases where
 - 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
 - 2.2.2 Cyclophosphamide treatment is contraindicated.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist			
Inj 50 mg per ml, 5 ml	2,137.50	5	✓ ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist			
Subsidised only for bladder cancer.			
Inj 2-8 × 100 million CFU	187.37	1	✓ OncoTICE
RITUXIMAB – PCT only – Specialist – Special Authority see SA1050 below			
Inj 100 mg per 10 ml vial	1,195.00	2	✓ Mabthera
Inj 500 mg per 50 ml vial	2,987.00	1	✓ Mabthera
Inj 1 mg for ECP	6.27	1 mg	✓ Baxter

►SA1050 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab is not funded for Chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

- 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab is not funded for Chronic lymphocytic leukaemia/small lymphocytic lymphoma

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1017 below

Inj 150 mg vial	1,350.00	1	✓ Herceptin
Inj 440 mg vial	3,875.00	1	✓ Herceptin
Inj 1 mg for ECP	9.36	1 mg	✓ Baxter

SA1017 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has metastatic breast cancer expressing HER-2 IHC 3+ or FISH+.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer; and
- 2 The cancer has not progressed.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
--	---	-----	---------------------	-------------------------------------

continued...

- 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
- 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
- 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
- 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Note: For patients with previous Special Authority approvals for a maximum cumulative dose of 20mg/kg (9 weeks treatment) granted after 1 April 2009 the approval period has been extended to allow claims for a maximum cumulative dose of 106mg/kg (12 months treatment).

Other Immunosuppressants

CYCLOSPORIN

Cap 25 mg	59.50	50	✓ Neoral
Cap 50 mg	118.54	50	✓ Neoral
Cap 100 mg	237.08	50	✓ Neoral
Oral liq 100 mg per ml	264.17	50 ml OP	✓ Neoral

SIROLIMUS – Special Authority see SA0866 below – Retail pharmacy

Tab 1 mg	813.00	100	✓ Rapamune
Tab 2 mg	1,626.00	100	✓ Rapamune
Oral liq 1 mg per ml	487.80	60 ml OP	✓ Rapamune

SA0866 | Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see SA0669 below – Retail pharmacy

Cap 0.5 mg	214.00	100	✓ Prograf
Cap 1 mg	428.00	100	✓ Prograf
Cap 5 mg	1,070.00	50	✓ Prograf

SA0669 | Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Antiallergy Preparations

BEE VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Retail pharmacy

Maintenance kit - 6 vials 120 µg freeze dried venom, 6 diluent			
1.8 ml	285.00	1 OP	✓ Albany
Treatment kit - 1 vial 550 µg freeze dried venom, 1 diluent			
9 ml, 3 diluent 1.8 ml	285.00	1 OP	✓ Albany

▶SA0053 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

WASP VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Retail pharmacy

Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried			
polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml	285.00	1 OP	✓ Albany
Treatment kit (Yellow jacket venom) - 1 vial 550 µg freeze			
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml	285.00	1 OP	✓ Albany

▶SA0053 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Antihistamines

CETIRIZINE HYDROCHLORIDE

* Tab 10 mg	2.21	100	✓ <u>Zetop</u>
*‡ Oral liq 1 mg per ml	3.50	200 ml	✓ <u>Cetirizine - AFT</u>

CHLORPHENIRAMINE MALEATE

*‡ Oral liq 2 mg per 5 ml	8.06	500 ml	✓ <u>Histafen</u>
---------------------------------	------	--------	-------------------

DEXTROCHLORPHENIRAMINE MALEATE

* Tab 2 mg	1.01	20	
	(4.93)		Polaramine
	2.02	40	
	(7.99)		Polaramine
*‡ Oral liq 2 mg per 5 ml	1.77	100 ml	
	(10.29)		Polaramine

FEXOFENADINE HYDROCHLORIDE

* Tab 60 mg	4.34	20	
	(11.53)		Telfast
* Tab 120 mg	4.74	10	
	(11.53)		Telfast
	14.22	30	
	(29.81)		Telfast

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LORATADINE				
* Tab 10 mg	2.09	100	✓	Loraclear Hayfever Relief
* Oral liq 1 mg per ml	3.10	100 ml	✓	Lorapaed
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	2.72	50	✓	Allersoothe
* Tab 25 mg	4.44	50	✓	Allersoothe
*‡ Oral liq 5 mg per 5 ml	3.10	100 ml	✓	Promethazine Winthrop Elixir
* Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	11.00	5	✓	Mayne
TRIMEPRAZINE TARTRATE				
‡ Oral liq 30 mg per 5 ml	2.79 (8.06)	100 ml OP		Vallergan Forte

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 100 µg per dose CFC-free	12.50	200 dose OP	✓	Beclazone 100
Aerosol inhaler, 250 µg per dose CFC-free	22.67	200 dose OP	✓	Beclazone 250
Aerosol inhaler, 50 µg per dose CFC-free	8.54	200 dose OP	✓	Beclazone 50
BUDESONIDE				
Powder for inhalation, 100 µg per dose	17.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 200 µg per dose	19.00	200 dose OP	✓	Budenocort
			✓	Pulmicort Turbuhaler
Powder for inhalation, 400 µg per dose	32.00	200 dose OP	✓	Budenocort
			✓	Pulmicort Turbuhaler
FLUTICASONE				
Aerosol inhaler, 50 µg per dose CFC-free	7.50	120 dose OP	✓	Flixotide
Powder for inhalation, 50 µg per dose	5.10 (8.67)	60 dose OP		Flixotide Accuhaler
Powder for inhalation, 100 µg per dose	7.50 (13.87)	60 dose OP		Flixotide Accuhaler
Aerosol inhaler, 125 µg per dose CFC-free	13.60	120 dose OP	✓	Flixotide
Aerosol inhaler, 250 µg per dose CFC-free	27.20	120 dose OP	✓	Flixotide
Powder for inhalation, 250 µg per dose	13.60 (24.51)	60 dose OP		Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 µg beclomethasone or budesonide (or 100 µg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
EFORMOTEROL FUMARATE – See prescribing guideline on the preceding page				
Powder for inhalation, 6 µg per dose, breath activated	16.90	60 dose OP	✓	Oxis Turbuhaler
Powder for inhalation, 12 µg per dose, and monodose device	35.80	60 dose	✓	Foradil
SALMETEROL – See prescribing guideline on the preceding page				
Aerosol inhaler CFC-free, 25 µg per dose	26.46	120 dose OP	✓	Serevent
Powder for inhalation, 50 µg per dose, breath activated	26.46	60 dose OP	✓	Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

►SA0958 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Both:
 - Has, for 3 months or more, been treated with:
 - 1.2.1 An inhaled long-acting beta adrenoceptor agonist; and
 - 1.2.2 Inhaled corticosteroids at a dose of at least 400 µg per day beclomethasone or budesonide, or 200 µg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Both:
 - Has, for 3 months or more, been treated with:
 - 2.2.1 An inhaled long-acting beta adrenoceptor agonist; and
 - 2.2.2 Inhaled corticosteroids at a dose of at least 800 µg per day beclomethasone or budesonide, or 500 µg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0958 above – Retail pharmacy

Aerosol inhaler 100 µg with eformoterol fumarate 6 µg	55.00	120 dose OP	✓	Vannair
Powder for inhalation 100 µg with eformoterol fumarate 6 µg	55.00	120 dose OP	✓	Symbicort Turbuhaler 100/6
Aerosol inhaler 200 µg with eformoterol fumarate 6 µg	60.00	120 dose OP	✓	Vannair
Powder for inhalation 200 µg with eformoterol fumarate 6 µg	60.00	120 dose OP	✓	Symbicort Turbuhaler 200/6
Powder for inhalation 400 µg with eformoterol fumarate 12 µg – No more than 2 dose per day	60.00	60 dose OP	✓	Symbicort Turbuhaler 400/12

FLUTICASONE WITH SALMETEROL – Special Authority see SA0958 above – Retail pharmacy

Aerosol inhaler 50 µg with salmeterol 25 µg	37.48	120 dose OP	✓	Seretide
Aerosol inhaler 125 µg with salmeterol 25 µg	49.69	120 dose OP	✓	Seretide
Powder for inhalation 100 µg with salmeterol 50 µg – No more than 2 dose per day	37.48	60 dose OP	✓	Seretide Accuhaler
Powder for inhalation 250 µg with salmeterol 50 µg – No more than 2 dose per day	49.69	60 dose OP	✓	Seretide Accuhaler

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Beta-Adrenoceptor Agonists

SALBUTAMOL

‡ Oral liq 2 mg per 5 ml	1.99	150 ml	✓	Salapin
Infusion 1 mg per ml, 5 ml	118.38	10		
	(130.21)			Ventolin
Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO	12.90	5	✓	Ventolin

Inhaled Beta-Adrenoceptor Agonists

SALBUTAMOL

Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO	3.80	200 dose OP	✓	Respigen
	(6.00)		✓	Salamol Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	3.52	20	✓	Asthalin
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	3.70	20	✓	Asthalin

TERBUTALINE SULPHATE

Powder for inhalation, 250 µg per dose, breath activated	22.00	200 dose OP	✓	Bricanyl Turbuhaler
--	-------	-------------	---	----------------------------

Inhaled Anticholinergic Agents

Inhaled Anticholinergic agents

IPRATROPIUM BROMIDE

Aerosol inhaler, 20 µg per dose CFC-free	16.20	200 dose OP	✓	Atrovent
Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO	3.79	20	✓	Ipratropium Steri-Neb
			✓	Univent
Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO	4.06	20	✓	Ipratropium Steri-Neb
			✓	Univent

(Ipratropium Steri-Neb Nebuliser soln, 250 µg per ml, 1 ml to be delisted 1 January 2011)

(Ipratropium Steri-Neb Nebuliser soln, 250 µg per ml, 2 ml to be delisted 1 January 2011)

TIOTROPIUM BROMIDE – Special Authority see SA0872 below – Retail pharmacy

Powder for inhalation, 18 µg per dose	70.00	30 dose	✓	Spiriva
---	-------	---------	---	----------------

SA0872 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialed a dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either:

The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:

- 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or

continued...

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
 4 Actual FEV₁ (litres) < 0.6 × predicted (litres); and
 5 Either:
 5.1 Patient is not a smoker (for reporting purposes only); or
 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
 6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and
- 3 Applicant must state recent measurement of FEV₁ (% of predicted).

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose	13.50	200 dose OP	✓	Combivent
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO	4.29	20	✓	Duolin

Mast Cell Stabilisers

Mast cell stabilisers

NEDOCROMIL

Aerosol inhaler, 2 mg per dose CFC-free	28.07	112 dose OP	✓	Tilade
---	-------	-------------	---	---------------

SODIUM CROMOGLYCAT

Powder for inhalation, 20 mg per dose	17.94	50 dose	✓	Intal Spincaps
Aerosol inhaler, 5 mg per dose CFC-free	28.07	112 dose OP	✓	Vicrom

Methylxanthines

AMINOPHYLLINE

* Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO	12.84	5	✓	Mayne
--	-------	---	---	--------------

THEOPHYLLINE

* Tab long-acting 250 mg	21.51	100	✓	Nuelin-SR
*‡ Oral liq 80 mg per 15 ml	15.50	500 ml	✓	Nuelin

Cystic Fibrosis

DORNASE ALFA – Special Authority see SA0611 below – Retail pharmacy

Nebuliser soln, 2.5 mg per 2.5 ml ampoule	294.30	6	✓	Pulmozyme
---	--------	---	---	------------------

►SA0611 Special Authority for Subsidy

Special Authority approved by the Cystic Fibrosis Advisory Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Cystic Fibrosis Advisory Panel	Phone: (04) 460 4990
PHARMAC, PO Box 10 254	Facsimile: (04) 916 7571
Wellington	Email: CFFPanel@pharmac.govt.nz

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

Nasal Preparations

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE			
Metered aqueous nasal spray, 50 µg per dose	2.35 (4.00)	200 dose OP	Alanase
Metered aqueous nasal spray, 100 µg per dose	2.46 (4.81)	200 dose OP	Alanase
BUDESONIDE			
Metered aqueous nasal spray, 50 µg per dose	2.35 (4.00)	200 dose OP	Butacort Aqueous
Metered aqueous nasal spray, 100 µg per dose	2.61 (4.81)	200 dose OP	Butacort Aqueous
FLUTICASONE PROPIONATE			
Metered aqueous nasal spray, 50 µg per dose	13.34	120 dose OP	✓ <u>Flixonase Hayfever & Allergy</u>
IPRATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%	12.66	30 ml OP	✓ <u>Apo-Ipravent</u>
SODIUM CROMOGLYCATE			
Nasal spray, 4%	15.85	22 ml OP	✓ <u>Rex</u>

Respiratory Devices

MASK FOR SPACER DEVICE			
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
c) Only for children aged six years and under			
Size 2	3.28	1	✓ <u>Foremount Child's Silicone Mask</u>
PEAK FLOW METER			
a) Up to 10 dev available on a PSO			
b) Only on a PSO			
Low range	13.75	1	✓ <u>Breath-Alert</u>
Normal range	13.75	1	✓ <u>Breath-Alert</u>
SPACER DEVICE			
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
230 ml (autoclavable) – Subsidy by endorsement.....	11.60	1	✓ <u>Space Chamber</u>
Available where the prescriber requires a spacer device that is capable of sterilisation in an autoclave and the PSO is endorsed accordingly.			
230 ml (single patient)	8.38	1	✓ <u>Space Chamber</u>
800 ml	8.50	1	✓ <u>Volumatic</u>

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Ear Preparations				
ACETIC ACID WITH 1, 2-PROPANEDIOL DIACETATE AND BENZETHONIUM				
For Vosol ear drops with hydrocortisone powder refer, page 176				
Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02%	6.97	35 ml OP	✓	Vosol
CHLORAMPHENICOL				
Ear drops 0.5%	1.87	5 ml OP	✓	Chloromycetin
FLUMETASONE PIVALATE				
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	✓	Locacorten-Viaform ED's ✓ Locorten-Vioform
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN				
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g	3.35	7.5 ml OP	✓	Kenacomb

Ear/Eye Preparations

DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN				
Ear/Eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml	4.50 (9.27)	8 ml OP		Sofradex
FRAMYCETIN SULPHATE				
Ear/Eye drops 0.5%	4.13 (8.65)	8 ml OP		Soframycin

Eye Preparations

Anti-Infective Preparations

ACICLOVIR				
* Eye oint 3%	37.53	4.5 g OP	✓	Zovirax
CHLORAMPHENICOL				
Eye oint 1%	2.37	4 g OP	✓	Chlorsig
Eye drops 0.5%	1.28 (2.40)	10 ml OP	✓	Chlorafast Chlorsig
<i>(Chlorsig Eye drops 0.5% to be delisted 1 March 2011)</i>				
CIPROFLOXACIN				
Eye Drops 0.3%	12.43	5 ml OP	✓	Ciloxan
For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.				
FUSIDIC ACID				
Eye drops 1%	4.50 (10.68)	5 g OP		Fucithalmic
GENTAMICIN SULPHATE				
Eye drops 0.3%	11.40	5 ml OP	✓	Genoptic
PROPAMIDINE ISETHIONATE				
* Eye drops 0.1%	2.97 (7.99)	10 ml OP		Brolene

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

SULPHACETAMIDE SODIUM

* Eye drops 10% 4.41 15 ml OP ✓ **Bleph 10**

TOBRAMYCIN

Eye oint 0.3% 10.45 3.5 g OP ✓ **Tobrex**

Eye drops 0.3% 11.48 5 ml OP ✓ **Tobrex**

Corticosteroids and Other Anti-Inflammatory Preparations

DEXAMETHASONE

* Eye oint 0.1% 5.86 3.5 g OP ✓ **Maxidex**

* Eye drops 0.1% 4.50 5 ml OP ✓ **Maxidex**

DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SULPHATE

* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g 5.39 3.5 g OP ✓ **Maxitrol**

* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml 4.50 5 ml OP ✓ **Maxitrol**

DICLOFENAC SODIUM

* Eye drops 1 mg per ml 13.80 5 ml OP ✓ **Voltaren Ophtha**

FLUOROMETHOLONE

* Eye drops 0.1% 4.05 5 ml OP ✓ **FML**

LEVOCABASTINE

Eye drops 0.5 mg per ml 8.71 4 ml OP
(10.34) Livostin

LODOXAMIDE TROMETAMOL

Eye drops 0.1% 8.71 10 ml OP ✓ **Lomide**

PREDNISOLONE ACETATE

* Eye drops 0.12% 4.50 5 ml OP ✓ **Pred Mild**

* Eye drops 1% 4.50 5 ml OP ✓ **Pred Forte**

SODIUM CROMOGLYCAT

Eye drops 2% 1.18 5 ml OP ✓ **Rexacrom**
2.36 10 ml OP
(3.95) Cromolux

(Cromolux Eye drops 2% to be delisted 1 February 2011)

Glaucoma Preparations - Beta Blockers

BETAXOLOL HYDROCHLORIDE

* Eye drops 0.25% 11.80 5 ml OP ✓ **Betoptic S**

* Eye drops 0.5% 7.50 5 ml OP ✓ **Betoptic**

LEVOBUNOLOL

* Eye drops 0.25% 7.00 5 ml OP ✓ **Betagan**

* Eye drops 0.5% 7.00 5 ml OP ✓ **Betagan**

TIMOLOL MALEATE

* Eye drops 0.25% 2.37 5 ml OP ✓ **Apo-Timop**

* Eye drops 0.25%, gel forming 3.30 2.5 ml OP ✓ **Timoptol XE**

* Eye drops 0.5% 2.29 5 ml OP ✓ **Apo-Timop**

* Eye drops 0.5%, gel forming 3.78 2.5 ml OP ✓ **Timoptol XE**

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Glaucoma Preparations - Carbonic Anhydrase Inhibitors

Prescribing Guidelines

Trusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- 1) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); and
- 2) those trials have indicated that that person does not respond adequately to treatment with those other agents.

ACETAZOLAMIDE

* Tab 250 mg 10.40 100 ✓ Diamox

BRINZOLAMIDE

▲ Eye Drops 1% 9.77 5 ml OP ✓ Azopt

DORZOLAMIDE HYDROCHLORIDE

* Eye drops 2% 9.77 5 ml OP
(13.95) Trusopt

DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE

* Eye drops 2% with timolol maleate 0.5% 15.50 5 ml OP ✓ Cosopt

Glaucoma Preparations - Prostaglandin Analogues

Prescribing Guideline

Bimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure. Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- 1) That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and
- 2) Those trials have indicated that that person does not respond adequately to treatment with those other agents.

BIMATOPROST – Retail pharmacy-Specialist

See prescribing guideline above

▲ Eye Drops 0.03% 19.50 3 ml OP ✓ Lumigan

LATANOPROST – Retail pharmacy-Specialist

See prescribing guideline above

▲ Eye drops 50 µg per ml, 2.5ml 9.75 2.5 ml OP ✓ Hysite

TRAVOPROST – Retail pharmacy-Specialist

See prescribing guideline above

▲ Eye drops 0.004% 19.50 2.5 ml OP ✓ Travatan

Glaucoma Preparations - Other

BRIMONIDINE TARTRATE

* Eye Drops 0.2% 7.93 5 ml OP ✓ AFT

Prescribing Guidelines

Brimonidine tartrate is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma.

Brimonidine tartrate should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and
- those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.

BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE

▲ Eye drops 0.2% with timolol maleate 0.5% 18.50 5 ml OP ✓ Combigan

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
--	---	-----	---------------------	-------------------------------------

Prescribing Guidelines

Combigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma.

Combigan should only be prescribed when:

- 1) less expensive first line agents for the treatment of glaucoma are contraindicated; or
- 2) the response to such subsidised agents is inadequate; or
- 3) the patient cannot tolerate such subsidised agents.

PILOCARPINE

* Eye drops 1%	4.26	15 ml OP	✓	Isopto Carpine
* Eye drops 2%	5.35	15 ml OP	✓	Isopto Carpine
* Eye drops 4%	7.99	15 ml OP	✓	Isopto Carpine
* Eye drops 2% single dose – Special Authority see SA0895 below – Retail pharmacy	31.95 (32.72)	20 dose		Minims

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:
Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE

* Eye drops 1%	17.36	15 ml OP	✓	Atropt
----------------------	-------	----------	---	---------------

CYCLOPENTOLATE HYDROCHLORIDE

* Eye drops 1%	8.76	15 ml OP	✓	Cyclogyl
----------------------	------	----------	---	-----------------

HOMATROPINE HYDROBROMIDE

* Eye drops 2%	7.18	15 ml OP	✓	Isopto Homatropine
----------------------	------	----------	---	---------------------------

TROPICAMIDE

* Eye drops 0.5%	7.15	15 ml OP	✓	Mydriacyl
* Eye drops 1%	8.66	15 ml OP	✓	Mydriacyl

Preparations for Tear Deficiency

For acetylcysteine eye drops refer, page 176

HYPROMELLOSE

* Eye drops 0.3%	2.62	15 ml OP	✓	Poly-Tears
* Eye drops 0.5%	2.00	15 ml OP	✓	Method

POLYVINYL ALCOHOL

* Eye drops 1.4%	2.68	15 ml OP	✓	Vistil
* Eye drops 3%	3.75	15 ml OP	✓	Vistil Forte

TYLOXAPOL

* Eye drops 0.25%	8.63	15 ml OP	✓	Enuclene
-------------------------	------	----------	---	-----------------

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE

* Eye drops 0.1%	4.15	15 ml OP	✓	Naphcon Forte
------------------------	------	----------	---	----------------------

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN				
* Eye oint with soft white paraffin	3.63	3.5 g OP	✓	<u>Lacri-Lube</u>
PARAFFIN LIQUID WITH WOOL FAT LIQUID				
* Eye oint 3% with wool fat liq 3%	3.63	3.5 g OP	✓	<u>Poly-Visc</u>
PHENYLEPHRINE HYDROCHLORIDE				
* Eye drops 0.12%	4.47	15 ml OP	✓	<u>Prefrin</u>

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

Various

May only be claimed once per patient.

PHARMACY SERVICES

* Brand switch fee	0.01	1 fee	✓ BSF Arrow-Enalapril
--------------------------	------	-------	------------------------------

The Pharmacode for BSF Arrow-Enalapril is 2375613

(BSF Arrow-Enalapril Brand switch fee to be delisted 1 February 2011)

‡ safety cap

*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
 - c) Menthol crystals only in the following bases:
 - Aqueous cream
 - Urea cream 10%
 - Wool fat with mineral oil lotion
 - Hydrocortisone 1% with wool fat and mineral oil lotion
 - Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Glycerol with paraffin and cetyl alcohol lotion
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Oily cream
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc cream BP
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP - up to 10%
- Hydrocortisone powder - up to 5%
- Menthol crystals
- Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of formulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website (<http://www.pharminfotech.co.nz/manual/Formulation/mixtures/index.htm>) has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand. PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form	qs
Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF	to 100%

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 172) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).


One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on page 175 may assist you in deciding whether or not a dermatological ECP is subsidised.

Dermatological ECPs

Is it subsidised?



Standard Formulae

ACETYL CYSTEINE EYE DROPS

Acetylcysteine inj 200 mg per ml, 10 ml qs
 Suitable eye drop base qs

ASPIRIN AND CHLOROFORM APPLICATION

Aspirin Soluble tabs 300 mg 12 tabs
 Chloroform to 100 ml

CODEINE LINCTUS PAEDIATRIC (3 mg per 5 ml)

Codeine phosphate 60 mg
 Glycerol 40 ml
 Preservative qs
 Water to 100 ml

CODEINE LINCTUS DIABETIC (15 mg per 5 ml)

Codeine phosphate 300 mg
 Glycerol 40 ml
 Preservative qs
 Water to 100 ml

FOLINIC MOUTHWASH

Calcium folinate 15 mg tab 1 tab
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

MAGNESIUM HYDROXIDE MIXTURE

Magnesium hydroxide paste 275 g
 Methyl hydroxybenzoate 1.5 g
 Water 770 ml

METHADONE MIXTURE

Methadone powder qs
 Glycerol qs
 Water to 100 ml

METHYL HYDROXYBENZOATE 10% SOLUTION

Methyl hydroxybenzoate 10 g
 Propylene glycol to 100 ml

(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

OMEPRAZOLE SUSPENSION

Omeprazole capules qs
 Sodium bicarbonate powder BP 8.4 g
 Water to 100 ml

PHENOBARBITONE ORAL LIQUID

Phenobarbitone Sodium 1 g
 Glycerol BP 70 ml
 Water to 100 ml

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)

Phenobarbitone Sodium 400 mg
 Glycerol BP 4 ml
 Water to 40 ml

PILOCARPINE ORAL LIQUID

Pilocarpine 4% eye drops qs
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

SALIVA SUBSTITUTE FORMULA

Methylcellulose 5 g
 Preservative qs
 Water to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

VOSOL EAR DROPS

WITH HYDROCORTISONE POWDER 1%

Hydrocortisone powder 1%
 Vosol Ear Drops to 35 ml

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations and Galenicals				
ACETYLCYSTEINE – Retail pharmacy-Specialist				
Inj 200 mg per ml, 10 ml	137.06 (219.75)	10		Martindale Acetylcysteine
	(255.35)			Hospira
Inj 200 mg per ml, 30 ml	219.00	4	✓	Acetadote
BENZOIN				
Tincture compound BP	2.44 (5.10)	50 ml		PSM
	24.42 (38.00)	500 ml		PSM
CHLOROFORM – Only in combination				
Only in aspirin and chloroform application.				
Chloroform BP	25.50	500 ml	✓	PSM
CODEINE PHOSPHATE				
Powder – Only in combination	12.62 (25.46)	5 g		Douglas
	63.09 (90.09)	25 g		Douglas
a) Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric.				
b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.				
COLLODION FLEXIBLE				
Collodion flexible	19.30	100 ml	✓	PSM
COMPOUND HYDROXYBENZOATE – Only in combination				
Only in extemporaneously compounded oral mixtures.				
Soln	34.18	100 ml	✓	David Craig
GLYCERIN WITH SODIUM SACCHARIN – Only in combination				
Only in combination with Ora-Plus.				
Suspension	38.00	473 ml	✓	Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination				
Only in combination with Ora-Plus.				
Suspension	38.00	473 ml	✓	Ora-Sweet
GLYCEROL				
* Liquid – Only in combination	17.86	2,000 ml	✓	healthE
Only in extemporaneously compounded oral liquid preparations.				
MAGNESIUM HYDROXIDE				
Paste	22.61	500 g	✓	PSM
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).				
Powder	7.84	1 g	✓	AFT
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYL HYDROXYBENZOATE				
Powder	8.00	25 g	✓	PSM
	8.98		✓	Midwest
	10.00		✓	ABM
METHYLCELLULOSE				
Powder	14.00	100 g	✓	ABM
	(17.72)			MidWest
Suspension – Only in combination	38.00	473 ml	✓	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination				
Suspension	38.00	473 ml	✓	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination				
Suspension	38.00	473 ml	✓	Ora-Blend
PHENOBARBITONE SODIUM				
Powder – Only in combination	52.50	10 g	✓	MidWest
	325.00	100 g	✓	MidWest
				a) Only in children up to 12 years
				b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq	10.50	500 ml	✓	PSM
	11.25		✓	Midwest
	12.00		✓	ABM
SODIUM BICARBONATE				
Powder BP – Only in combination	8.95	500 g	✓	Midwest
	9.80		✓	ABM
	(11.99)			Biomed
	(29.50)			David Craig
				Only in extemporaneously compounded omeprazole suspension.
SYRUP (PHARMACEUTICAL GRADE) – Only in combination				
Only in extemporaneously compounded oral liquid preparations.				
Liq	21.75	2,000 ml	✓	Midwest
WATER				
Tap – Only in combination	0.00	1 ml	✓	Tap water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

Initial Applications: Only Specialists

Reapplications: Specialist or general practitioner on recommendation of specialist. Reapplications by general practitioners on specialist recommendation must include the name of the specialist and the date the specialist was contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. A supporting letter may be included if desired. Applications must be forwarded to:

Ministry of Health Sector Services
Private Bag 3015
WHANGANUI 4540
Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

Failure to thrive An inability to gain or maintain weight resulting in physiological impairment.
Growth deficiency Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

SPECIAL FOODS

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ALPHA TOCOPHERYL ACETATE
Water solubilised soln 156 iu/ml,
with calibrated dropper

ASCORBIC ACID
Tab 100 mg

CALCIUM CARBONATE
Tab 1.25 g (500 mg elemental)
Tab 1.5 g (600 mg elemental)
Tab 1.75 g (1 g elemental)

COMPOUND ELECTROLYTES
Powder for soln for oral use 5 g

DEXTROSE WITH ELECTROLYTES
Soln with electrolytes

FERROUS FUMARATE
Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID
Tab 310 mg (100 mg elemental)
with folic acid 350 µg

FERROUS SULPHATE
Tab long-acting 325 mg (105 mg elemental)
Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)

FERROUS SULPHATE WITH FOLIC ACID
Tab long-acting 325 mg (105 mg elemental)
with folic acid 350 µg

MULTIVITAMINS
Tab
Powder
Oral liq

POTASSIUM BICARBONATE
Tab eff 315 mg
with sodium acid phosphate 1.937 g
and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE
Tab eff 584 mg (14 m eq)
with chloride 385 mg (8 m eq)
Tab long-acting 600 mg

PYRIDOXINE HYDROCHLORIDE
Tab 25 mg
Tab 50 mg

SODIUM FLUORIDE
Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE
Tab 50 mg

VITAMIN A WITH VITAMINS D AND C
Soln 1000 u with Vitamin D 400 u
and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX
Tab, strong, BPC

VITAMINS
Tab (BPC cap strength)
Cap (fat soluble vitamins A, D, E, K)

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

Nutrient Modules

Carbohydrate

SA0912 Special Authority for Subsidy

Initial application — (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA0912 above – Hospital pharmacy [HP3]

Powder	36.50	5,000 g	✓	Morrex Maltodextrin
	182.50	25,000 g	✓	Morrex Maltodextrin
	1.30	400 g OP		
	(5.29)			Polycal
	(12.00)	368 g OP		Moducal

Carbohydrate And Fat

SA0581 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 Any of the following:

continued...

SPECIAL FOODS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 2.1 cancer in children; or
- 2.2 failure to thrive; or
- 2.3 growth deficiency; or
- 2.4 bronchopulmonary dysplasia; or
- 2.5 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA0581 on the preceding page – Hospital pharmacy [HP3]

Powder (neutral)	60.31	400 g OP	✓ Duocal Super Soluble Powder
------------------------	-------	----------	----------------------------------

Fat

▶SA0899 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FAT SUPPLEMENT – Special Authority see SA0899 above – Hospital pharmacy [HP3]

Emulsion (neutral)	12.30	200 ml OP	✓ Calogen
	30.75	500 ml OP	✓ Calogen
Emulsion (strawberry)	12.30	200 ml OP	✓ Calogen
Oil	28.73	250 ml OP	✓ Liqigen
	30.00	500 ml OP	✓ MCT oil (Nutricia)

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

Protein

►SA0582 | **Special Authority for Subsidy**

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:
 Either:

- 1 protein losing enteropathy; or
- 2 high protein needs (eg burns).

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA0582 above – Hospital pharmacy [HP3]

Powder	7.90	225 g OP	✓ Protifar
	8.95	227 g OP	✓ Resource Beneprotein
Powder (vanilla)	12.90	275 g OP	✓ Promod

Oral Supplements

These products are to be used only as supplements to a person's dietary needs. Subsidy for up to 500 ml a day. Amounts prescribed in excess of this amount must be paid for by the patient.

►SA0583 | **Special Authority for Subsidy**

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years where the patient has cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 inflammatory bowel disease; or
- 3 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 4 malnutrition requiring nutritional support.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 above – Hospital pharmacy [HP3]

Powder (chocolate)	4.22	400 g OP	✓ Ensure
	9.50	900 g OP	✓ Ensure
	10.22		✓ Sustagen Hospital Formula
Powder (strawberry)	4.22	400 g OP	✓ Ensure
Powder (vanilla)	4.22	400 g OP	✓ Ensure
	9.50	900 g OP	✓ Ensure
	10.22		✓ Sustagen Hospital Formula

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

▶▶SA0588 **Special Authority for Subsidy**

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. CORD patients who have hypercapnia; and
2. Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
3. General Practitioners must include the name of the specialist and date contacted.

CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA0588 above – Hospital pharmacy [HP3]

Liquid	1.66	237 ml OP	✓ Pulmocare
--------------	------	-----------	-------------

Diabetic Products

▶▶SA0594 **Special Authority for Subsidy**

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. Type I and II diabetics who require nutritional supplementation; and
2. Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
3. General Practitioners must include the name of the specialist and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 above – Hospital pharmacy [HP3]

Liquid	7.50	1,000 ml OP	✓ Diason RTH
			✓ Glucerna Select RTH

ORAL FEED 1KCAL/ML – Special Authority see SA0594 above – Hospital pharmacy [HP3]

Liquid (strawberry)	1.50	200 ml OP	✓ Diasip
	1.78	237 ml OP	✓ Resource Diabetic
Liquid (vanilla)	1.50	200 ml OP	✓ Diasip
	1.88	250 ml OP	✓ Glucerna Select
	1.78	237 ml OP	
	(2.10)		Resource Diabetic

(Resource Diabetic Liquid (strawberry) to be delisted 1 February 2011)

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

Fat Modified Products

▶▶SA0615 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The product is to be used as a complete diet; and
- 2 Either:
 - 2.1 Patient has metabolic disorders of fat metabolism; or
 - 2.2 Patient has chylothorax.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FAT MODIFIED FEED – Special Authority see SA0615 above – Hospital pharmacy [HP3]

Powder	60.48	400 g OP	✓ Monogen
--------------	-------	----------	-----------

High Protein Products

▶▶SA0589 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Anorexia and weight loss; and
- 2 Either:
 - 2.1 decompensating liver disease without encephalopathy; or
 - 2.2 protein losing gastro-enteropathy; and
- 3 Either:
 - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 3.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ORAL FEED 1KCAL/ML – Special Authority see SA0589 above – Hospital pharmacy [HP3]

Liquid	1.90	200 ml OP	✓ Fortimel Regular
--------------	------	-----------	--------------------

Paediatric Products For Children Awaiting Liver Transplant

▶▶SA0607 Special Authority for Subsidy

Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Child (up to 18 years) who is awaiting liver transplant; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

continued...

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0607 on the preceding page – Hospital pharmacy [HP3]
 Powder78.97 400 g OP ✓ **Generaid Plus**

Paediatric Products For Children With Chronic Renal Failure

▶SA0606 Special Authority for Subsidy

Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 child (up to 18 years) with chronic renal failure; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0606 above – Hospital pharmacy [HP3]
 Liquid54.00 400 g OP ✓ **Kindergen**

Paediatric Products

▶SA0896 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 infant aged one to eight years; and
- 2 Any of the following:
 - 2.1 any condition causing malabsorption; or
 - 2.2 failure to thrive; or
 - 2.3 increased nutritional requirements; and
- 3 Either:
 - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 3.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]
 Liquid6.00 500 ml OP ✓ **Nutrini Energy RTH**

PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]
 Liquid2.68 500 ml OP ✓ **Nutrini RTH**
 ✓ **Pediasure RTH**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA0896 on the preceding page – Hospital pharmacy [HP3]				
Liquid (strawberry)	1.60	200 ml OP	✓	NutriniDrink
Liquid (vanilla)	1.60	200 ml OP	✓	NutriniDrink
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA0896 on the preceding page – Hospital pharmacy [HP3]				
Liquid (chocolate)	1.07	200 ml OP	✓	Pediasure
Liquid (strawberry)	1.07	200 ml OP	✓	Pediasure
Liquid (vanilla)	1.07	200 ml OP	✓	Pediasure
	1.27	237 ml OP	✓	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0896 on the preceding page – Hospital pharmacy [HP3]				
Liquid (chocolate)	1.60	200 ml OP	✓	NutriniDrink Multifibre
Liquid (strawberry)	1.60	200 ml OP	✓	NutriniDrink Multifibre
Liquid (vanilla)	1.60	200 ml OP	✓	NutriniDrink Multifibre

Renal Products

SA0587 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 acute or chronic renal failure; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ENTERAL FEED 2KCAL/ML – Special Authority see SA0587 above – Hospital pharmacy [HP3]

Liquid	6.08	500 ml OP	✓	Nutrison Concentrated
--------------	------	-----------	---	----------------------------------

RENAL ORAL FEED 2KCAL/ML – Special Authority see SA0587 above – Hospital pharmacy [HP3]

Liquid	2.43	200 ml OP	✓	Nepro (strawberry)
	2.88	237 ml OP	✓	Nepro (vanilla)
	(3.31)			NovaSource Renal
Liquid (apricot)	2.88	125 ml OP	✓	Renilon 7.5
Liquid (caramel)	2.88	125 ml OP	✓	Renilon 7.5

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Specialised And Elemental Products

▶SA0592 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 malabsorption; or
 - 1.2 short bowel syndrome; or
 - 1.3 enterocutaneous fistulas; or
 - 1.4 pancreatitis; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA0592 above – Hospital pharmacy [HP3]

Powder	4.40	79 g OP	✓ Vital HN
	7.50	76 g OP	✓ Alitraq

ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA0592 above – Hospital pharmacy [HP3]

Liquid (grapefruit)	9.50	250 ml OP	✓ Elemental 028 Extra
Liquid (pineapple & orange)	9.50	250 ml OP	✓ Elemental 028 Extra
Liquid (summer fruit)	9.50	250 ml OP	✓ Elemental 028 Extra

ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA0592 above – Hospital pharmacy [HP3]

Powder (unflavoured)	4.50	80.4 g OP	✓ Vivonex TEN
----------------------------	------	-----------	---------------

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA0592 above – Hospital pharmacy [HP3]

Liquid	12.04	1,000 ml OP	✓ Peptisorb
--------------	-------	-------------	-------------

Undialysed End Stage Renal Failure

▶SA0586 Special Authority for Subsidy

Initial application only from a gastroenterologist or renal physician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 undialysed end stage renal patients; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietician.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓ Suplena

continued...

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

RENAL ORAL FEED 1KCAL/ML – Special Authority see SA0586 on the preceding page – Hospital pharmacy [HP3]

Liquid3.80 237 ml OP ✓ **Suplena**

Adult Products Standard

▶SA0702 Special Authority for Subsidy

Initial application — (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Cystic fibrosis; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet.

Initial application — (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet.

Renewal — (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

Initial application — (Enteral feed) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 enteral feeding; or
 - 1.2 nasogastric; or
 - 1.3 nasoduodenal; or
 - 1.4 nasojejunal; or
 - 1.5 gastrostomy/jejunostomy; and
- 2 Either:

continued...

SPECIAL FOODS

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.1 The product is to be used as a supplement; or
- 2.2 The product is to be used as a complete diet.

Renewal — (Enteral feed or Oral feed for indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

Notes: This group of products can be used either as a supplement or as a complete diet.

If a product is being used as a supplement, the limit is 500 ml per day.

Cystic fibrosis patients are exempt the 500 ml per day volume restriction when using Ensure Plus, Fortisip or Resource Plus as a supplement.

ENTERAL FEED 1KCAL/ML – Special Authority see SA0702 on the preceding page – Hospital pharmacy [HP3]

Liquid	1.24	250 ml OP	✓ Isosource Standard
			✓ Osmolite
	2.65	500 ml OP	✓ Nutrison Standard
			RTH
	5.29	1,000 ml OP	✓ Nutrison Standard
			RTH
			✓ Isosource Standard
			RTH
	2.65	500 ml OP	✓ Osmolite RTH
	5.29	1,000 ml OP	✓ Osmolite RTH

ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA0702 on the preceding page – Hospital pharmacy [HP3]

Liquid	1.32	237 ml OP	✓ Jevity
	2.65	500 ml OP	✓ Nutrison Multi Fibre
	5.29	1,000 ml OP	✓ Nutrison Multi Fibre
	2.65	500 ml OP	✓ Jevity RTH
	5.29	1,000 ml OP	✓ Jevity RTH

ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 on the preceding page – Hospital pharmacy [HP3]

Liquid	1.75	250 ml OP	✓ Ensure Plus HN
			✓ Isosource 1.5
	7.00	1,000 ml OP	✓ Ensure Plus RTH
			✓ Nutrison Energy
			Multi Fibre

(Isosource 1.5 Liquid to be delisted 1 January 2011)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 on page 189 – Hospital pharmacy [HP3]				
Liquid (banana)	1.12	200 ml OP	✓	Fortisip
	(1.45)			Ensure Plus
Liquid (chocolate)	1.12	200 ml OP	✓	Fortisip
	1.33	237 ml OP	✓	Resource Plus
	1.12	200 ml OP		Ensure Plus
	(1.45)			
	1.33	237 ml OP	✓	Ensure Plus
Liquid (coffee latte)	1.33	237 ml OP	✓	Ensure Plus
Liquid (fruit of the forest)	1.12	200 ml OP		Ensure Plus
	(1.45)			
Liquid (strawberry)	1.12	200 ml OP	✓	Fortisip
	1.33	237 ml OP	✓	Resource Plus
	1.12	200 ml OP		Ensure Plus
	(1.45)			
	1.33	237 ml OP	✓	Ensure Plus
Liquid (toffee)	1.12	200 ml OP	✓	Fortisip
Liquid (tropical fruit)	1.12	200 ml OP	✓	Fortisip
Liquid (vanilla)	1.12	200 ml OP	✓	Fortisip
	(1.45)			Ensure Plus
	1.33	237 ml OP	✓	Ensure Plus

(Resource Plus Liquid (chocolate) to be delisted 1 January 2011)

(Resource Plus Liquid (strawberry) to be delisted 1 February 2011)

ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA0702 on page 189 – Hospital pharmacy [HP3]

Liquid (chocolate)	1.12	200 ml OP	✓	Fortisip Multi Fibre
Liquid (strawberry)	1.12	200 ml OP	✓	Fortisip Multi Fibre
Liquid (vanilla)	1.12	200 ml OP	✓	Fortisip Multi Fibre

Adult Products High Calorie

▶SA0585 | Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:
 - 4.1 The product is to be used as a supplement; or
 - 4.2 The product is to be used as a complete diet.

Initial application — (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:

continued...

SPECIAL FOODS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 4.1 The product is to be used as a supplement; or
- 4.2 The product is to be used as a complete diet.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
 - 3.1 The product is to be used as a supplement; or
 - 3.2 The product is to be used as a complete diet.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
 - 3.1 The product is to be used as a supplement; or
 - 3.2 The product is to be used as a complete diet.

Notes: This product can be used either as a supplement or as a complete diet.

If it is being used as a supplement, the limit is 500 ml per day.

ORAL FEED 2KCAL/ML – Special Authority see SA0585 on the preceding page – Hospital pharmacy [HP3]

Liquid (vanilla)2.25 237 ml OP ✓ **Two Cal HN**

Food Thickeners

▶SA0595 **Special Authority for Subsidy**

Initial application only from a relevant specialist. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FOOD THICKENER – Special Authority see SA0595 above – Hospital pharmacy [HP3]

Powder7.25 380 g OP ✓ **Karicare Food Thickener**

Gluten Free Foods

▶SA0722 **Special Authority for Subsidy**

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX – Special Authority see SA0722 above – Hospital pharmacy [HP3]

Powder2.81 1,000 g OP
(5.15) **Healtheries Simple Baking Mix**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLUTEN FREE BREAD MIX – Special Authority see SA0722 on the preceding page – Hospital pharmacy [HP3]				
Powder	3.93	1,000 g OP		
	(7.32)			NZB Low Gluten Bread Mix
	4.77			
	(8.71)			Bakels Gluten Free Health Bread Mix
	3.51			
	(10.87)			Horleys Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA0722 on the preceding page – Hospital pharmacy [HP3]				
Powder	5.62	2,000 g OP		
	(18.10)			Horleys Flour
GLUTEN FREE PASTA – Special Authority see SA0722 on the preceding page – Hospital pharmacy [HP3]				
Buckwheat Spirals	2.00	250 g OP		
	(3.11)			Orgran
Corn and Vegetable Shells	2.00	250 g OP		
	(2.92)			Orgran
Corn and Vegetable Spirals	2.00	250 g OP		
	(2.92)			Orgran
Rice and Corn Lasagne Sheets	1.60	200 g OP		
	(3.82)			Orgran
Rice and Corn Macaroni	2.00	250 g OP		
	(2.92)			Orgran
Rice and Corn Penne	2.00	250 g OP		
	(2.92)			Orgran
Rice and Maize Pasta Spirals	2.00	250 g OP		
	(2.92)			Orgran
Rice and Millet Spirals	2.00	250 g OP		
	(3.11)			Orgran
Rice and corn spaghetti noodles	2.00	375 g OP		
	(2.92)			Orgran
Vegetable and Rice Spirals	2.00	250 g OP		
	(2.92)			Orgran
Italian long style spaghetti	2.00	220 g OP		
	(3.11)			Orgran

Foods And Supplements For Inborn Errors Of Metabolism - Other

SA0732 | Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:
 Either:

- 1 dietary management of homocystinuria; or
- 2 dietary management of maple syrup urine disease.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Prescribing Guideline

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA0732 on the preceding page – Hospital pharmacy [HP3]

See prescribing guideline above

Powder	461.94	500 g OP	✓ XMET Maxamum
--------------	--------	----------	-----------------------

Supplements For MSUD

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA0732 on the preceding page – Hospital pharmacy [HP3]

See prescribing guideline above

Powder	300.54	500 g OP	✓ MSUD Maxamaid
	437.22		✓ MSUD Maxamum

Foods And Supplements For Inborn Errors Of Metabolism - PKU

Prescribing Guideline

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Foods and Supplements For PKU

▶SA0733 **Special Authority for Subsidy**

Initial application — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 dietary management of PKU; and
- 2 The patient's blood phenylalanine level is < 900 mmol/litre (average of tests over last 12 months).

Initial application — (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where the patient requires dietary management of PKU.

Renewal — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year where blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months).

Renewal — (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]				
See prescribing guideline on the preceding page				
Tabs	99.00	75 OP	✓	Phlexy 10
Sachets (pineapple/vanilla) 29 g	330.10	30 OP	✓	Minaphlex
Sachets (tropical)	324.00	30	✓	Phlexy 10
Infant formula	174.72	400 g OP	✓	PKU Anamix Infant
			✓	XP Analog LCP
Powder (orange)	221.00	500 g OP	✓	XP Maxamaid
	320.00		✓	XP Maxamum
Powder (unflavoured)	221.00	500 g OP	✓	XP Maxamaid
	320.00		✓	XP Maxamum
Liquid (berry)	15.65	62.5 ml OP	✓	Lophlex LQ
	31.20	125 ml OP	✓	Lophlex LQ
	15.65	62.5 ml OP	✓	PKU Lophlex LQ
	31.20	125 ml OP	✓	PKU Lophlex LQ
Liquid (citrus)	15.65	62.5 ml OP	✓	Lophlex LQ
	31.20	125 ml OP	✓	Lophlex LQ
	15.65	62.5 ml OP	✓	PKU Lophlex LQ
	31.20	125 ml OP	✓	PKU Lophlex LQ
Liquid (forest berries)	30.00	250 ml OP	✓	Easiphen Liquid
Liquid (orange)	15.65	62.5 ml OP	✓	Lophlex LQ
	31.20	125 ml OP	✓	Lophlex LQ
	15.65	62.5 ml OP	✓	PKU Lophlex LQ
	31.20	125 ml OP	✓	PKU Lophlex LQ
Liquid (tropical)	30.00	250 ml OP	✓	Easiphen
PHENYL FREE BAKING MIX – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]				
See prescribing guideline on the preceding page				
Powder	6.70	500 g OP		Loprofin Mix
	(8.22)			
PHENYL FREE PASTA – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]				
See prescribing guideline on the preceding page				
Animal shapes	10.65	500 g OP		Loprofin
	(11.91)			
Lasagne	5.32	250 g OP		Loprofin
	(5.95)			
Low protein rice pasta	10.65	500 g OP		Loprofin
	(11.91)			
Macaroni	5.32	250 g OP		Loprofin
	(5.95)			
Penne	10.65	500 g OP		Loprofin
	(11.91)			
Spaghetti	10.65	500 g OP		Loprofin
	(11.91)			
Spirals	10.65	500 g OP		Loprofin
	(11.91)			

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
---	----------------------------	--

Multivitamin And Mineral Supplements

▶▶SA0962 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of phenylketonuria (PKU); or
- 2 For use as a supplement to the ketogenic diet in patients diagnosed with epilepsy; or
- 3 Patient has had a previous approval for metabolic mineral mixture.

AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 above – Retail pharmacy
See prescribing guideline on page 194

Powder	23.38	100 g OP	✓ Metabolic Mineral Mixture
--------------	-------	----------	------------------------------------

Infant Formulae

For Premature Infants

▶▶SA0602 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 6 months where the patient is infant weighing less than 1.5 kg at birth.

PREMATURE BIRTH FORMULA – Special Authority see SA0602 above – Hospital pharmacy [HP3]

Liquid	0.75	100 ml OP	✓ S26LBW Gold RTF
--------------	------	-----------	--------------------------

For Williams Syndrome

▶▶SA0601 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA0601 above – Hospital pharmacy [HP3]

Powder	44.40	400 g OP	✓ Locasol
--------------	-------	----------	------------------

For Gastrointestinal And Other Malabsorptive Problems

▶▶SA0603 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year where the patient is infant suffering from malabsorption and other gastrointestinal problems.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Neocate should be used only as a last resort when the infant is unable to absorb any of the below formulae. The objective with each of the formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate. These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ELEMENTAL FORMULA – Special Authority see SA0603 on the preceding page – Hospital pharmacy [HP3]				
Powder	11.72	450 g OP		
	(15.21)			Pepti Junior Gold
	15.52			
	(19.01)			Pepti Junior
	63.97	400 g OP		
	(67.08)			Neocate
	(67.08)			Neocate LCP
	5.62	48.5 g OP		
	(6.00)			Vivonex Pediatric
Powder (tropical)	52.90	400 g OP		
	(56.00)			Neocate Advance
Powder (unflavoured)	52.90	400 g OP		
	(56.00)			Elecare
	(56.00)			Elecare LCP
	(56.00)			Neocate Advance
Powder (vanilla)	52.90	400 g OP		
	(56.00)			Elecare

For Milk Intolerance

SA0604 Special Authority for Subsidy

Initial application — (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is less than 3 years of age; and
- 2 Either:
 - 2.1 diagnosed as suffering from congenital lactase deficiency; or
 - 2.2 suffering from disaccharide intolerance.

Notes: Secondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Initial application — (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 intolerant to cows' milk; and
- 2 patient is less than 3 years of age.

Note: The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Renewal — (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 patient is less than 3 years of age.

GOATS MILK INFANT FORMULA – Special Authority see SA0604 above – Retail pharmacy

Powder	9.42	900 g OP		
	(22.75)			Karicare Goats Milk Infant Formula

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LACTOSE FREE INFANT FORMULA – Special Authority see SA0604 on the preceding page – Retail pharmacy				
Powder	5.66	900 g OP		
	(17.95)			Delact
SOYA INFANT FORMULA – Special Authority see SA0604 on the preceding page – Retail pharmacy				
Powder	6.34	900 g OP		
	(19.57)			S26 Soy

Infant Formulae - Lactose Intolerance and Cows' Milk Protein Intolerance

▶SA0757 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is less than 2 years of age; and
- 2 Intolerant to cows' milk; and
- 3 Diagnosed as suffering from congenital lactase deficiency.

Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

INFANT SOY FORMULA – Special Authority see SA0757 above – Retail pharmacy

Powder	7.27	900 g		
	(16.35)			Karicare Soy All Ages

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE	CHARCOAL
✓ Inj 1 in 1,000, 1 ml 5	✓ Oral liq 50 g per 250 ml 250 ml
✓ Inj 1 in 10,000, 10 ml 5	
AMINOPHYLLINE	CHLORPROMAZINE HYDROCHLORIDE
✓ Inj 25 mg per ml, 10 ml 5	✓ Tab 10 mg 30
	✓ Tab 25 mg 30
AMIODARONE HYDROCHLORIDE	✓ Tab 100 mg 30
✓ Inj 50 mg per ml, 3 ml 5	✓ Inj 25 mg per ml, 2 ml 5
AMOXYCILLIN	CIPROFLOXACIN
✓ Cap 250 mg 30	✓ Tab 250 mg 5
✓ Grans for oral liq 125 mg per 5 ml 200 ml	✓ Tab 500 mg 5
✓ Grans for oral liq 250 mg per 5 ml 200 ml	
✓ Inj 1 g 5	CO-TRIMOXAZOLE
AMOXYCILLIN CLAVULANATE	✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg 30
✓ Tab amoxicillin 500 mg with potassium clavulanate 125 mg 30	✓ Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml 200 ml
✓ Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml 200 ml	
✓ Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml 200 ml	COMPOUND ELECTROLYTES
APPLICATOR	✓ Powder for soln for oral use 5 g 10
✓ Applicator – See note on page 68 1	
ASPIRIN	CONDOMS
✓ Tab dispersible 300 mg 30	✓ 49 mm 144
ATROPINE SULPHATE	✓ 52 mm 144
✓ Inj 600 µg, 1 ml 5	✓ 52 mm extra strength 144
AZITHROMYCIN	✓ 53 mm 144
✓ Tab 500 mg – Subsidy by endorsement – See note on page 83 8	✓ 53 mm (chocolate) 144
	✓ 53 mm (strawberry) 144
BENDROFLUAZIDE	✓ 53 mm extra strength 144
✓ Tab 2.5 mg – See note on page 54 150	54 mm, shaped 144
BENZATHINE BENZYL PENICILLIN	✓ 55 mm 144
✓ Inj 1.2 mega u per 2.3 ml 5	✓ 56 mm 144
BENZTROPINE MESYLATE	✓ 56 mm extra strength 144
✓ Inj 1 mg per ml, 2 ml 5	✓ 56 mm, shaped 144
BENZYL PENICILLIN SODIUM (PENICILLIN G)	✓ 60 mm 144
✓ Inj 1 mega u 5	DEXAMETHASONE
CEFTRIAXONE SODIUM	✓ Tab 1 mg – Retail pharmacy-Specialist 30
✓ Inj 500 mg – Subsidy by endorsement – See note on page 82 5	✓ Tab 4 mg – Retail pharmacy-Specialist 30
✓ Inj 1 g – Subsidy by endorsement – See note on page 82 5	DEXAMETHASONE SODIUM PHOSPHATE
	✓ Inj 4 mg per ml, 1 ml 5
	✓ Inj 4 mg per ml, 2 ml 5
	DEXTROSE
	✓ Inj 50%, 10 ml 5
	✓ Inj 50%, 90 ml 5
	DIAPHRAGM
	✓ 55 mm – See note on page 69 1
	✓ 60 mm – See note on page 69 1

continued...

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

PRACTITIONER'S SUPPLY ORDERS

(continued)

✓ 65 mm – See note on page 69	1
✓ 70 mm – See note on page 69	1
✓ 75 mm – See note on page 69	1
✓ 80 mm – See note on page 69	1
✓ 85 mm – See note on page 69	1
✓ 90 mm – See note on page 69	1

DIAZEPAM

✓ Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 122	5
✓ Rectal tubes 5 mg	5
✓ Rectal tubes 10 mg	5

DICLOFENAC SODIUM

✓ Inj 25 mg per ml, 3 ml	5
✓ Suppos 50 mg	10

DIGOXIN

✓ Tab 62.5 µg	30
✓ Tab 250 µg	30

DOXYCYCLINE HYDROCHLORIDE

Tab 50 mg	30
✓ Tab 100 mg	30

ERGOMETRINE MALEATE

✓ Inj 500 µg per ml, 1 ml	5
---------------------------------	---

ERYTHROMYCIN ETHYL SUCCINATE

✓ Tab 400 mg	30
✓ Grans for oral liq 200 mg per 5 ml	200 ml
✓ Grans for oral liq 400 mg per 5 ml	200 ml

ERYTHROMYCIN STEARATE

Tab 250 mg	30
------------------	----

ETHINYLOESTRADIOL WITH DESOGESTREL

Tab 20 µg with desogestrel 150 µg	63
Tab 20 µg with desogestrel 150 µg and 7 inert tab	84
Tab 30 µg with desogestrel 150 µg	63
Tab 30 µg with desogestrel 150 µg and 7 inert tab	84

ETHINYLOESTRADIOL WITH LEVONORGESTREL

✓ Tab 50 µg with levonorgestrel 125 µg and 7 inert tab	84
Tab 30 µg with levonorgestrel 150 µg	63
✓ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab	84
Tab 20 µg with levonorgestrel 100 µg and 7 inert tab	84

ETHINYLOESTRADIOL WITH NORETHISTERONE

✓ Tab 35 µg with norethisterone 1 mg	63
--	----

✓ Tab 35 µg with norethisterone 1 mg and 7 inert tab	84
✓ Tab 35 µg with norethisterone 500 µg	63
✓ Tab 35 µg with norethisterone 500 µg and 7 inert tab	84

FLUCLOXACILLIN SODIUM

✓ Cap 250 mg	30
✓ Grans for oral liq 125 mg per 5 ml	200 ml
✓ Grans for oral liq 250 mg per 5 ml	200 ml
✓ Inj 1 g	5

FLUPENTHIXOL DECANOATE

✓ Inj 20 mg per ml, 1 ml	5
✓ Inj 20 mg per ml, 2 ml	5
✓ Inj 100 mg per ml, 1 ml	5

FLUPHENAZINE DECANOATE

✓ Inj 12.5 mg per 0.5 ml, 0.5 ml	5
✓ Inj 25 mg per ml, 1 ml	5
✓ Inj 100 mg per ml, 1 ml	5

FUROSEMIDE

✓ Tab 40 mg	30
✓ Inj 10 mg per ml, 2 ml	5

GLUCAGON HYDROCHLORIDE

✓ Inj 1 mg syringe kit	5
------------------------------	---

GLYCERYL TRINITRATE

✓ Tab 600 µg	100
✓ Oral pump spray 400 µg per dose	250 dose

HALOPERIDOL

✓ Tab 500 µg	30
✓ Tab 1.5 mg	30
✓ Tab 5 mg	30
✓ Oral liq 2 mg per ml	200 ml
✓ Inj 5 mg per ml, 1 ml	5

HALOPERIDOL DECANOATE

✓ Inj 50 mg per ml, 1 ml	5
✓ Inj 100 mg per ml, 1 ml	5

HYDROCORTISONE

✓ Inj 50 mg per ml, 2 ml	5
--------------------------------	---

HYDROXOCOBALAMIN

✓ Inj 1 mg per ml, 1 ml	6
-------------------------------	---

HYOSCINE N-BUTYLBROMIDE

✓ Inj 20 mg, 1 ml	5
-------------------------	---

INTRA-UTERINE DEVICE

✓ IUD	40
-------------	----

continued...

✓ fully subsidised brand available

(continued)

IPRATROPIUM BROMIDE
 ✓ Nebuliser soln, 250 µg per ml, 1 ml 40
 ✓ Nebuliser soln, 250 µg per ml, 2 ml 40

LEVONORGESTREL
 Tab 30 µg 84
 ✓ Tab 1.5 mg 5

LIGNOCAINE
 ✓ Gel 2%, 10 ml urethral syringe 5

LIGNOCAINE HYDROCHLORIDE
 ✓ Inj 0.5%, 5 ml 5
 ✓ Inj 1%, 5 ml 5
 ✓ Inj 2%, 5 ml 5
 ✓ Inj 1%, 20 ml 5
 ✓ Inj 2%, 20 ml 5

LIGNOCAINE WITH CHLORHEXIDINE
 ✓ Gel 2% with chlorhexidine 0.05%,
 10 ml urethral syringes 5

LOPERAMIDE HYDROCHLORIDE
 ✓ Tab 2 mg 30
 ✓ Cap 2 mg 30

MASK FOR SPACER DEVICE
 ✓ Size 2 – See note on page 165 20

MEDROXYPROGESTERONE ACETATE
 ✓ Inj 150 mg per ml, 1 ml syringe 5

METHYLERGOMETRINE
 ✓ Inj 200 µg per ml, 1 ml 10

METOCLOPRAMIDE HYDROCHLORIDE
 ✓ Inj 5 mg per ml, 2 ml 5

METRONIDAZOLE
 ✓ Tab 200 mg 30

MORPHINE SULPHATE
 ✓ Inj 5 mg per ml, 1 ml – Only on a controlled
 drug form 5
 ✓ Inj 10 mg per ml, 1 ml – Only on a controlled
 drug form 5
 ✓ Inj 15 mg per ml, 1 ml – Only on a controlled
 drug form 5
 ✓ Inj 30 mg per ml, 1 ml – Only on a controlled
 drug form 5

NALOXONE HYDROCHLORIDE
 ✓ Inj 400 µg per ml, 1 ml 5

NONOXYNOL-9
 ✓ Jelly 2% 108 g

NORETHISTERONE
 ✓ Tab 350 µg 84
 ✓ Tab 5 mg 30

NORETHISTERONE WITH MESTRANOL
 Tab 1 mg with mestranol 50 µg and 7 inert tab 84

OXYTOCIN
 ✓ Inj 5 iu per ml, 1 ml 5
 ✓ Inj 10 iu per ml, 1 ml 5
 ✓ Inj 5 iu with ergometrine maleate 500 µg per
 ml, 1 ml 5

PARACETAMOL
 ✓ Tab 500 mg 30
 ✓ Oral liq 120 mg per 5 ml 200 ml
 ✓ Oral liq 250 mg per 5 ml 100 ml

PEAK FLOW METER
 ✓ Low range 10
 ✓ Normal range 10

PETHIDINE HYDROCHLORIDE
 ✓ Inj 50 mg per ml, 1 ml – Only on a controlled
 drug form 5
 ✓ Inj 50 mg per ml, 1.5 ml – Only on a
 controlled drug form 5
 ✓ Inj 50 mg per ml, 2 ml – Only on a controlled
 drug form 5

PHENOXYMETHYLPENICILLIN (PENICILLIN V)
 ✓ Cap potassium salt 250 mg 30
 ✓ Grans for oral liq 125 mg per 5 ml 200 ml
 ✓ Grans for oral liq 250 mg per 5 ml 200 ml

PHENYTOIN SODIUM
 ✓ Inj 50 mg per ml, 2 ml 5
 ✓ Inj 50 mg per ml, 5 ml 5

PHYTOMENADIONE
 ✓ Inj 2 mg per 0.2 ml – See note on page 41 5
 ✓ Inj 10 mg per ml, 1 ml – See note on page 41 5

PIPOTHIAZINE PALMITATE
 ✓ Inj 50 mg per ml, 1 ml 5
 ✓ Inj 50 mg per ml, 2 ml 5

PREDNISOLONE SODIUM PHOSPHATE
 ✓ Oral liq 5 mg per ml – See note on
 page 75 30 ml

PREDNISONE
 ✓ Tab 5 mg 30

PREGNANCY TESTS - HCG URINE
 ✓ Cassette 200 test

continued...

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

PRACTITIONER'S SUPPLY ORDERS

(continued)

PROCAINE PENICILLIN	
✓ Inj 1.5 mega u	5
PROCHLORPERAZINE	
✓ Tab 5 mg	30
✓ Inj 12.5 mg per ml, 1 ml	5
PROMETHAZINE HYDROCHLORIDE	
✓ Inj 25 mg per ml, 2 ml	5
SALBUTAMOL	
✓ Inj 500 µg per ml, 1 ml	5
✓ Aerosol inhaler, 100 µg per dose CFC free	1000 dose
✓ Nebuliser soln, 1 mg per ml, 2.5 ml	30
✓ Nebuliser soln, 2 mg per ml, 2.5 ml	30
SALBUTAMOL WITH IPRATROPIUM BROMIDE	
✓ Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	20
SILVER SULPHADIAZINE	
✓ Crm 1%	250 g
SODIUM BICARBONATE	
✓ Inj 8.4%, 50ml	5
✓ Inj 8.4%, 100 ml	5
SODIUM CHLORIDE	
✓ Inf 0.9% – See note on page 43	2000 ml
✓ Inj 0.9%, 5 ml	5
✓ Inj 0.9%, 10 ml	5
SPACER DEVICE	
✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 165	20
✓ 230 ml (single patient)	20
✓ 800 ml	20
TRIMETHOPRIM	
✓ Tab 300 mg	30
VERAPAMIL HYDROCHLORIDE	
✓ Inj 2.5 mg per ml, 2 ml	5
WATER	
✓ Purified for inj, 5 ml – See note on page 44	5
✓ Purified for inj, 10 ml – See note on page 44	5
✓ Purified for inj, 20 ml – See note on page 44	5
ZUCLOPENTHIXOL DECANOATE	
✓ Inj 200 mg per ml, 1 ml	5

✓ fully subsidised brand available

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND	Tairua	Marlon	Leeston
Northland DHB	Taumarunui	Ohakune	Lincoln
Dargaville	Te Aroha	Raetihi	Methven
Hikurangi	Te Kauwhata	Taihape	Oxford
Kaeo	Te Kuiti	Waiouru	Rakaia
Kaikohe	Tokoroa	MidCentral DHB	Rolleston
Kaitiāia	Waihi	Dannevirke	Rotherham
Kawakawa	Whangamata	Foxton	Templeton
Kerikeri	Whitianga	Levin	Waikari
Mangonui	Bay of Plenty DHB	Otaki	
Maungaturoto	Edgecumbe	Pahiatua	
Moerewa	Katikati	Shannon	
Ngunguru	Kawerau	Woodville	South Canterbury DHB
Paihia	Murupara	Wairarapa DHB	Fairlie
Rawene	Opotiki	Carteron	Geraldine
Ruakaka	Taneatua	Featherston	Pleasant Point
Russell	Te Kaha	Greytown	Temuka
Tutukaka	Waihi Beach	Martinborough	Twizel
Waipu	Whakatane		Waimate
Whangaroa	Lakes DHB	SOUTH ISLAND	
Waitemata DHB	Mangakino	Nelson/Marlborough DHB	Southern DHB
Helensville	Turangi	Havelock	Alexandra
Huapai	Tairāwhiti DHB	Mapua	Balclutha
Kumeu	Ruatoria	Motueka	Cromwell
Snells Beach	Te Araroa	Murchison	Gore
Waimauku	Te Karaka	Picton	Kurou
Warkworth	Te Puia Springs	Takaka	Lawrence
Wellsford	Tikitiki	Wakefield	Lumsden
Auckland DHB	Tokomaru Bay	West Coast DHB	Mataura
Great Barrier Island	Tolaga Bay	Dobson	Milton
Oneroa	Taranaki DHB	Greymouth	Oamaru
Ostend	Eltham	Hokitika	Oban
Counties Manukau DHB	Inglewood	Karamea	Otautau
Tuakau	Manaia	Reefton	Outram
Waiuku	Oakura	South Westland	Owaka
Waikato DHB	Okato	Westport	Palmerston
Coromandel	Opunake	Whataroa	Queenstown
Huntly	Patea	Canterbury DHB	Ranfurlly
Kawhia	Stratford	Akaroa	Riverton
Matamata	Waverley	Amberley	Roxburgh
Morrinsville	Hawkes Bay DHB	Amuri	Tapanui
Ngatea	Chatham Islands	Cheviot	Te Anau
Otorohanga	Waipawa	Darfield	Tokonui
Paeroa	Waipukurau	Diamond Harbour	Tuatapere
Pauanui Beach	Wairoa	Hanmer Springs	Wanaka
Putaruru	Whanganui DHB	Kaikoura	Winton
Raglan	Bulls		

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

SECTION F: COMMUNITY PHARMACEUTICALS DISPENSING PERIOD EXEMPTIONS

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is Close Control.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber has endorsed the Prescription item(s) on the Prescription to which the exemption applies "certified exemption". In endorsing the Prescription items for a certified exemption, the prescriber is certifying that:
 - i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
 - ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
 - iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART
 INSULIN GLARGINE
 INSULIN GLULISINE
 INSULIN ISOPHANE
 INSULIN ISOPHANE WITH INSULIN NEUTRAL
 INSULIN LISPRO
 INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE
 INSULIN NEUTRAL

CARDIOVASCULAR SYSTEM

AMIODARONE HYDROCHLORIDE
 Tab 100 mg Cordarone-X
 Tab 200 mg Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE
 Tab 50 mg Tambocor
 Tab 100 mg Tambocor
 Cap long-acting 100 mg Tambocor CR
 Cap long-acting 200 mg Tambocor CR

MEXILETINE HYDROCHLORIDE

PROPAPENONE HYDROCHLORIDE

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES**DESMOPRESSIN**

Nasal drops 100 µg per Minirin
 ml
 Nasal spray 10 µg per Desmopressin-PH&T
 dose

MUSCULOSKELETAL SYSTEM

PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE
 APOMORPHINE HYDROCHLORIDE
 ENTACAPONE
 GABAPENTIN
 GABAPENTIN (NEURONTIN)
 LAMOTRIGINE
 LISURIDE HYDROGEN MALEATE
 PERGOLIDE
 ROPINIROLE HYDROCHLORIDE
 TOLCAPONE
 TOPIRAMATE
 VIGABATRIN

SENSORY ORGANS

BIMATOPROST
 BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE
 BRINZOLAMIDE
 LATANOPROST
 TRAVOPROST

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursement

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA PDL Squeezlok PDL FG

ALIMENTARY TRACT AND METABOLISM**FERROUS SULPHATE**

Oral liq 30 mg per 1 ml Ferodan
(6 mg elemental per
1 ml)

CARDIOVASCULAR SYSTEM**AMILORIDE**

Oral liq 1 mg per ml Biomed

CAPTOPRIL

Oral liq 5 mg per ml Capoten

CHLOROTHIAZIDE

Oral liq 50 mg per ml Biomed

DIGOXIN

Oral liq 50 µg per ml Lanoxin

FUROSEMIDE

Oral liq 10 mg per ml Lasix

SPIRONOLACTONE

Oral liq 5 mg per ml Biomed

**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING
CONTRACEPTIVE HORMONES****LEVOTHYROXINE**

Tab 50 µg Eltroxin
Goldshield
Synthroid
Tab 100 µg Eltroxin
Goldshield
Synthroid
Tab 25 µg Synthroid

(Extemporaneously compounded oral liquid preparations)

MUSCULOSKELETAL SYSTEM**IBUPROFEN**

Oral liq 100 mg per 5 ml Fenpaed

QUININE SULPHATE

Tab 200 mg Q 200
Tab 300 mg Q 300

(Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM**ALPRAZOLAM**

Tab 250 µg Arrow-Alprazolam
Tab 500 µg Arrow-Alprazolam
Tab 1 mg Arrow-Alprazolam

(Extemporaneously compounded oral liquid preparations)

CARBAMAZEPINE

Oral liq 100 mg per 5 ml Tegretol

CLOBAZAM

Tab 10 mg Frisium
(Extemporaneously compounded oral liquid preparations)

CLONAZEPAM

Oral drops 2.5 mg per ml Rivotril

DIAZEPAM

Tab 2 mg Arrow-Diazepam
Tab 5 mg Arrow-Diazepam
(Extemporaneously compounded oral liquid preparations)

ETHOSUXIMIDE

Oral liq 250 mg per 5 ml Zaronin

LORAZEPAM

Tab 1 mg Ativan
Tab 2.5 mg Ativan
(Extemporaneously compounded oral liquid preparations)

LORMETAZEPAM

Tab 1 mg Noctamid
(Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Oral liq 2 mg per ml Biodone
Oral liq 5 mg per ml Biodone Forte
Oral liq 10 mg per ml Biodone Extra Forte

MIDAZOLAM

Tab 7.5 mg Hypnovel
(Extemporaneously compounded oral liquid preparations)

MORPHINE HYDROCHLORIDE

Oral liq 1 mg per ml RA-Morph
Oral liq 2 mg per ml RA-Morph
Oral liq 5 mg per ml RA-Morph
Oral liq 10 mg per ml RA-Morph

NITRAZEPAM

Tab 5 mg Nitrados
(Extemporaneously compounded oral liquid preparations)

OXAZEPAM

Tab 10 mg Ox-Pam
Tab 15 mg Ox-Pam
(Extemporaneously compounded oral liquid preparations)

OXYCODONE HYDROCHLORIDE

Oral liq 5 mg per 5 ml OxyNorm

SAFETY CAP MEDICINES

PARACETAMOL

Oral liq 120 mg per 5 ml Paracare Junior
Oral liq 250 mg per 5 ml Paracare Double Strength

PHENYTOIN SODIUM

Oral liq 30 mg per 5 ml Dilantin

SODIUM VALPROATE

Oral liq 200 mg per 5 ml Epilim S/F Liquid
Epilim Syrup

TEMAZEPAM

Tab 10 mg Normison

(Extemporaneously compounded oral liquid preparations)

TRIAZOLAM

Tab 125 µg Hypam
Tab 250 µg Hypam

(Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE

Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE

Oral liq 5 mg per 5 ml Promethazine Elixir
Winthrop

SALBUTAMOL

Oral liq 2 mg per 5 ml Salapin

THEOPHYLLINE

Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE

Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE

Powder Douglas

(Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Powder AFT

(Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM

Powder MidWest

(Extemporaneously compounded oral liquid preparations)

- Symbols -		Alanase165	Drugs (NSAIDs) 99
3TC94		Albany160	Antiacne Preparations57
- A -		Albustix74	Antiallergy Preparations160
A-Lices64		Aldara66	Antianaemics40
A-Scabies64		Alendronate sodium111	Antandrogen Oral
Abacavir sulphate93		Alendronate sodium with	Contraceptives 72
Abacavir sulphate with		cholecalciferol 111	Antiarrhythmics50
lamivudine 93		Alfacalcidol36	Antibacterials82
Abilify128		Alginate acid25	Antibacterials Topical58
ABM Hydroxocobalamin36		Alitraq188	Anticholinesterases99
Acarbose29		Alkeran143	Antidepressants119
Accu-Chek Performa30, 31		Allersoothe161	Antidiarrhoeals25
Accupril49		Allopurinol114	Antiepilepsy Drugs122
Accuretic 1049		Alpha Adrenoceptor Blockers47	Antifibrinolytics, Haemostatics
Accuretic 2049		Alpha tocopheryl acetate37	and Local Sclerosants 41
Acetadote177		Alpha-Keri Lotion63	Antifungals87
Acetazolamide168		Alphamox84	Antifungals Topical58
Acetic acid with 1, 2- propanediol		Alprazolam133	Antihaemorrhoidals26
diacetate and		Alu-Tab25	Antihistamines160
benzethonium166		Aluminium hydroxide25	Antihypotensives51
Acetic acid with hydroxyquinoline		Amantadine hydrochloride115	Antimalarials87
and ricinoleic acid 72		Ambrisentan55	Antimigraine Preparations126
Acetylcysteine177		Amiloride54	Antinausea128
Aci-Jel72		Amiloride with	Antinausea and Vertigo
Aciclovir		hydrochlorothiazide 54	Agents 126
Infection90		Aminophylline164	Antipruritic Preparations59
Sensory166		Amiodarone hydrochloride50	Antipsychotics128
Acidex25		Amirol119	Antiretrovirals92
Acipimox45		Amisulpride128	Antiretrovirals - Additional
Acitretin64		Amitriptyline119	Therapies 94
Aclasta112		Amitypyline119	Antirheumatoid Agents100
Actigall33		Amizide54	Antispasmodics and Other
Actrapid28		Amlodipine52	Agents Altering Gut
Actrapid Penfill28		Amorolfine58	Motility 27
Acupan117		Amoxicillin84	Antithrombotic Agents41
Adalat 1052		Amoxicillin clavulanate84	Antithymocyte globulin
Adalat Oros52		Amphotericin B35	(equine) 157
Adalimumab101		Amsacrine147	Antitrichomonal Agents87
Adapalene57		Amsidine147	Antituberculosics and
Adefovir dipivoxil88		Amyl nitrite55	Antileptotics 87
Adrenaline55		Anabolic Agents75	Antiulcerants27
Advantan61		Anaesthetics116	Antivirals88
AFT-Leflunomide100		Anagrelide hydrochloride147	Anusol27
AFT-Pyrazinamide88		Analgesics117	Anxiolytics133
Agents Affecting the		Anastrozole156	Apidra29
Renin-Angiotensin System48		Androderm76	Apidra SoloStar29
Agents for Parkinsonism and		Antabuse141	Apo-Allopurinol114
Related Disorders 115		Antacids and Antiflatulants25	Apo-Amlodipine52
Agents Used in the Treatment of		Anten120	Apo-Amoxi84
Poisonings 38		Anthelmintics82	Apo-Ascorbic Acid36
Agrilyn147		Anti-inflammatory Non Steroidal	Apo-B-Complex36
			Apo-Bromocriptine115

INDEX

Generic Chemicals and Brands

Apo-Captopril	48	Arrow-Lisinopril	48	B-D Ultra Fine	32
Apo-Cimetidine	27	Arrow-Meloxicam	100	B-D Ultra Fine II	32
Apo-Clomipramine	119	Arrow-Nifedipine XR	52	B-PlexADE	36
Apo-Clopidogrel	41	Arrow-Norfloxacin	97	Bacillus calmette-guerin (BCG) vaccine	157
Apo-Doxazosin	47	Arrow-Ranitidine	27	Baclofen	114
Apo-Folic Acid	40	Arrow-Roxithromycin	84	Bactroban	58
Apo-Gliclazide	29	Arrow-Sertraline	121	Bakels Gluten Free Health Bread Mix	193
Apo-Ipravent	165	Arrow-Simva 10mg	45	Baraclude	88
Apo-Megestrol	154	Arrow-Simva 20mg	45	Barrier Creams and Emollients	62
Apo-Moclobemide	120	Arrow-Simva 40mg	45	Batrafen	58
Apo-Nadolol	52	Arrow-Simva 80mg	45	Beclazone 100	161
Apo-Nicotinic Acid	45	Arrow-Sumatriptan	126	Beclazone 250	161
Apo-Oxybutynin	73	Arrow-Testosterone	76	Beclazone 50	161
Apo-Pindolol	52	Arrow-Topiramate	125	Beclomethasone dipropionate	161, 165
Apo-Prazo	47	Arrow-Tramadol	117	Bee venom allergy treatment	160
Apo-Prednisone	76	Arsenic trioxide	147	Bendrofluzide	54
Apo-Primidone	124	Arthrexin	100	Benhex	64
Apo-Pyridoxine	36	Asacol	26	Benzathine benzylpenicillin	84
Apo-Risperidone	131	Asamax	26	Benzoin	177
Apo-Selegiline	115	Ascorbic acid	36	Benzotrop	116
Apo-Selegiline S29	115	Aspec 300	117	Benztropine mesylate	116
Apo-Terazosin	47	Aspen Adrenaline	55	Benzylamine hydrochloride	35
Apo-Terbinafine	87	Aspen Ceftriaxone	82	Benzylpenicillin sodium (penicillin G)	84
Apo-Thiamine	36	Aspirin		Beta Adrenoceptor Blockers	51
Apo-Timol	52	Blood	41	Beta Cream	60
Apo-Timop	167	Nervous	117	Beta Ointment	60
Apo-Zopiclone	136	Asthalin	163	Beta Scalp	66
Apomine	115	Atacand	49	Beta-Adrenoceptor Agonists	163
Apomorphine hydrochloride	115	Atazanavir sulphate	94	Betadine	64
Applicator	68	Atenolol	51	Betadine Skin Prep	64
Aprepitant	126	Atenolol Tablet USP	51	Betaferon	136
Apresoline	55	ATGAM	157	Betagan	167
Aquasun 30+	66	Ativan	134	Betahistine dihydrochloride	127
Aquasun Oil Free Faces SPF30+	66	Atomoxetine	136	Betaloc	52
Aqueous cream	62	Atorvastatin	45	Betaloc CR	51
Aratac	50	Atropine sulphate		Betamethasone dipropionate	60
Arava	100	Alimentary	27	Betamethasone sodium phosphate with betamethasone acetate	75
Aremed	156	Sensory	169	Betamethasone valerate	60, 66
Arimidex	156	Atropt	169	Betamethasone valerate with clioquinol	61
Aripiprazole	128	Atrovent	163	Betamethasone valerate with fusidic acid	61
Aristocort	61	Auranofin	100	Betaxolol hydrochloride	167
Aromasin	156	Avanza	121	Betnovate	60
Arrow-Alprazolam	133	Avelox	86	Betnovate-C	61
Arrow-Azithromycin	83	Avomine	128		
Arrow-Bendrofluzide	54	Avonex	136		
Arrow-Cabergoline	80	Azamun	156		
Arrow-Citalopram	121	Azathioprine	156		
Arrow-Clopidogrel	41	Azithromycin	83		
Arrow-Diazepam	134	Azol	80		
Arrow-Enalapril	48	Azopt	168		
Arrow-Etidronate	111	AZT	94		
Arrow-Lamotrigine	124				
		- B -			
		B-D Micro-Fine	31		

Betoptic167
 Betoptic S167
 Bezafibrate44
 Bezalip Retard44
 Bicalox154
 Bicalutamide154
 Bicillin LA84
 BiCNU143
 Bimatoprost168
 Biodone118
 Biodone Extra Forte118
 Biodone Forte118
 Bisacodyl34
 BK Lotion63
 Bleomycin sulphate147
 Bleph 10167
 Blood glucose diagnostic test
 meter30
 Blood glucose diagnostic test
 strip31
 Bonjela35
 Bosentan55
 Breath-Alert165
 Brevinor 1/2171
 Brevinor 1/2871
 Brevinor 2171
 Bricanyl Turbuhaler163
 Brimonidine tartrate168
 Brimonidine tartrate with timolol
 maleate168
 Brinzolamide168
 Brolene166
 Bromocriptine mesylate115
 Brufen99
 Brufen Retard99
 BSF Arrow-Enalapril171
 Buccastem128
 Budenocort161
 Budesonide
 Alimentary25
 Respiratory161, 165
 Budesonide with
 eformoterol162
 Bumetanide53
 Buprenorphine
 hydrochloride117
 Bupropion hydrochloride141
 Burinex53
 Buscopan27
 Buspirone hydrochloride133
 Busulphan143
 Butacort Aqueous165

- C -

Cabergoline80
 Cafergot126
 Cal-d-Forte37
 Calamine59
 Calci-Tab 50037
 Calci-Tab 60037
 Calcipotriol65
 Calcitonin111
 Calcitriol36
 Calcium carbonate37
 Calcium carbonate with
 aminoacetic acid25
 Calcium Channel Blockers52
 Calcium Disodium Versenate39
 Calcium folinate144
 Calcium Folate Ebewe144
 Calcium gluconate37
 Calcium Homeostasis110
 Calcium polystyrene
 sulphonate44
 Calcium Resonium44
 Calogen182
 Calsource37
 Camptosar146
 Candesartan49
 Canesten58
 Capecitabine144
 Capoten48
 Capsaicin67
 Captopril48
 Carafate28
 Carbamazepine122
 Carbimazole79
 Carboplatin143
 Carboplatin Ebewe143
 Carbosorb-X38
 Cardinol52
 Cardinol LA52
 Cardizem CD53
 CareSens31
 CareSens II30
 CareSens POP30
 Carmustine143
 Carvedilol51
 Catapres53
 Catapres-TTS-153
 Catapres-TTS-253
 Catapres-TTS-353
 CeeNU143
 Cefaclor monohydrate82
 Cefalexin Sandoz83

Cefazolin sodium82
 Cefoxitin sodium82
 Ceftriaxone sodium82
 Cefuroxime axetil82
 Cefuroxime sodium82
 Celestone Chronodose75
 Celiprolol51
 Cellcept156
 Celol51
 Cephalixin ABM83
 Cephalixin monohydrate83
 Cerezyme35
 Cetirizine - AFT160
 Cetirizine hydrochloride160
 Cetomacrogol62
 Champix141
 Charcoal38
 Chemotherapeutic Agents143
 Chlorafast166
 Chlorambucil143
 Chloramphenicol166
 Chlorhexidine gluconate
 Alimentary35
 Dermatological61
 Chloroform177
 Chloromycetin166
 Chlorothiazide54
 Chlorpheniramine maleate160
 Chlorpromazine
 hydrochloride129
 Chlorsig166
 Chlorthalidone54
 Chlorvescent44
 Cholecalciferol37
 Cholestyramine with
 aspartame45
 Choline salicylate with
 cetalkonium chloride35
 Ciclopiroxolamine58
 Cilazapril48
 Cilazapril with
 hydrochlorothiazide49
 Cilicaine85
 Cilicaine VK85
 Ciloxan166
 Cimetidine27
 Ciprofloxacin
 Infection85
 Sensory166
 Cisplatin143
 Cisplatin Ebewe143
 Citalopram hydrobromide121
 Cladribine145

Diamox	168	Dorzolamide hydrochloride	168	Emend Tri-Pack	126
Diaphragm	69	Dorzolamide hydrochloride with timolol maleate	168	EMLA	116
Diasip	184	Dostinex	80	Emtricitabine	93
Diason RTH	184	Dothiepin hydrochloride	119	Emtriva	93
Diastop	25	Doxazosin mesylate	47	Emulsifying ointment	62
Diazepam	122, 134	Doxepin hydrochloride	120	Enalapril	48
Dibenyline	47	Doxine	85	Enalapril with hydrochlorothiazide	49
Diclax SR	99	Doxorubicin	148	Enbrel	105
Diclofenac Sandoz	99	Doxorubicin Ebewe	148	Endocrine Therapy	154
Diclofenac sodium Musculoskeletal System	99	Doxy-50	85	Endoxan	143
Sensory	167	Doxycycline hydrochloride	85	Enerlyte	44
Didanosine [DDI]	93	DP Lotion	63	Enfuvirtide	94
Diferin	57	DP Lotn HC	61	Enoxaparin sodium	41
Diffiam	35	DP-Anastrozole	156	Ensure	183
Diflucortolone valerate	60	Dr Reddy's Omeprazole	28	Ensure Plus	191
Digestives Including Enzymes	32	Dr Reddy's Ondansetron	127	Ensure Plus HN	190
Digoxin	50	Dr Reddy's Pantoprazole	28	Ensure Plus RTH	190
Dihydrocodeine tartrate	117	Dr Reddy's Quetiapine	130	Entacapone	115
Dilantin	124	Dr Reddy's Risperidone	131	Entecavir	88
Dilantin Infatab	124	Dulcolax	34	Entocort CLR	25
Dilatrend	51	Duocal Super Soluble Powder	182	Enuclene	169
Diltiazem hydrochloride	53	Duolin	164	Enzymes	113
Diizem	53	Duphalac	34	Epilim	125
Dimetriose	81	Duphaston	78	Epilim Crushable	125
Dipentum	26	Durex Confidence	68	Epilim IV	125
Diphemanil methylsulphate	62	Durex Extra Safe	68	Epilim S/F Liquid	125
Diphenoxylate hydrochloride with atropine sulphate	25	Durex Select Flavours	68	Epilim Syrup	125
Diprosone	60	Duride	55	Epirubicin	149
Diprosone OV	60	Durogesic	117	Epirubicin Ebewe	149
Dipyridamole	41	Dusting Powders	62	Eprex	40
Disinfecting and Cleansing Agents	61	Dydrogesterone	78	ERA	84
Disipal	116	Dynacirc-SRO	52	Ergometrine maleate	72
Disopyramide phosphate	50			Ergotamine tartrate with caffeine	126
Disulfiram	141	- E -		Erlotinib hydrochloride	152
Diuretics	53	E-Mycin	83	Erythrocin IV	83
Diurin 40	54	Ear Preparations	166	Erythromycin ethyl succinate	83
Dixarit	126	Ear/Eye Preparations	166	Erythromycin lactobionate	83
DM Ject	32	Easiphen	195	Erythromycin stearate	84
Docetaxel	148	Easiphen Liquid	195	Erythropoietin alpha	40
Docetaxel Ebewe	148	Econazole nitrate	59	Erythropoietin beta	40
Docusate sodium	33	Efavirenz	93	Escitalopram	121
Docusate sodium with sennosides	34	Efexor XR	121	Estraderm TTS 100	77
Domperidone	127	Eformoterol fumarate	162	Estraderm TTS 25	77
Donepezil hydrochloride	140	Efudix	67	Estraderm TTS 50	77
Donepezil-Rex	140	Egoposryl TA	65	Estrofem	77
Dopergin	115	Elecare	197	Etanercept	105
Dopress	119	Elecare LCP	197	Ethambutol hydrochloride	87
Dornase alfa	164	Elemental Q28 Extra	188	Ethics Aspirin	117
		Eligard	80	Ethics Aspirin EC	41
		Elocon	61	Ethics Ibuprofen	99
		Eloxatin	143	Ethinylloestradiol	78
		Eltroxin	79		

INDEX

Generic Chemicals and Brands

Ethinylloestradiol with desogestrel	70	Flamazine	58	Fosamax Plus	111
Ethinylloestradiol with levonorgestrel	70-71	Flecainide acetate	50	Framycetin sulphate	166
Ethinylloestradiol with norethisterone	71	Fleet Phosphate Enema	34	FreeStyle Lite	30, 31
Ethosuximide	123	Flixonase Hayfever & Allergy	165	Frisium	122
Etidronate disodium	111	Flixotide	161	Frumil	54
Etopophos	149	Flixotide Accuhaler	161	Frusemide-Claris	54
Etoposide	149	Florinef	75	Fucicort	61
Etoposide phosphate	149	Fluanxol	131	Fucidin	86
Etravirine	93	Flucloxacillin sodium	85	Fucithalmic	166
Eumovate	60	Flucloxin	85	Fungilin	35
Exemestane	156	Fluconazole	87	Furosemide	54
Extemporaneously Compounded Preparations and Galenicals	177	Fludara	145	Fusidic acid Dermatological	58
Eye Preparations	166	Fludara Oral	145	Infection	86
Ezetimibe	45	Fludarabine phosphate	145	Sensory	166
Ezetimibe with simvastatin	46	Fludrocortisone acetate	75	Fuzeon	94
Ezetrol	45	Fluids and Electrolytes	43		
		Flumetasone pivalate	166	- G -	
- F -		Fluocortolone caproate with flucortolone pivalate and cinchocaine	26	Gabapentin	123
Famotidine	27	Fluorometholone	167	Gabapentin (Neurontin)	124
Famox	27	Fluorouracil Ebewe	145	Gamma benzene hexachloride	64
Felo 10 ER	52	Fluorouracil sodium Dermatological	67	Gastrosoothe	27
Felo 5 ER	52	Oncology	145	Gaviscon	25
Felodipine	52	Fluoxetine hydrochloride	121	Gaviscon Double Strength	25
Femtran 100	77	Flupenthixol decanoate	131	Gaviscon Infant	25
Femtran 50	77	Fluphenazine decanoate	132	Gemcitabine Ebewe	145
Fenpaed	99	Flutamide	154	Gemcitabine hydrochloride	145
Fentanyl	117	Flutamin	154	Gemfibrozil	44
Fentanyl citrate	118	Fluticasone	161	Gemzar	145
Ferodan	38	Fluticasone propionate	165	Generaid Plus	186
Ferriprox	46	Fluticasone with salmeterol	162	Genoptic	166
Ferro-F-Tabs	38	Fluvax	98	Genotropin	79
Ferro-Gradumet	38	FML	167	Genox	156
Ferro-tab	38	Foban	58	Gentamicin sulphate Infection	86
Ferrograd-Folic	38	Folic acid	40	Sensory	166
Ferrous fumarate	38	Food Thickeners	192	Gestrinone	81
Ferrous fumarate with folic acid	38	Foods And Supplements For Inborn Errors Of Metabolism - Other	193	Ginet 84	72
Ferrous sulphate	38	Foods And Supplements For Inborn Errors Of Metabolism - PKU	194	Glatiramer acetate	135
Ferrous sulphate with folic acid	38	Foradil	162	Glibenclamide	29
Ferrum H	38	Foremount Child's Silicone Mask	165	Gliclazide	29
Fexofenadine hydrochloride	160	Fortimel Regular	185	Glipizide	30
Fibalip	44	Fortisip	191	Glivec	152
Fibro-vein	41	Fortisip Multi Fibre	191	Glucagen Hypokit	28
Finasteride	73	Fosamax	111	Glucagon hydrochloride	28
Fine Ject	31			Glucerna Select	184
Fintral	73			Glucerna Select RTH	184
Flagyl	87			Glucobay	29
Flagyl-S	87			Gluten Free Foods	192
				Gluten with sodium saccharin	177
				Glycerin with sucrose	177
				Glycerol	

Alimentary	34	Dermatological	60	Influvac	98
Extemporaneous	177	Hormone	75	Inhaled Anticholinergic	
Glycerol with paraffin and cetyl		Hydrocortisone acetate	26	Agents	163
alcohol	62	Hydrocortisone butyrate	60, 66	Inhaled Corticosteroids	161
Glyceryl trinitrate	55	Hydrocortisone butyrate with		Inhaled Long-acting	
Gold Knight	68	chlorquinaldol	61	Beta-adrenoceptor	
Gopten	49	Hydrocortisone with		Agonists	161
Goserelin acetate	80	cinchocaine	26	Inhibace	48
Gutron	51	Hydrocortisone with		Inhibace Plus	49
Gynaecological		miconazole	61	Innovacon hCG One Step	
Anti-infectives	72	Hydrocortisone with natamycin		Pregnancy Test	73
Gynol II	68	and neomycin	61	Insulin aspart	29
		Hydrocortisone with wool fat and		Insulin glargine	29
		mineral oil	61	Insulin glulisine	29
- H -		Hydroderm Lotion	63	Insulin isophane	28
Habitrol	142	Hydrogen peroxide		Insulin isophane with insulin	
Haldol	132	Alimentary	36	neutral	29
Haldol Concentrate	132	Dermatological	58, 67	Insulin lispro	29
Haloperidol	129	Hydroxocobalamin	36	Insulin lispro with insulin lispro	
Haloperidol decanoate	132	Hydroxychloroquine sulphate	87	protamine	29
Hamilton Sunscreen	66	Hydroxyurea	149	Insulin neutral	28
healthE Fatty Cream	62	Hygroton	54	Insulin pen needles	31
Healtheries Multi-vitamin		Hyoscine (scopolamine)	127	Insulin syringes, disposable with	
tablets	37	Hyoscine hydrobromide	127	attached needle	32
Healtheries Simple Baking		Hyoscine N-butylbromide	27	Intal Spincaps	164
Mix	192	Hypam	136	Intelence	93
Hemastix	74	Hyperuricaemia and		Interferon alpha-2a	96
Heparin sodium	42	Antigout	114	Interferon alpha-2b	96
Heparinised saline	42	Hypnovel	136	Interferon beta-1-alpha	136
Hepsera	88	Hypromellose	169	Interferon beta-1-beta	136
Herceptin	158	Hysite	168	Intra-uterine device	69
Hexamine hippurate	97	Hytrin Starter Pack	47	Intron-A	96
Hiprex	97	Hyzaar	50	Ipecacuanha	38
Histafen	160			Ipratropium bromide	163, 165
Holoxan	143	- I -		Ipratropium Steri-Neb	163
Homatropine hydrobromide	169	Ibiamox	84	Irinotecan	146
Horleys Bread Mix	193	Ibuprofen	99	Irinotecan-Rex	146
Horleys Flour	193	Idarubicin hydrochloride	149	Iron Overload	46
Hormone Replacement Therapy -		Ifosfamide	143	Iron polymaltose	38
Systemic	76	Iloprost	56	Isentress	94
Humalog	29	Imatinib mesylate	152	Ismo 20	55
Humalog Mix 25	29	Imiglycerase	35	Isogel	33
Humalog Mix 50	29	Imigran	126	Isoniazid	87
Humira	101	Imipramine hydrochloride	120	Isoprenaline hydrochloride	55
HumiraPen	101	Imiquimod	66	Isoptin	53
Humulin 30/70	29	Immune Modulators	95	Isopto Carpine	169
Humulin NPH	28	Immunosuppressants	156	Isopto Homatropine	169
Humulin R	28	Imuprine	156	Isosorbide mononitrate	55
Hyalase	113	Imuran	156	Isosource 1.5	190
Hyaluronidase	113	Indapamide	54	Isosource Standard	190
Hybloc	51	Indinavir	94	Isosource Standard RTH	190
Hydralazine	55	Indomethacin	100	Isotretinoin	57
Hydrea	149	Infant Formulae	196	Isradipine	52
Hydrocortisone		Influenza vaccine	98		

INDEX

Generic Chemicals and Brands

Isuprel	55	Latanoprost	168	Lomustine	143
Itch-Soothe	59	Lax-Tab	34	Loperamide hydrochloride	25
Itraconazole	87	Laxatives	33	Lophlex LQ	195
Itrazole	87	Laxofast 120	33	Lopinavir with ritonavir	94
		Laxofast 50	33	Lopresor	52
	- J -	Laxsol	34	Loprofin	195
Jadelle	71	Leffunomide	100	Loprofin Mix	195
Janola	62	Letara	156	Loraclear Hayfever Relief	161
Jevity	190	Letrozole	156	Lorapaed	161
Jevity RTH	190	Leukeran FC	143	Loratadine	161
	- K -	Leunase	147	Lorazepam	134
Kaletra	94	Leuprorelin	80	Lormetazepam	136
Karicare Food Thickener	192	Leustatin	145	Losartan	50
Karicare Goats Milk Infant		Levetiracetam	124	Lovir	90
Formula	197	Levetiracetam-Rex	124	Loxalate	121
Karicare Soy All Ages	198	Levlen ED	70	Loxamine	121
Kemadrin	116	Levobunolol	167	Lucrin Depot	80
Kenacomb	166	Levocabastine	167	Lucrin Depot PDS	80
Kenacort-A	76	Levodopa with benserazide	115	Ludiomil	120
Kenacort-A40	76	Levodopa with carbidopa	115	Lumigan	168
Ketoconazole		Levomepromazine	129	Lycinate	55
Dermatological	66	Levonorgestrel			
Infection	87	Genito-Urinary	71-72		
Ketone blood beta-ketone		Hormone	78	- M -	
electrodes	30	Levothyroxine	79	m-Captopril	48
Ketoprofen	99	Lifestyles Flared	68	m-Eslon	118
Ketostix	30	Lignocaine	116	m-Mometasone	61
Kindergen	186	Lignocaine hydrochloride	116	Mabthera	157
Kivexa	93	Lignocaine with		Macrogol 3350	34
Klacid	83	chlorhexidine	116	Madopar 125	115
Klamycin		Lignocaine with prilocaine	116	Madopar 250	115
Alimentary	27	Lipazil	44	Madopar 62.5	115
Infection	83	Lipid Modifying Agents	44	Madopar Dispersible	115
Kliogest	78	Lipitor	45	Madopar HBS	115
Kliovance	78	Liquigen	182	Magnesium hydroxide	177
Konakion MM	41	Lisinopril	48	Magnesium sulphate	
Konsyl-D	33	Lisuride hydrogen maleate	115	Alimentary	38
		Litak	145	Dermatological	67
	- L -	Lithicarb	129	Malathion	64
LA-Morph	118	Lithium carbonate	129	Maprotiline hydrochloride	120
Labetalol	51	Livostin	167	Marevan	43
Lacri-Lube	170	Locacorten-Viaform ED's	166	Marine Blue Lotion SPF 30+	66
Lactulose	34	Locasol	196	Marquis Black	68
Lamictal	124	Loceryl	58	Marquis Conforma	68
Lamivudine	89, 94	Locoid	60, 66	Marquis Protecta	68
Lamotrigine	124	Locoid C	61	Marquis Selecta	68
Lanoxin	50	Locoid Crelo	60	Marquis Sensolite	68
Lanoxin PG	50	Locoid Lipocream	60	Marquis Supalite	68
Lansoprazole	28	Locorten-Vioform	166	Marquis Titillata	68
Lantus	29	Lodoxamide trometamol	167	MarquisTantiliza	68
Lantus SoloStar	29	Loette	71	Martindale Acetylcysteine	177
Lanvis	147	Logem	124	Marvelon 21	70
Largactil	129	Lomide	167	Marvelon 28	70
Lasix	54			Mask for spacer device	165

Maxalt Melt	126	succinate	75	Mometasone furoate	61
Maxidex	167	Methylxanthines	164	Monofeme	70
Maxitrol	167	Metoclopramide		Monogen	185
MCT oil (Nutricia)	182	hydrochloride	127	Morphine hydrochloride	118
Mebendazole	82	Metoclopramide hydrochloride		Morphine sulphate	118
Mebeverine hydrochloride	27	with paracetamol	126	Morphine tartrate	119
Medrol	75	Metopirone	81	Morrex Maltodextrin	181
Medroxyprogesterone acetate		Metoprolol - AFT CR	51	Motilium	127
Genito-Urinary	72	Metoprolol succinate	51	Mouth and Throat	35
Hormone	77, 79	Metoprolol tartrate	52	Movicol	34
Mefenamic acid	99	Metronidazole	87	Moxifloxacin	86
Megestrol acetate	154	Metyrapone	81	MSUD Maxamaid	194
Meloxicam	100	Mexiletine hydrochloride	50	MSUD Maxamum	194
Melphalan	143	Mexitil	50	Mucilaginous laxatives	33
Menthol	59	Miacalcic	111	Mucilaginous laxatives with	
Mercaptopurine	146	Mianserin hydrochloride	120	stimulants	33
Mercilon 21	70	Micelle E	37	Mucilax	33
Mercilon 28	70	Micolette	34	MultiADE	37
Mesalazine	26	Miconazole	35	Multiloal Cu 375	69
Mesna	149	Miconazole nitrate		Multiloal Cu 375 SL	69
Mestinon	99	Dermatological	59	Multiple Sclerosis	
Metabolic Disorder Agents	35	Genito-Urinary	72	Treatments	134
Metabolic Mineral Mixture	196	Micreme	72	Multivitamins	37
Metamide	127	Micreme H	61	Mupirocin	58
Metamucil	33	Microgynon 20 ED	71	Muscle Relaxants	114
Metformin hydrochloride	30	Microgynon 30	70	Myaccord	156
Methadone hydrochloride		Microgynon 30 ED	70	Myambutol	87
Extemporaneous	177	Microgynon 50 ED	70	Mycobutin	88
Nervous	118	Microlax	34	Mycophenolate mofetil	156
Methatabs	118	Microlut	71	Mycostatin	59
Methoblastin	147	Midazolam	136	Mydriacyl	169
Methopt	169	Midodrine	51	Mylanta P	25
Methotrexate	147	Minaphlex	195	Myleran	143
Methotrexate Ebewe	147	Minerals	37	Mycocrisin	101
Methyl hydroxybenzoate	178	Minidiab	30	Myometrial and Vaginal Hormone	
Methylcellulose	178	Minirin	80	Preparations	72
Methylcellulose with glycerin and		Mino-tabs	85		
sodium saccharin	178	Minocycline hydrochloride	85	- N -	
Methylcellulose with glycerin and		Minomycin	85	Nadolol	52
sucrose	178	Minor Skin Infections	64	Nalcrom	26
Methylidopa	53	Mirena	78	Naloxone hydrochloride	140
Methylethylgometriner	72	Mirtazapine	121	Naltrexone hydrochloride	141
Methylphenidate		Misoprostol	27	Nandrolone decanoate	75
hydrochloride	138	Mitomycin C	149	Napamide	54
Methylphenidate hydrochloride		Mitomycin-C	149	Naphazoline hydrochloride	169
extended-release	140	Mitozantrone	149	Naphcon Forte	169
Methylprednisolone	75	Mitozantrone Ebewe	149	Naprosyn SR 1000	99
Methylprednisolone		Mixtard 30	29	Naprosyn SR 750	99
aceponate	61	Moclobemide	120	Naproxen	99
Methylprednisolone acetate	75	Modecate	132	Naproxen sodium	100
Methylprednisolone acetate with		Moducal	181	Nardil	120
lignocaine	75	Moduretic	54	Nasal Preparations	165
Methylprednisolone sodium		Mogine	124	Natulan	150
				Nausicalm	127

Pacific Atenolol	51	Pergolide	115	Ponstan	99
Pacific Buspirone	133	Perhexiline maleate	53	Postinor-1	72
Paclitaxel	149	Pericyazine	130	Potassium bicarbonate	44
Paclitaxel Ebewe	149	Perindopril	48	Potassium chloride	43-44
Paediatric Seravit	37	Permax	115	Potassium iodate	38
Pamidronate disodium	112	Permethrin	64	Povidone iodine	64
Pamisol	112	Persantin	41	Prantal	62
Panadol	117	Pethidine hydrochloride	119	Pravachol	45
Pancreatic enzyme	32	Pevaryl	59	Pravastatin	45
Pancrex V	32	Pexsig	53	Prazosin hydrochloride	47
Pancrex V Forte	32	Pharmacare	117	Pred Forte	167
Pantocid IV	28	Pharmacy Services	171	Pred Mild	167
Pantoprazole	28	Phenate	80	Prednisolone acetate	167
Panzytrat	32	Phenelzine sulphate	120	Prednisolone sodium phosphate	75
Papaverine hydrochloride	55	Phenobarbitone	124	Prednisone	76
Paracare	117	Phenobarbitone sodium	178	Prefrin	170
Paracare Double Strength	117	Phenoxybenzamine hydrochloride	47	Pregnancy Tests - hCG Urine	73
Paracare Junior	117	Phenoxyethylpenicillin (Penicillin V)	85	Pregnancy tests - HCG urine	73
Paracetamol	117	Phentolamine mesylate	47	Premarin	77
Paracetamol with codeine	119	Phenylephrine hydrochloride	170	Premia 2.5 Continuous	78
ParaCode	119	Phenytoin sodium	122, 124	Premia 5 Continuous	78
Paraffin	63	Phlexy 10	195	Prezista	94
Paraffin liquid with soft white paraffin	170	Phosphate-Sandoz	44	Priadel	129
Paraffin liquid with wool fat liquid	170	Phytomenadione	41	Primidone	124
Paraldehyde	122	Pilocarpine	169	Primolut N	79
Paramax	126	Pindolol	52	Probenecid	114
Parasitocidal Preparations	64	Pinetarsol	66	Probenecid-AFT	114
Parnate	120	Pinorax	34	Procaine penicillin	85
Paroxetine hydrochloride	121	Pinorax Forte	34	Procarbazine hydrochloride	150
Paxam	122	Pioglitazone	30	Prochlorperazine	128
Peak flow meter	165	Piportil	132	Proctosedyl	26
Pedialyte - Bubblegum	44	Pipothiazine palmitate	132	Procyclidine hydrochloride	116
Pedialyte - Fruit	44	Piram-D	100	Prodopa	53
Pedialyte - Plain	44	Piroxicam	100	Prograf	159
Pediasure	187	Pizaccord	30	Progynova	77
Pediasure RTH	186	Pizotifen	126	Promethazine hydrochloride	161
Pegasys	96	PKU Anamix Infant	195	Promethazine theoclate	128
Pegasys RBV Combination Pack	96	PKU Lophlex LQ	195	Promethazine Winthrop Elixir	161
Pegylated interferon alpha-2a	96	Plaquenil	87	Promod	183
Penicillamine	101	Plavix	41	Propafenone hydrochloride	50
PenMix 30	29	Plendil ER	52	Propamide isethionate	166
PenMix 40	29	Podophyllotoxin	67	Propranolol	52
PenMix 50	29	Polaramine	160	Propylene glycol	178
Pentasa	26	Poloxamer	34	Protamine sulphate	42
Pentostatin (deoxycoformycin)	149	Poly-Tears	169	Protaphane	28
Pepti Junior	197	Poly-Visc	170	Protaphane Penfill	28
Pepti Junior Gold	197	Polycal	181	Protifar	183
Peptisoothe	27	Polytar Emollient	66	Provera	77, 79
Peptisorb	188	Polyvinyl alcohol	169	PSO	199-202
				Psoriasis and Eczema Preparations	64

AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: _____ NZMC: _____

Signature: _____ Date: _____

Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Freephone Information line (9am-5pm weekdays) 0800 66 00 50

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)



PHARMAC is the Government agency responsible for deciding which medicines are subsidised for New Zealanders. It manages spending on pharmaceuticals for the District Health Boards, and ensures that a comprehensive list of medicines (the Pharmaceutical Schedule) is subsidised for New Zealanders.